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ABSTRACT 
Michael Kelly Altenburg:  Mechanisms Underlying the Atherosclerosis Risk of 
Apolipoprotein E Isoforms in Humans 
(Under the direction of Nobuyo Maeda) 
 
Apolipoprotein E (apoE) is a ligand for the low density lipoprotein receptor (LDLR), 
both of which are well recognized determinants of atherosclerosis risk in humans.  In humans 
the APOE gene is polymorphic, with three alleles APOE2, APOE3, and APOE4 coding for 
the protein apoE2, apoE3, and apoE4.  Despite increased LDLR affinity, apoE4 is associated 
with elevated and apoE2 reduced cholesterol concentration compared to apoE3.  Mice that 
have had their endogenous apoE replaced with the human apoE’s do not replicate their 
human counterparts, and mice with apoE3 and apoE4 are similar to wildtype mice, yet those 
with apoE2 have drastically elevated lipids, a phenotype observed in only 5% of APOE2 
homozygous humans. Either by adenovirus-mediated or global overexpression, elevated 
LDLR decreased plasma cholesterol in mice with apoE2, but led to a dramatic accumulation 
of cholesterol-rich VLDL in mice with apoE4 on a western-type high fat diet.   
In addition to the liver, where both apoE and LDLR are highly expressed and 
contribute to plasma lipoprotein clearance, they are expressed in vascular cells and 
macrophages. Increases in LDLR expression in macrophages significantly increased 
cholesterol uptake in culture, more prominently with lipoproteins containing apoE4 than 
those containing apoE3.  In LDLR-deficient mice expressing the human apoE4 isoform, the 
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replacement of bone marrow cells with those expressing LDLR increased atherosclerotic 
lesions in a dose-dependent manner compared with mice transplanted with cells having no 
LDLR. Thus apoE4, but not apoE3, in macrophages enhances atherosclerotic plaque 
development in mice in an LDLR-dependent manner and this interaction may contribute to 
the association of apoE4 with an increased cardiovascular risk in humans.   
Higher LDLR expression decreased the secretion of apoE4 and increased its 
degradation in both macrophages and hepatocytes.  ApoE localization using apoE-GFP 
fusion proteins expressed by adenovirus in the liver of apoE-deficient mice revealed that 
apoE4 accumulated in the space of Disse, but apoE2 did not.  Using several genetic 
approaches, apoE4s association with increased atherosclerosis risk can be replicated in mice.  
ApoE4 binding to the LDLR in macrophages and localization in hepatocytes both contribute 
to apoE4 pathogenesis. 
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Chapter I 
 
Introduction 
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Hyperlipoproteinemia in Human Disease 
 Cardiovascular disease causes the death of approximately 1 million people in the 
United States each year [1].  According to the American Heart Association, elevated total and 
LDL cholesterol levels is one of seven primary risk factors linked to coronary heart disease 
(CHD).  It has been estimated that the apolipoprotein E (apoE) locus accounts for as much as 
10% of the variation of plasma cholesterol levels and that apoE4 is associated with a modest 
increase in cholesterol [2, 3].  One study estimated a 40% increased risk for CHD mortality 
for middle aged male apoE4 carriers compared to apoE3 homozygote or apoE2 carriers [4].  
Considering that 25% of the population carries at least one copy of the apoE4 allele, the 
impacts of its effects are significant.  Mice with human apoE that overexpress the LDLR 
approximate the relationship between apoE and atherosclerosis in humans.  Understanding 
the mechanism of human apoE4-induced atherosclerosis in mice may translate to 
understanding the disease in humans and discovering therapies for its intervention.    
 
3  
Lipoprotein Metabolism 
In mammals, there are two main sources of plasma lipoproteins (Figure 1.1). The 
absorption of dietary fats in the gut begins the exogenous pathway of lipoprotein formation.  
The enterocytes of the small intestine package triglycerides, cholesterol, and phospholipids 
into Chylomicrons (CM), which are then secreted into the mesenteric lymphatics, and empty 
into the subclavian vein and the circulation via the thoracic duct.  In the circulation, CM 
particles can acquire apoE and the apolipoprotein CI, CII, and CIII (apoCI, apoCII, and 
apoCIII) from other plasma lipoproteins, such as high-density lipoproteins (HDL) [5].  
Lipoproteins undergo processing in the plasma and their triglyceride content is hydrolyzed by 
lipoprotein lipase (LPL) in the capillary beds into free fatty acids (FFA) and glycerol.  Now 
smaller and more dense, these cholesterol-rich remnants can then be removed from the 
plasma by apoE binding the low-density lipoprotein receptor (LDLR), heparan sulphate 
proteoglycans, and the LDL receptor-related protein (LRP) [6].  Several hours after a meal, 
the CM production by the small intestine is exhausted and the liver becomes the main source 
of plasma lipoproteins.  This endogenous pathway transports lipids from the liver, in humans, 
as ApoB100-containing Very Low Density Lipoproteins (VLDL) particles that are secreted 
into the plasma through the space of Disse.  Similar to CM’s, newly secreted triglyceride-rich 
VLDL is processed by LPL in the peripheral circulation to VLDL remnants.  VLDL 
remnants can then be removed from the circulation by apoE binding to the LDLR.  If not 
removed, VLDL remnants can be further processed into LDL [7].  These small, dense, 
cholesterol ester-rich particles do not contain apoE and can be removed only by the lower 
affinity ApoB100 binding the LDLR [8]. The reduced affinity of ApoB100 LDL results in a 
greater plasma half-life for LDL than VLDL.   ApoE is also a constituent of HDL, a class of 
plasma lipoproteins that contains apolipoprotein A1 as its constitutive protein instead of 
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apoB as in the larger lipoprotein classes.  HDL is thought to mediate reverse-cholesterol 
transport (RCT); sending cholesterol from the peripheral tissues back to the liver via the 
cholesterol ester transfer protein (CETP) or directly through the scavenger receptor B-1 (SR-
B1) [9].  A key player in HDL formation is the ATP-binding cassette, sub-family A, member 
1 (ABCA1) protein which effluxes cholesterol and other lipids from cells to nascent HDL 
[10].  However in contrast to the long held RCT hypotheses, recent work with hepatic 
ABCA1 overexpression or deletion has revealed that the liver may be the source for most of 
the cholesterol in plasma HDL [11, 12].   
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Figure 1.1 Review of Lipoprotein Metabolism. Human lipoprotein metabolism is divided 
into two pathways: the exogenous pathway (left) which after dietary lipid absorption in 
enterocytes of the small intestine are packaged into apoB48 containing TG-rich large 
chylomicrons which are secreted into the lymphatic system (blue).  During fasting, the 
endogenous pathway (bottom left), the liver secretes apoB100 containing VLDL (both 
apoB48 and apoB100 are secreted in mice) which transport lipid derived from the liver.  
Chylomicrons and VLDL are both TG rich and can undergo lipolysis in the capillaries by 
lipases such as LPL.  While in the circulation these particles aquire apoE as well as various 
other apoproteins.  Loss of TG and surface constituents (phospholipid, apoproteins) 
decreases the size, and these smaller more dense cholesterol enriched remnants can, if they 
have sufficient apoE, be cleared by the liver via LDLR, LRP, or HSPG (bottom).  LDL in 
humans does not have apoE and must rely on lower affinity LDLR mediated apoB100 
clearance.  Increased particle residence time, such as that of LDL or apoE-poor remnants, 
increases the likelihood of modification and oxidative changes and subsequent uptake by 
intimal scavenger macrophages in developing atheromas and foam cell formation (lower 
right).  Efflux of cholesterol through ABCA1 and other transporters to HDL can remove 
excess cholesterol from macrophages delaying lesion development.  Most apoA1 and HDL 
are secreted from the liver (bottom). 
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ApoE in lipoprotein metabolism  
 ApoE is a 299 amino acid, 34 kDa protein found on the surface of most lipoproteins 
and is an important ligand for their receptor-mediated endocytosis from the circulation.  In 
humans apoE is polymorphic with three isoforms, apoE2, apoE3, and apoE4, which differ by 
the amino acids at positions 112 and 158.  ApoE2 has two cysteines, while apoE3 has a 
cysteine at 112 and an arginine at 158, and apoE4 has two arginines.  These amino acid 
changes are responsible for apoE2 having a reduced LDLR affinity and apoE4 an increased 
affinity compared to apoE3 [13-15].  Paradoxically, however, apoE2 is associated with 
reduced cholesterol and atherosclerosis risk, except for 5% of homozygotes who develop 
type III hyperlipoproteinemia [16].  In contrast, apoE4, despite its increased LDLR affinity, 
is associated with an elevated plasma cholesterol level and atherosclerotic risk [2, 3].  
Weisgraber, et al has shown that apoE4 has a higher affinity for large TG rich lipoproteins, 
especially VLDL, than apoE3  [17].  The increased risk associated with apoE4 is thought to 
reflect increased intracellular apoE4 mediated lipid delivery, leading to LDLR down-
regulation and accumulation of plasma LDL [3, 18, 19].  However, this has not been proven 
and is difficult to reconcile with both LDL and VLDL being able to bind the LDLR.  ApoE is 
involved in several different lipoprotein metabolic pathways.  Secreted apoE can redistribute 
to chylomicrons, VLDL, remnant lipoprotein particles, and HDL [6, 20].  Lipoprotein-
associated apoE can interact with many cell surface molecules, and can facilitate endocytosis 
via the LDLR, LDLR related protein (LRP), and heparan sulfate proteoglycans (HSPG) [6].  
Hepatocytes secrete lipoprotein-free apoE into the space of Disse, where it associates with 
chylomicron remnants in a process called secretion capture [21].  Accumulation of apoE on 
lipoprotein surfaces can inhibit lipolysis of triglycerides by lipases [22].  In addition to its 
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role in the catabolism of lipoproteins, increased apoE secretion is associated with increased 
VLDL triglyceride production [23].   ApoE can also initiate HDL particle formation [24].  
On cell surfaces, LPL mediates the hydrolysis of triglycerides in CMs and their conversion to 
CMRs.  CMRs, which become enriched with HDL-derived apoE, can then be internalized via 
binding of apoE and LPL to LRP.  The lipid core with apoB48 is targeted to late 
endosomes/prelysosomal compartments.  CMR surface remnants containing apoE with LPL 
and some lipids are retained in early endosomes to mobilize intracellular cholesterol.  Some 
apoE/cholesterol complexes with HDL or lipid poor apoA1 in these peripheral endosomes 
and can be recycled to the cell surface as apoE containing HDL.  In the postprandial state, 
secretion of apoE-HDL can facilitate the enrichment of CMRs with apoE and thereby ensure 
the efficient hepatic clearance of CMRs.  This HDL mediated transfer of apoE to facilitate 
CMR or VLDL remnants is likely to depend on apoE isoform differences in receptor binding 
and recycling.   ApoE affinity to the LDLR may be a key regulator of this process. 
 
 
9  
The LDL Receptor in Lipoprotein Metabolism 
The LDL receptor plays a vital role in lipoprotein metabolism.  The LDLR is a 
receptor for lipoproteins containing the ligands apoE and apoB100.  After binding the 
receptor, these particles are endocytosed via clathrin-coated pits.  The importance of this 
receptor is illustrated by the genetic deficiency of the LDLR, resulting in severe increases in 
low density lipoprotein (LDL) cholesterol and premature atherosclerosis known as familial 
hypercholesterolemia (FH) [25].  In 1974 Goldstein et al determined that elevated lipids in 
patients with FH were due to defects in a  cell surface receptor that has a high affinity for 
apoB and apoE, which they named the LDLR [26].  FH patients have an increase in 
atherosclerosis and early death from myocardial infarction.  Goldstein and Brown went on  to 
show that the cellular levels of the LDLR are feed-back regulated at the transcriptional level 
by concentrations of intracellular cholesterol  [26, 27] 
Mice lacking LDLR, like FH in humans, have elevated LDL and develop 
atherosclerosis.  Overexpression of the LDLR by adenovirus mediated gene transfer has been 
shown to reduce the cholesterol in LDLR knock out mice [28].  
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Species differences 
 Unlike humans, mice do not normally develop atherosclerosis because of key 
differences in lipoprotein metabolism.  For example, the average plasma cholesterol level of 
wild type mice on a regular mouse normal chow (NC) diet (4.5% fat, 0.022% cholesterol) is 
approximately 80mg/dl; most of this cholesterol is carried by HDL particles.   Indeed mice 
have very low levels of LDL and other atherogenic lipoproteins, such as remnants of diet-
derived chylomicrons and liver-derived VLDL.  This is in marked contrast to humans in 
which most of the plasma cholesterol (200 mg/dL) is associated with apolipoprotein B100 
(apoB) containing LDL particles.  These differences are often attributed to differences in 
lipoprotein metabolism between mice and humans. For example, approximately 70% of liver 
apoB mRNA in mice undergoes post transcriptional editing, with a corresponding production 
of apoB48-containing VLDL from the liver, while humans do not have hepatic editing 
activity and secrete only the LDL precursor, apoB100 containing VLDL [4].  While all 
mammals appear to have apoB editing activity in the small intestine, humans do not edit 
apoB mRNA in the liver, while mice do [29].  The notation apoB48 indicates that it contains 
only the N-terminal 48% of the 4536 residues of apoB100.  Consequently, apoB48 lacks the 
putative C-terminal LDL receptor-binding region of apoB100.   ApoB48 is generated by a 
unique RNA editing system where a premature stop codon is created in the apoB mRNA, by 
demethylation of a cytosine to a uracil residue.  This is done by an editing complex that 
contains apobec-1, the catalytic activity of the protein complex, and RNA binding proteins 
that increase the specificity [30].   Another important species difference is in transfer of lipids 
among different lipoprotein classes.  Mice lack cholesterol ester transfer protein (CETP) 
activity which can transfer cholesterol esters from HDL to VLDL [3].  Mice show little to no 
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activity of this enzyme and this results in the characteristically low levels of LDL cholesterol 
seen in mice, which instead transport cholesterol mainly in HDL particles and are resistant to 
atherosclerosis [31].  However, while mice have a less atherogenic profile than humans, the 
pathways for cholesterol transport and metabolism in humans and mice are sufficiently 
similar that mice with mutations or deletions in specific lipoprotein metabolism genes can 
produce human-like hyperlipidemia and atherogenesis.   
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Genetic Approaches to Studying apoE and the LDLR 
Mouse models 
Gene targeting has been used extensively over the past two decades to investigate in 
vivo gene function in mice.  Targeting has several advantages over traditional transgenic 
models, in that only mutations to the germ line generated by homologous recombination are 
selected, giving precise control over target copy number and genome location and 
expression.  This has resulted in “knocking out” specific gene functions by replacing coding 
gene sequences with a selectable marker gene duplication and gene replacement [32].  Gene 
replacement by homologous recombination allows one to change specific gene sequences 
while leaving other regions intact.  
 In the late 90’s our laboratory used gene targeting to replace the murine apoE gene 
with each of the three human apoE alleles[14, 33, 34].  The murine regulatory regions remain 
intact and the mice produce solely the human apoE isoforms (All mouse models used in 
experiments and their abbreviated names are listed in Table 1.1 below).  The resultant lipid 
profiles of these mice reflect their apoE LDLR affinity.  Mice with apoE2, which has less 
than 2% the LDLR affinity of apoE3, exhibit hallmarks of type III hyperlipoproteinemia and 
develop atherosclerosis on a normal chow diet (NC) [34].  Mice expressing apoE3 and apoE4 
had a more mild phenotype and, unlike their human counterparts, did not exhibit 
hyperlipidemia or develop atherosclerosis on NC or high fat western diet (HFW) [14, 33].    
Not long after the apoE-targeted mice were characterized we made mice that 
modestly overexpress a human Ldlr minigene in place of the murine Ldlr, via enhanced 
mRNA stability.  A fragment containing the human LDLR minigene was isolated from 
plasmid pMY3, which was used for generating LDLR transgenic mice by Yokode et al, and 
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was kindly provided by Dr. Masahiro Yokode, [35].  Message stability was increased by 
deleting two of the three 3' "AU-rich elements" in the 3’UTR that normally destabilize the 
mRNA transcript [36].  In addition, the human LDLR minigene contains the poly(A) addition 
signal sequences of the human growth hormone gene.  Homologous recombination between 
the endogenous locus and the targeting construct results in a human LDLR minigene that is 
expressed under the control of the endogenous promoter.  All 5'-regulatory sequences of the 
endogenous mouse locus are intact. Heterozygous mice, via stabilization of the Ldlr mRNA, 
express 2.5 fold higher total LDLR than wildtypes [37, 38].   
 Chimeras were generated from targeted ES cells and bred with C57BL/6 mice to 
obtain germ line transmission of the modified chromosome.  The genotype of the modified 
allele in the animals was determined by the presence of a 300bp PCR fragment produced by 
using the Neo specific primer. 
 Mice that expressed the human apoE’s were crossed to mice that were heterozygous 
for the human Ldlr minigene that results in the stabilized Ldlr mRNA, ultimately generating 
mice that were homozygous for human apoE’s and heterozygous for the stabilized human 
Ldlr (h).  All the mutant mouse strains used in this work were individually backcrossed at 
least 6 generations to the C57BL/6 genetic background before intercrossing.  Mice 
heterozygous for a targeted replacement of the mouse Ldlr gene with the stabilized human 
Ldlr minigene (Apoe+/+Ldlrh/+) [37] were bred to mice homozygous for replacement of the 
mouse apoE gene with either the human APOE*2,  APOE*3, or APOE*4 allele 
(Apoe2/2Ldlr+/+ , Apoe3/3Ldlr+/+ , and Apoe4/4Ldlr+/+) [14, 33, 34].  The littermates generated by 
crossing Apoe2/2Ldlr+/+ (2m) with Apoe2/2Ldlrh/+ (2h), Apoe3/3Ldlr+/+ (3m) with Apoe3/3Ldlrh/+ 
(3h) and Apoe4/4Ldlr+/+ (4m) with Apoe4/4Ldlrh/+ (4h) respectively, were used in experiments 
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as donors of bone marrow cells.  Mice with human APOE*3 and lacking LDLR (3ko) and 
mice with human APOE*4 and lacking LDLR (4ko) were generated by crossing either 
Apoe3/3 or Apoe4/4 mice with Ldlr-/- mice [39], and maintained as Apoe3/3 Ldlr-/- (3ko) or 
Apoe4/4 Ldlr-/- (4ko) respectively (see Table 1.1 for genotypes and nomenclature). 
 The phenotypes of the replacement mice show that the apoE isoforms behave 
similarly when physiologically regulated in humans and mice.  However, there are some 
important differences.  Although 2m mice exhibit features of type III hyperlipidemia, the 
phenotype is fully penetrant in these mice, while only 5-10% of 2/2 humans develop type III.  
The 4m mice have an increase in non-HDL cholesterol compared to 3m mice, but in mice the 
increase is in VLDL-cholesterol, not in LDL-cholesterol as in humans.  Furthermore, steady 
state apoB48 levels are increased in the 4m mice, while only steady state apoB100 levels are 
increased in 4/4 compared to 3/3 human subjects. Surprisingly, introduction of the Ldlrh 
allele into mice expressing human apoE isoforms reproduced the human-like phenotypes 
associated with apoE isoforms.  On a HFW diet, mice with apoE4 overexpressing the LDLR 
(Apoe4/4Ldlrh/+) have increased plasma VLDL/Chylomicron Remnants, decreased HDL 
cholesterol levels, and develop atherosclerosis, while mice with human apoE3 and the Ldlrh 
allele (Apoe3/3Ldlrh/+) have significantly decreased HDL cholesterols as well as total 
cholesterol levels and do not develop atherosclerosis.  Global overexpression of LDLR in 
mice with apoE2 (Apoe2/2Ldlrh/+) resulted in lower plasma cholesterol and the absence of 
atherosclerotic lesions [37-40].   
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Abb Genotype TC, Diet Athero 
2m Apoe2/2,  Human apoE2, wildtype (murine) LDLR 242±59, NC yes 
3m Apoe3/3 ,  Human apoE3, wildtype (murine) LDLR 75±26,   NC no 
4m Apoe4/4,  Human apoE4, wildtype (murine) LDLR 73±27,   NC no 
2h Apoe2/2Ldlrh/+ ,  Human apoE2, Heterozygous for stabilized (human) LDLR 172±43, HFW no 
3h Apoe3/3Ldlrh/+ ,  Human apoE3, Heterozygous for stabilized (human) LDLR 92±9, HFW no 
4h Apoe4/4Ldlrh/+ ,  Human apoE4, Heterozygous for stabilized (human) LDLR   199±17, HFW yes 
2- Apoe2/2Ldlr-/- ,  Human apoE2, LDLR Knockout 747±143, NC yes 
3- Apoe3/3Ldlr-/- ,  Human apoE3, LDLR Knockout 420±77,   NC yes 
4- Apoe4/4Ldlr-/- ,  Human apoE4, LDLR Knockout 340±82,   NC yes 
ee Apoe-/-,  apoE Knockout,  wildtype (murine) LDLR 455±82,  NC yes 
eehh Apoe-/-Ldlrh/h,  apoE Knockout, Homozygous for stabilized (human) LDLR 250±32,  NC yes 
eell Apoe-/-Ldlr-/- ,  apoE Knockout, LDLR Knockout 800NC yes 
TC= Total Cholesterol, NC= Normal Chow,  HFW= High Fat Western 
 
Table 1.1 Genotypes and cholesterol levels of mice used in this work. 
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Figure 1.2 Effect of LDLR level on lipoprotein distribution in mice with human apoE. Mice 
with apoE2 (left), apoE3 (center) and apoE4 (right) with no LDLR (bottom), wildtype 
(center), and overexpression of the huLDLR (top).  All mice were on a HFW diet.  
Lipoprotein distributions of cholesterol (solid lines) and triglycerides (dotted lines) within 
plasma lipoproteins separated by FPLC. 
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Adenovirus-Mediated Gene Expression 
Adenovirae are excellent tools for in vivo gene transfer. This is due to the ability of 
the adenovirus to infect non-dividing cells and to be concentrated to high titers (greater than 
1012 plaque-forming units (pfu)/ml). However, adenovirus–mediated expression of a 
transgene drops in vivo after 4-7 days due to host immune response [41].  A low level of 
adenoviral gene expression induces CD8 T lymphocyte-mediated removal of infected cells 
and CD4 T cell-mediated facilitation of B cell neutralizing antibody production.  
The adenovirae (Ad) are non-enveloped viruses packaged in an icosohedral capsid.  
The adenovirus genome is composed of eight transcriptional units; six are transcribed in the 
early phase of viral infection before viral DNA replication.  The E1 gene is the first gene 
transcribed after infection and its product is involved in the preparation of the viral 
productive cycle through interaction with cellular cyclins and activation of other viral genes 
through interaction with cellular transcription factors.  All the experiments outlined in this 
proposal utilize first-generation adenoviruses that were generated by deletion of the E1 
region as well as the E3 region, which is not required for infection.  Recombinant 
adenoviruses were generated by cloning the gene of interest, with an upstream promoter into 
a cloning site within the deleted E1 region of a shuttle plasmid.  This recombinant plasmid is 
transformed into bacteria that harbor the remaining adenoviral genome.  The two plasmids 
undergo homologous recombination, resulting in generation of the full length Ad5 genome, 
with the E1 region replaced by the inserted gene of interest.  These recombinant adenoviruses 
can be propagated in kidney 293 cells in which the missing E1 gene is expressed in trans.  
The recombinant adenovirus is isolated by CsCl gradient ultracentrifugation, dialyzed, 
tittered in 293 cells, and typically 1 x 109 pfu of virus is injected via tail vein into mice.  This 
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procedure results in greater than 99% reporter gene activity to be found in the liver, with 
more than 90% of all hepatocytes exhibiting gene expression [42].  However, with visual 
detection of GFP transgenes in the liver, adjustment of the pfu-injected was necessary to 
achieve greater than 90% hepatocytes infection and expression. 
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Bone Marrow Transfer 
Atherosclerosis now has established oxidative and immunologic pathways that may 
have larger roles in foam cell formation and lesion progression [43-45].  Hematopoietic stem 
cells (HSC), especially monocyte-derived macrophages, are the chief regulators of 
cholesterol efflux and conversely uptake and foam cell formation.  This role in lipid uptake is 
in addition to their important role in immunoregulation through chemokine secretion.  Bone 
Marrow Transfer (BMT) has been used successfully in many experiments to investigate 
macrophage-dependant pathways of the atherosclerotic process.  Reconstitution of lethally 
irradiated atherosclerosis models, such as Apoe-/-,  or Ldlr-/- mice, with bone marrow cells that 
are harvested from mice carrying additional mutations allows investigators to separate the 
function of gene products in the macrophage from their function in the liver and remaining 
tissues of the recipient animals.  This is important given the potential dual roles some 
proteins play in atherosclerosis development.   
 ApoE isoforms have established liver-dependant pathways that control atherosclerosis 
risk. Apoe-/- or Ldlr-/- BMT models support liver-independent atherosclerosis changes induced 
by both proteins.  Given their different atherosclerosis and disease associations it seemed 
logical to investigate if there were additional macrophage pathways behind this risk.  Many 
of the functions of apoE in vascular tissues are isoform-specific and have been implicated as 
contributing factors to the well-established increased atherosclerosis risk associated with 
apoE4 in humans.  ApoE has been shown to reduce atherosclerosis when expressed in the 
arterial wall without affecting lipid levels [46].  Human apoE3 expressed in macrophages 
binds LDLR and is internalized, and a proportion of the internalized apoE is recycled in both 
hepatocytes and macrophages [47, 48].  The apoE3 and apoE2 proteins carry either one or 
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two free cysteinyl groups respectively, and may function as a better antioxidant than apoE4 
protein which does not have a free cysteinyl group.  It has been shown in vitro that 
lipoprotein oxidation is apoE isoform-dependant [49, 50].   
 While they do not mimic a common pathologic phenomenon, human hematopoietic 
mutations occur only after stem cell therapy.  BMT is useful for the separation of function 
and analysis of HSC monocyte-derived macrophages from hepatic and whole body 
contributions.  This is important in delineating the specific contributions of proteins which 
have roles in inflammation and lipoprotein metabolism in the liver and macrophage such as 
apoE and the LDLR.  
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Abstract 
Objective— Increased expression of the low-density lipoprotein receptor (LDLR) is 
generally considered beneficial for reducing plasma cholesterol and atherosclerosis, and its 
downregulation has been thought to explain the association between apolipoprotein (apo) E4 
and increased risk of coronary heart disease in humans.  
Methods and Results— Contrary to this hypothesis, doubling Ldlr expression caused 
severe atherosclerosis with marked accumulation of cholesterol-rich, apoE-poor remnants in 
mice with human apoE4, but not apoE3, when the animals were fed a Western-type diet. The 
increased Ldlr expression enhanced in vivo clearance of exogenously introduced remnants in 
mice with apoE4 only when the remnants were already enriched with apoE4. The rates of 
nascent lipoprotein production were the same. The adverse effects of increased LDLR 
suggest a possibility that the receptor can trap apoE4, reducing its availability for the transfer 
to nascent lipoproteins needed for their rapid clearance, thereby increasing the production of 
apoE-poor remnants that are slowly cleared. The lower affinity for the LDLR of apoE3 
compared with apoE4 could then explain why increased receptor expression had no adverse 
effects with apoE3.  
Conclusions— Our results emphasize the occurrence of important and unexpected 
interactions between APOE genotype, LDLR expression, and diet.  
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Introduction 
Apolipoprotein E (apoE) plays a central role in the clearance of atherogenic 
lipoprotein particles from the circulation [6] The APOE gene in humans is polymorphic with 
3 common alleles, APOE*2, APOE*3, and APOE*4, which code for apoE2, apoE3, and 
apoE4. These isoforms differ by the amino acids at positions 112 and 158, where apoE2 has 
Cys at both sites, apoE4 has Arg at both sites, and apoE3 has Cys-112 and Arg-158. There is 
a well-established association between the APOE polymorphism and the risk for vascular 
diseases; individuals with APOE*4 allele have increased plasma cholesterol and an increased 
risk of atherosclerosis[2, 3].  Although these increases are modest, they have a large impact 
on the overall human population, because 25% carry 1 or 2 APOE*4 alleles. However, this 
association is paradoxical when one considers that apoE4 binds to the LDL receptor (LDLR) 
with equal or a slightly greater affinity than apoE3, the most common isoform [13-15].  
Additionally, individuals homozygous for apoE2, which binds to the LDLR with much less 
affinity than either apoE3 or apoE4, have low plasma cholesterol and are generally protected 
from atherosclerosis, except for the 5% to 10% of apoE2 homozygotes who develop type III 
hyperlipoproteinemia [6].  The present explanation of this paradox is that the high affinity of 
apoE4 for the receptor leads to increased apoE-mediated cholesterol uptake followed 
subsequently by downregulation of the LDLR gene. This then leads to reduced apoB100-
mediated uptake of LDL, accumulation of LDL cholesterol, and the vascular problems [3, 18, 
19].  Conversely, the low affinity of apoE2 is thought to lead to upregulation of LDLR. 
Although this explanation seems reasonable given that the loss of function of even one LDLR 
allele leads to markedly elevated plasma LDL and premature atherosclerosis,[25] it has not 
been proven.  
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In the present study, we find that, contrary to the expectations of this hypothesis, 
increased Ldlr expression in mice with human APOE*4 causes severe atherosclerosis with 
marked elevation of plasma cholesterol when they are fed a Western-type diet. Mice with 
APOE*3, on the other hand, are not harmed by the increase in Ldlr expression. Based on 
these studies, we propose an alternative mechanism that the increased amount of LDLR can 
trap apoE and deplete the pool of apoE transferable to nascent lipoproteins.  
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Methods 
Mice heterozygous for targeted replacement of the mouse Ldlr gene with the human 
LDLR minigene (Apoe+/+Ldlrh/+) [37] were bred to mice homozygous for replacement of the 
mouse apoE gene with either the human APOE*3 or APOE*4 allele (Apoe3/3Ldlr+/+ and 
Apoe4/4Ldlr+/+).[14, 33]The experimental animals were mostly littermates generated by 
crossing Apoe3/3Ldlr+/+ (3m) with Apoe3/3Ldlrh/+ (3h) and Apoe4/4Ldlr+/+ (4m) with 
Apoe4/4Ldlrh/+ (4h), respectively. Mice with human APOE*4 and lacking LDLR (4KO) were 
generated by crossing Apoe4/4 and Ldlr-/- mice (see Table 2.1 for the definition of the 
shorthand designation of the mice used in this study). All mice were hybrids between 129 and 
C57BL/6, having approximately one fourth to one eighth of their genome from 129 and the 
remaining three fourths to seven eighths from C57BL/6. Twelve- to 36-week-old mice of 
both sexes were used for experiments that were conducted under protocols approved by the 
Institutional Animal Care and Use Committees. Littermates were used in each experiment as 
much as possible. Mice were fed either normal mouse chow (NC) containing 4.5% 
(wt/wt) fat and 0.022% (wt/wt) cholesterol (Prolab RMH 3000, Agway Inc) or a high-fat 
Western-type diet (HFW) containing 21% (wt/wt) fat and 0.2% (wt/wt) cholesterol 
(TD88137; Teklad).  
Lipid and lipoprotein analysis. Animals were fed normal chow (Prolab 
Rat/Mouse/Hamster 300, Agway, Syracuse, NY) or Western type diet (TD88137, Harlan 
Teklad, Madison WI). For analysis of plasma lipids, 200-300µl of blood were collected from 
retro-orbital plexus into tubes containing of EDTA 2mM, gentamicin 1ug/ml and aprotinin 
0.1UI (final concentrations). Mice were fasted for four hours unless otherwise stated in the 
text.  Total cholesterol and triglycerides were determined by using reagents from Sigma 
27  
(401-25P Infinity Cholesterol reagent and 339-20 Triglyceride (GPO-TRINDER) 20 
respectively).  HDL was precipitated using the method described4 and measured using the 
cholesterol reagent described above.  Plasma pooled from at least 6 mice (100 µl) was 
fractionated by fast protein liquid chromatography (FPLC) using a Superose 6HR column 
(Pharmacia Biotech Inc. Piscataway, NJ) and lipid analysis of the fractions (500 µl) was 
performed using Sigma reagents.  One ml of pooled plasma from each group was also 
fractionated by sequential density ultracentrifugation as described.5  Lipoprotein fractions 
were isolated by tube cutting and dialyzed against phosphate-buffered saline. 
Apolipoproteins were separated in a denaturing 3-20% SDS-polyacrylamide gel. Relative 
apoprotein ratios were determined by image densitometry using NIH Image following 
Commassie Brilliant Blue staining of the SDS-PAGE, or after Western blotting. Goat anti-
human apo E antibody was from Calbiochem (La Jolla, CA), and rabbit anti-mouse apoB was 
a gift from the late Dr. Harshini de Silva at the University of North Carolina Charlotte. Liver 
lipids were extracted using an adaptation of the method. 
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Mice 
 
Genotype 
 
Definition 
 
3m Apoe3/3Ldlr+/+ Mice with human apoE3 
3h Apoe3/3Ldlrh/+ Mice with human apoE3 and increased LDLR
4m Apoe4/4Ldlr+/+ Mice with human apoE4 
4h Apoe4/4Ldlrh/+ Mice with human apoE4 and increased LDLR
4KO Apoe4/4Ldlr-/- Mice with human apoE4 and no LDLR 
2m Apoe2/2Ldlr+/+ Mice with human apoE2 
2h Apoe2/2Ldlrh/+ Mice with human apoE2 and increased LDLR
Table 2.1. Keys to the Shorthand Definition of Mice Described in This Study 
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Message analysis. RNA was prepared from the livers, harvested from mice fasted for 
four hours, using Trizol reagent (Life Technologies, Geitesburg, MD) with standard 
protocols. The primer extension strategy was designed to simultaneously study both 
messages utilizing a primer (GGAGCACGTCTTGGGGGGACAGCCT) that hybridized to a 
shared homologous sequence of exon 3 of the LDLR.   ddCTP was utilized to terminate 
extension reaction, resulting in the murine message extension of 5 base pairs while the 
human message  extension is 3 base pairs. The amount of RNA was determined in a 
phosphoimager analyzer and normalized by the amount of Gapdh mRNA that was 
simultaneously determined in each reaction.  
Remnant clearance.  The VLDL fraction (d<1.006)) from chow-fed apoE-deficient 
mice  or chow-fed 4KO mice and remnant fraction (d<1.02) from 4h mice on HFW diet were 
isolated by ultracentrifugation.  Approximately 1 mg of VLDL protein was radioidinated  
with 125I or with 131I.  A dose of 5x106 to 107 cpm was injected through the tail vein or 
through the external jugular vein of recipient 4h and 4m mice fed HFW for at least two 
weeks.  Mice were bled (50 µl) at time points indicated, and the radioactivity remaining in 
plasma was measured using a 1272 CliniGamma Gamma Counter (LKB, Turku, Finland) 
assuming that blood volume is 3.5% of total body weight. 
 
VLDL secretion and fat loading. 16 week old 4m and 4h mice were fed HFW diet for 
two weeks.  To examine VLDL secretion, female mice (n=8 for each group) were fasted for 4 
hours prior to injection of Triton WR1339 (Sigma, St. Louis, Mo) in saline solution at a dose 
of 0.7 mg/g body weight.  For fat tolerance test, female mice (n=5 for each group) were fed 
0.4 ml of a 1:1 (w/w) mixture of oil olive and dehydrated egg yolk (Sigma, St. Louis, MO) 
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by oral gavage.  Plasma was collected before and at time points indicated for cholesterol and 
triglyceride measurements.  Chylomicron secretion was estimated by fat loading on male 
mice (n=4 for 4h and n=4 for 4m) after iv injection of Triton WR1339 to inhibit the 
clearance. 
 
Atherosclerosis.   Mice were fed HFW diet for three months before euthanization 
with a lethal dose of 2,2,2-tribromoethanol.  The heart and the vascular tree were perfused at 
physiological pressure with 4% phosphate buffered paraformaldehyde, pH 7.4.  
Morphometric analysis of plaque size at the aortic root was made on four segments using 
methods described [14, 37].  
 
Statistical analysis.  All data were first analyzed with general linear modeling using 
JMP software (version 5, SAS Institute, Cary, NC) to assess effects of multiple variables of 
interest (e.g. gender, Apoe genotye and Ldlr genotype). Where interactions between variables 
were not significant, reduced models without interactions were used.   
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Results 
Increased Ldlr expression causes hypercholesterolemia in mice with human APOE*4 
We replaced the endogenous mouse Ldlr with a minigene coding for human LDLR (Ldlrh) 
that produces an mRNA with an increased half-life [37] and introduced 1 copy of this Ldlrh 
allele into mice expressing solely apoE3 (Apoe3/3) or apoE4 (Apoe4/4) [14, 33].  When mice 
were fed NC, the increase in Ldlr expression significantly lowered the plasma lipids in both 
Apoe3/3Ldlrh/+ (3h) and Apoe4/4Ldlrh/+ (4h) mice, relative to the Apoe3/3Ldlr+/+ (3m) or 
Apoe4/4Ldlr+/+ (4m) mice (Table 2). The Ldlr genotype had highly significant effects on total 
cholesterol (TC), triglyceride (TG), and HDL cholesterol (HDL-C) (P<0.0001). The effects 
of the Apoe genotype on TC and HDL-C were not significant, but females with apoE4 tended 
to have higher TG than those with apoE3 whereas males with apoE3 tended to have higher 
TG than those with apoE4 (P=0.0002 for Apoe, sex interaction). All classes of plasma 
lipoproteins including HDL were reduced in mice with increased LDLR, as assayed by FPLC 
analysis (Figure 2.1A,).   Feeding a HFW increased the plasma TC and the HDL-C levels of 
all of the mice (Table 2.2). Surprisingly, however, the increase in plasma TC was much 
greater in the 4h mice than in 4m mice (120±11 versus 32±5 mg/dL, P<0.0001). This increase 
resulted mainly from a dramatic accumulation of non-HDL particles that elute in the VLDL 
region during fast performance liquid chromatography (FPLC, Figure 2.1A). In contrast, the 
3h mice on HFW showed only a small increase in non-HDL particles, and they had 
significantly lower cholesterol levels than the 3m mice primarily because of reduced HDL. 
Thus, the Ldlr genotype has markedly different effects on the response to HFW in mice with 
apoE4 compared with those with apoE3.  
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Table 2.2 Plasma Lipids  
TC, mg/dL 
 
TG, mg/dL 
 
HDL-C, mg/dL 
 Mice Genotype 
(Apoe, Ldlr) 
 
Sex 
 
NC 
 
HFW 
 
NC 
 
HFW 
 
NC 
 
HFW 
 
3m (3/3, +/+) M 95±4 (14) 114±12 
(14)
79±6 (14) 49±5 (14) 77±4 (7) 102±16 (9)
 F 66±3 (18) 106±10 (9) 40±4 (18) 39±6 (9) 49±7 (5) 81±10 (9)
3h (3/3, h/+) M 53±4 (22) 72±8 (12) 44±5 (22) 22±3 (12) 22±2 (5) 31±3 (5)
 F 37±4 (11) 92±9 (7) 27±4 (11) 54±6 (7) 17±2 (7) 30±4 (7)
4m (4/4, +/+) M 78±3 (30) 124±8 (34) 54±2 (29) 63±5 (27) 68±6 (11) 89±8 (16)
 F 63±4 (16) 114±6 (28) 49±5 (16) 48±4 (26) 51±3 (11) 77±11 (8)
4h (4/4, h/+) M 52±4 (28) 187±19 
(22)
35±2 (29) 41±3 (17) 32±3 (11) 36±4 (6)
 F 53±4 (29) 199±17 
(27)
34±4 (29) 41±4 (22) 30±1 (7) 41±5 (4)
Sex effects  P=0.005 NS P<0.0001 NS P=0.001 NS 
Apoe effects  NS P<0.0001 P=0.04 NS NS NS 
Ldlr effects  P<0.0001 P=0.03 P<0.0001 P=0.003 P<0.0001 P<0.0001 
Apoe x Ldlr 
interaction 
 P=0.01 P<0.0001 NS NS NS NS 
Values are mean±SE. The effects of sex and 2 genotypes were estimated with three-way 
factorial analysis of pooled data for both sexes. Numbers of animals are in parentheses. 
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Figure 2.1. Plasma lipoproteins. A, FPLC of plasma lipoproteins of mice fed NC (○) and 
HFW (•). Plasma was pooled from at least 6 male mice of each genotype. Fractions 
containing VLDL, LDL, and HDL are indicated. B, SDS polyacrylamide gel electrophoresis. 
Plasma was collected from mice fed HFW and separated by ultracentrifugation. Lanes 1 
through 7 are density fractions d<1.006, 1.006<d<1.02, 1.02<d<1.04, 1.04<d<1.06, 
1.06<d<1.08, 1.08<d<1.10, and 1.10<d<1. 21,  respectively. Positions of apolipoproteins are 
indicated on the left. 
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The 4h remnants were mostly in very low to intermediate density fractions (d<1.02 
g/mL) by ultracentrifugation and were enriched in TC but poor in TG, with a TC/TG ratio of 
5.3 compared with 0.6, 0.6, and 1.2 in 4m, 3m, and 3h remnants, respectively. The 
apolipoprotein compositions of the VLDL fraction also differed significantly (Figure 1B). 
Densitometric analysis of at least 4 different preparations of the VLDL fractions showed that 
the 4h remnants had a marked reduction of apoE4 (x0.4) but increased apoB48 (x6.7) and 
apoAIV (x4.7) compared with 4m remnants. ApoE3 in the 3h remnants was also reduced 
(x0.5) compared with 3m remnants, but the increase in apoB48 (x3) was less prominent. The 
4h remnant fraction contains an average of 4.5 times more apoB proteins than that of the 3h 
mice and had a smaller apoE/apoB ratio (8±1% relative to that in 4m) compared with 36±4% 
in 3h fraction (P<0.005). Thus, the remnants of the 4h mice are cholesterol-rich, TG-poor, 
and apoE-poor compared with those of the 3h mice.  
The enrichment of apoAIV in the 4h remnants suggests that they are mainly from 
intestine-derived chylomicrons. Consistent with this possibility, plasma cholesterol levels 
declined steadily in fasting 4h mice but not in 4m mice (Figure 2.2A) and remnant particles 
were reduced in 4h mice fasted for 18 hours or longer. There were no significant differences 
in the TC and TG content in the livers of these mice. The relative amounts of apoE protein 
estimated by Western blot analysis indicate that the elevated LDLR expression increases 
liver-associated apoE by 30% but reduces plasma apoE by 60% regardless of their Apoe 
genotype. 
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Figure 2.2. Effects of increased LDLR expression on mice with human apoE4 on HFW. A, 
Fasting effects on plasma cholesterol levels in male 4h (●, n=8) and 4m (○, n=8) mice on 
HFW. Error bars are SEM. P<0.0001 by MANOVA. *P<0.001 and P<0.05 between 
genotypes by 2-tailed Student’s t test. B, Liver mRNA levels for the mouse Ldlr (black bars) 
and for the human Ldlr (white bars) expressed as percent of the Ldlr gene expression in 4m 
mice on NC. Numbers of animals (all males) are shown in the bottom of the bars. Error bars 
are SEM. P<0.05 for diet effect, P<0.0005 for Ldlr genotype effect by 2-way ANOVA. The 
effect of Apoe genotype is not significant. 
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The level of mouse Ldlr mRNA in the liver of 4h mice with a single copy of the gene 
was 61% of that in 4m mice with 2 copies (100%, Figure 2.2B). The human Ldlr message 
was 155% (total, 216%). The regulatory machinery of the Ldlrh allele is intact, because HFW 
downregulated the mouse and human Ldlr messages equally to 60% of their levels in mice 
fed NC. The total Ldlr mRNA level in 4h mice fed HFW was 2-fold higher than in 4m mice 
on HFW and a trace higher than in 4m mice fed NC. Thus, the marked hypercholesterolemia 
in the 4h mice fed HFW occurs despite their having high levels of LDLR expression. Ldlr 
expression is similar in the livers of 4h and 3h mice on HFW, indicating that the 
hypercholesterolemia in the 4h mice, but not the 3h mice, is not attributable to any 
differences in the diet-induced downregulation of Ldlr expression in the liver.  
 
In Vivo Lipoprotein Metabolism in 4h Mice  To estimate the production of VLDL, we 
injected Triton WR1339 into 4h and 4m mice fed the HFW to inhibit lipolysis and the uptake 
of TG-rich particles. The initial rate of TG accumulation in plasma was not different between 
the 4h and 4m mice (Figure 2.3A). Plasma TC increased steadily and equally in both mice. 
They also responded similarly to the fat loading. The rates of plasma TG increase after fat 
loading in 4h mice treated with Triton WR1339 (604±33 mg/dL per h, n=4) was similar to 
those in 4m mice (656±37 mg/dL per h, n=4). Thus, increased LDLR expression seems to 
have no effect on the chylomicron production. These data suggest that the dramatic 
accumulation of remnants in the 4h mice compared with 4m mice is not attributable to 
oversecretion of TG-rich particles. 
39  
Figure 2.3. In vivo lipoprotein metabolism. A, Triglyceride (left) and cholesterol (right) 
secretion of 4m (○ )and 4h (●) mice after inhibition of lipolysis with Triton WR1339. The 
overall rate of TG secretion was not significantly different between the genotypes by 
MANOVA. B, Clearance of remnants. Radioactivity remaining in the plasma after injection 
of I125-labeled VLDL obtained from 4h remnants into HFW-fed 4h males (n=10) and 4m 
males (n=9) was not significantly different at any time points except at 10 minutes (left, 
P<0.05). Clearance of the 131I radiolabeled apoE4-rich 4KO remnants (right) in 4h males 
(n=5) was significantly faster than in 4m males (n=5, P<0.0001 by MANOVA, and P<0.01 at 
all times up to 120 minutes). 
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To examine the ability of mice to clear cholesterol-enriched remnant particles, we 
isolated remnants (d<1.02) from HFW-fed 4h mice, radiolabeled the particles with 125I, and 
injected them into the jugular vein of 4h and 4m mice fed the HFW diet. Despite the 
increased Ldlr expression in the 4h mice, removal of the apoE-poor remnants from their 
plasma (0.04 pools/min) was not different from that in the 4m mice (0.04 pools/min, Figure 
3B, left). Similar results were obtained with remnants (d<1.006) isolated from apoE-deficient 
mice (not shown). To test whether the 4h mice having increased LDLR are able to clear 
apoE4-enriched remnants, we isolated lipoproteins (d<1.006) from mice expressing apoE4 
but lacking LDLR (4KO) that are markedly enriched with apoE but not with apoAIV (C. 
Knouff and N. Maeda, unpublished data). The plasma decay of 131I-radiolabeled 4KO 
remnants (Figure 2.3B, right) was significantly faster in the 4h mice (0.07 pools/min) than in 
the 4m mice (0.03 pools/min, P<0.0001). Thus, the 4h mice with genetically increased LDLR 
expression clear remnant lipoproteins at an enhanced rate as long as these particles are 
enriched in apoE.  
Taken together, these data indicate that the marked accumulation of remnant particles 
in the 4h mice is neither because they have increased secretion of nascent TG-rich 
lipoproteins nor because they have reduced clearance of apoE-poor remnants compared with 
4m mice. The inference from these data is that the conversion of large TG-rich particles to 
smaller cholesterol-rich remnants is enhanced in the 4h mice.  
Severe Atherosclerosis in 4h But Not 3h Mice on HFW Diet. Accumulation of 
remnant particles and reduction of HDL-cholesterol in HFW-fed 4h mice is a high-risk 
profile for atherosclerosis, even though the average plasma total cholesterol of these mice is 
only marginally elevated (200 mg/dL). We therefore evaluated the development of 
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atherosclerosis in mice fed HFW containing 21% fat and 0.5% cholesterol for 3 months. No 
plaques were found in any of the 3m mice (5 females) or 4m mice (8 females and 5 males) on 
HFW. Similarly, none of the 7 female 3h mice on HFW developed plaques (Figure 2.4A). In 
contrast, all of the 15 female and 7 male 4h mice on HFW developed significant plaques at 
the aortic sinus area (Figures 2.4B through 2.4D) with average plaque sizes of 59±15x103 
µm2 in females and 22±7x103 µm2 in males. Although the numbers and sizes of plaques 
varied in individual animals, most of the mice had mature complex plaques with fibrous caps, 
necrotic lipid cores, cholesterol clefts, and calcifications (Figures 2.4C and 2.4D). Thus, mice 
having human APOE*4 and a moderately increased amount of LDLR develop significant 
atherosclerosis when fed a diet similar in composition to that of Western societies.  
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Figure 2.4. Representative atherosclerotic plaques in the aortic sinus of mice fed HFW for 3 
months. A, 3h female; B, 4h female; C, 4h male; and D, 4h female. Frozen sections were 
stained with Sudan IVB for lipids and counterstained with hematoxylin. Black arrowheads 
indicate fibrous caps. Yellow and blue arrows designate calcification and cholesterol clefts, 
respectively. L indicates lumen; M, media; and A, adventitia. Scale bars=500 µm in a and b 
and 100 µm in c and d. 
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Discussion 
Our clear demonstration of hypercholesterolemia and atherosclerosis in mice that 
have human apoE4, but not apoE3, replicates in mice fed a Western diet the paradoxical 
association between APOE polymorphisms and the risk of atherosclerosis in humans. 
However, contrary to the currently accepted hypothesis that downregulation of LDLR in 
individuals with an APOE*4 allele is the cause of their high plasma cholesterol levels,[3, 18, 
19] we find that these isoform-specific effects are only present when LDLR is increased.  
How can increased LDLR expression ever be harmful? We suggest that this is 
because the LDLR, under some circumstances, traps sufficient apoE and the supply becomes 
inadequate to process a high dietary intake of lipids. Exchange of apoE onto nascent 
triglyceride-rich lipoproteins is a necessary prerequisite for their internalization via LDLR .  
The overall process that we envision is illustrated in Figure 2.5. ApoE4 may be particularly 
susceptible to this trapping because of its strong affinity for the LDLR. Transient particles 
that fail to acquire apoE4 are excellent substrates for lipases, and the resulting enhanced 
lipolysis will increase cholesterol-rich apoE-poor remnant particles in plasma [6]. We suggest 
that apoE3 is less susceptible to trapping than apoE4, perhaps because of its somewhat lower 
affinity for the LDLR [13, 14]. Consequently, the 3h mice have sufficient apoE3 to process 
nascent lipoproteins for rapid internalization. This differential transfer of apoE3 and apoE4 to 
lipoproteins can also explain our previous observation that in vivo clearance of exogenously 
introduced remnants is significantly faster in 3m mice than in 4m mice [14].  
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Figure 2.5. ApoE trapping by the LDLR. Triglyceride-rich chylomicrons (yellow) secreted 
by the intestine into lymph are remodeled to transient particles (orange) mainly in capillaries 
and in the space of Disse in the liver. This initial capturing phase is very rapid and does not 
depend on the LDLR; it probably involves heparan sulfate proteoglycans that facilitate 
lipolysis and apolipoprotein exchange. Enrichment with apoE is a requirement for the fast 
internalization of the transient particles primarily via LDLR-mediated endocytosis. 
Otherwise, the particles are additionally processed to cholesterol-enriched remnants (red) that 
are slowly cleared from the plasma. The lipid composition of the remnants in plasma depends 
on both Apoe genotype and the amount of LDLR. The processing of liver-derived VLDL 
particles is likely to be similar to that illustrated for chylomicrons. 
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Previously we reported that mice expressing solely apoE2 (2m) show features typical 
of type III hyperlipoproteinemia in humans  but that increased LDLR expression in these 
mice (2h) completely ameliorates their hyperlipoproteinemia [14, 34] According to our 
hypothesis, apoE2 with its very low affinity for the LDLR should be virtually free from 
trapping and should therefore be efficiently transferred to transient TG-rich particles. 
Although such an apoE2 enrichment of TG-rich particles is likely to increase their LDLR-
mediated internalization, it will also severely inhibit lipolysis and could account for the 
prominent accumulation of TG-rich remnants seen in the circulation of the 2m mice [14, 34] 
In the 2h mice, however, high LDLR expression tips the balance toward more internalization 
and lowers their plasma cholesterol.  
Clearly, additional studies are necessary to refine and test our proposed apoE trapping 
by the LDLR. For example, we do not know whether it occurs on the cell surface, as 
illustrated in Figure 2.5, or during intracellular trafficking [51, 52].  The word trapping 
should not be taken too literally; difference in the interaction between apoE and LDLR or 
their subsequent processing may result not only from differences in binding affinities but also 
from other properties influenced by the specific amino acids that differ among 3 isoforms. 
Interactions of apoE with other molecules, such as proteoglycans and hepatic lipase, that are 
also expressed on the basolateral microvilli of hepatocytes may also influence the apoE 
interaction with LDLR in an isoform-specific fashion. Published studies have shown that 
newly synthesized apoE is incompletely secreted and partially degraded in HepG2 cells in 
culture and a significant portion of apoE synthesized by macrophages undergoes rapid 
cellular degradation in a non-lysosomal compartment in a sterol-regulated manner [53, 54]. 
Although the role of LDLR in these processes has not been addressed, LDLR is known to 
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bind to newly synthesized apoE in macrophages and limits its secretion [55] LDLR 
expression in macrophages could also contribute to atherogenesis in an apoE isoform–
specific fashion. For example, a differential effect on cholesterol homeostasis in macrophages 
by apoE isoforms with apoE4 being least effective in promoting cholesterol efflux from 
macrophage has been reported [56].  Additionally, Linton et al have shown that C57BL/6 
mice receiving Ldlr-/- marrow developed 63% smaller lesions than mice receiving Ldlr+/+ 
marrow after dietary atherogenic stimuli, demonstrating that macrophage LDLR affects the 
rate of foam cell formation under conditions of dietary stress [57].  
Some comments are required on the relevance of our findings in mice to the effects of 
different APOE genotypes in humans. We note that 4h mice preferentially accumulate 
apoB48-containing lipoproteins of an intermediate density, whereas humans with the 
APOE*4 allele mainly have elevated levels of apoB100-containing LDL [3] This is not 
incompatible with our hypothesis, which predicts that trapping of apoE4 by the LDLR will 
hinder enrichment of VLDL remnants with apoE4, thereby leading to an increase in their 
conversion to LDL. Because the clearance of LDL particles mediated by binding apoB100 to 
the receptor is much slower than apoE-mediated VLDL clearance, we expect that the plasma 
cholesterol levels in individuals with apoE4 will be increased. Supporting this explanation, an 
increased conversion of VLDL to smaller remnants and a relative decrease in direct removal 
of VLDL in APOE*4 homozygotes compared with APOE*3 subjects have been demonstrated 
[58-60].  
Our finding that hypercholesterolemia is seen only when the 4h mice are fed HFW 
diet is also consistent with observations that human subjects carrying the APOE*4 allele are 
more responsive than others to LDL cholesterol–lowering by diet [61, 62]  In addition, some 
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though not all studies have found prolonged postprandial lipemia in normolipidemic subjects 
that carry APOE*4 [63, 64] . Bergeron and Havel have proposed that prolonged residence 
times of chylomicron and VLDL remnants in persons with APOE*4 raise the concentration 
of LDL by increasing the amount of VLDL converted to LDL. We additionally note that an 
apoE5 variant with lysine in place of glutamic acid at position 3 is also associated with 
hyperlipidemia and atherosclerosis and it has a twice-normal LDLR binding activity [17]. 
Finally, some although not all studies have shown that the cholesterol-lowering effects of 
statins, thought to be primarily mediated by increased LDLR, are apoE isoform–dependent. 
In these studies, individuals with the APOE*3/4 and APOE*4/4 genotypes had significantly 
smaller LDL cholesterol reductions in response to statin treatment than those with the 
APOE*3/3 genotype [65] Clinical studies clearly indicate that statin therapies reduce the risk 
of cardiovascular disease in humans, including those with apoE4, and no serious adverse 
effects on plasma lipids have been reported [66, 67].  Nevertheless, our observations suggest 
the need for additional studies of the interaction between the cholesterol-lowering effect of 
statins and genetic variations.  
In conclusion, our studies demonstrate that, contrary to the presently accepted 
downregulation of LDLR hypothesis, increased LDLR has harmful effects in Western diet–
fed mice expressing human apoE4 and causes marked accumulation of apoE-poor lipoprotein 
remnants in plasma and severe atherosclerosis. The alternative mechanism of apoE-trapping 
by LDLR explains our observations and offers a plausible explanation why apoE4, which has 
a greater affinity for the LDLR than apoE3, is associated with higher plasma cholesterol and a 
greater risk of atherosclerosis in humans. Our unexpected findings in mice predict important 
interactions between APOE genotype, LDLR expression, and diet.  
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Abstract 
Low-density lipoprotein receptor (LDLR) is critical for plasma lipoprotein clearance and 
a decreased LDLR expression has been thought to explain the increased plasma cholesterol and 
atherosclerosis risk in humans with apolipoprotein (apo) E4.  However, in mice expressing 
human apoE4 instead of their mouse counterpart, increased LDLR expression caused 
accumulation of cholesterol-rich apoE-poor chylomicron remnants, and resulted in significant 
atherosclerosis.  The production rates of chylomicrons and very low density lipoproteins (VLDL) 
were unchanged, as was the clearance rate of exogenously given apoE deficient remnants.  These 
data suggest an enhanced conversion of nascent lipoprotein particles to cholesterol-rich remnants 
that are poorly cleared.  We hypothesize that the negative effects from elevated LDLR are due to 
the high binding affinity of apoE4 for the receptor which reduces the availability of apoE4 for 
transfer to triglyceride rich lipoproteins (TRL), thereby inhibiting their rapid internalization.  
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Introduction 
The low density lipoprotein receptor LDLR plays a pivotal role in the removal of 
atherogenic lipoproteins from the circulation by removing lipoproteins containing the LDLR 
ligands apoB100 and apoE [1].  In humans, apoE is polymorphic with three isoforms, apoE2, 
apoE3, and apoE4.  These isoforms differ at positions 112 and 158, with apoE2 having two 
Cysteines, apoE3 cysteine at 112 and arginine at 158, and apoE4 two arginines.  ApoE2 has a 
reduced LDLR affinity and apoE4 an increased affinity compared to apoE3 [13-15].  
Paradoxically, apoE4 is associated with an elevated plasma cholesterol level and atherosclerosis, 
while apoE2 a reduction in cholesterol and risk in humans [2, 3].  The increased risk associated 
with apoE4 is thought to be due to elevated intracellular cholesterol from increased apoE4-
mediated lipid delivery, leading to down-regulation of the LDLR [3, 18, 19].  Here we describe 
the over-expression of the LDLR in mice with apoE4 and found increased cholesterol and 
atherosclerosis.  
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Material and Methods 
Mice homozygous for the replacement of APOE*4 allele (Apoe4/4Ldlrh/+) were bred to 
mice heterozygous for targeted replacement of the mouse Ldlr gene with the human Ldlr 
minigene (Apoe+/+Ldlrh/+ )Experimental animals were made by crossing Apoe Apoe4/4Ldlr+/+ 
(4m) to Apoe4/4Ldlrh/+ (4h).  Twelve to 36 week old mice of both sexes were used for 
experiments that were conducted under protocols approved by the Institutional Animal Care and 
Use Committees.  Littermates were used when possible.  Mice were maintained on either a 
normal chow (NC) 4.5%(w/w) fat and 0.022% (w/w) cholesterol (Prolab RMH 3000, Agway 
Inc., Syracuse, NY) or a high fat Western diet (HFW) containing 21% fat and 0.2% cholesterol 
(TD88137; Teklad, Madison WI). 
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Results 
To examine the effects of LDLR expression level on mice with apoE4, mice homozygous 
for the replacement of APOE*4 allele (4m) were bred to mice heterozygous for targeted 
replacement of the mouse Ldlr gene with the human Ldlr minigene (4h) that results in a 
stabilized Ldlr mRNA [4-7].  Total mRNA for LDLR in 4h mice was 2.3 times that of 4m mice.  
On normal chow (NC), plasma cholesterol in 4h mice was about one third that of 4m mice, 
resulting from reduced HDL cholesterol.  When fed a high fat Western diet (HFW), 4h mice 
became markedly hypercholesterolemic with accumulation of apoE-poor, but cholesterol 
enriched, particles in their plasma predominantly in their chylomicron/very low density 
lipoproteins (VLDL) remnant (1.006<d<1.02) fractions [7].  Plasma lipoprotein fractions from 
4m mice fed HFW diet did not change before and after fasting (Figure 3.1).  In contrast, fasting 
18 h almost completely eliminated these 4h remnants, suggesting that these particles are derived 
primarily from the diet.  Interestingly similar prolonged postprandial lipemia has also been 
observed in humans with apoE4[68]. 
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Figure 3.1.  Ultracentrifugation Cholesterol distribution in apoE4 mice with elevated LDLR. 
(mg/dl) in UC fractions before (shaded) and after an 18 hour fast (white).  Plasma was pooled 
from HFW fed 4m (n=5) and 4h (n=5) and separated by ultracentrifugation into density fractions.  
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Figure 3.2. Triglyceride secretion of 4m (open symbol) and 4h (closed symbol) mice after 
inhibition of lipolysis and uptake with Triton WR1339.  Mice (n=4) after olive oil gavage 
reflects VLDL and chylomicron secretion (circles).  VLDL secretion in mice (n=4) fasted 4h 
(squares).  The difference between the top and bottom reflects chylomicron production 
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Triglyceride secretion was indistinguishable in 4m and 4h mice, suggesting that the 
VLDL production from the liver is the same. When mice were gavaged with a 200ul olive oil 
bolus immediately after Triton WR 1339 injection, the rate of TG accumulation after gavage was 
also the same in both 4m and 4h mice (Figure 3.2).  These results indicate that the chylomicron 
secretion there was no significant difference in clearance of remnant particles between 4m and 
4h mice (Figure 3.3).  Therefore, the elevated cholesterol associated with increased LDLR in the 
4h mice is not due to delayed clearance of cholesterol-rich apoE-poor remnants.  The inference 
from these data is that the conversion of nascent triglyceride-rich lipoproteins (TRL) to apoE-
poor remnants is increased in 4h mice. 
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Figure 3.3.  Clearance of apoE-/- VLDL in 4m and 4h mice.  Radioactivity remaining in the 
plasma after injection of  I125 labeled VLDL into HFW fed 4m and 4h mice.  There is no 
significant difference in clearance between 4m and 4h mice. 
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Discussion 
ApoE is normally associated with various proteins and proteoglycans on the surface of 
capillaries and the hepatic space of Disse where it can be transferred to circulating lipoproteins. 
We propose that the increased LDLR can “trap” apoE protein and limit its transfer to circulating 
nascent lipoproteins, which in turn reduces the apoE-mediated removal of larger particles and 
forces their remodeling to slowly cleared remnants.  The clearance of these cholesterol-rich apoE 
poor remnants is equally slow in both 4m and 4h and is seemingly LDLR-independent. The 
higher affinity of apoE4 for the receptor may make it more susceptible to trapping than apoE3 
and apoE2.    
Thus mice expressing human apoE isoforms have revealed important interactions 
between apoE genotype, LDLR expression, and diet.  Contrary to the currently accepted 
hypothesis that increased atherosclerosis risk in humans with apoE4 is due to down-regulation of 
LDLR, we found that increased LDLR has adverse effects on mice expressing apoE4. Our 
proposed mechanism of apoE4 trapping by LDLR is likely to be contributing to the paradoxical 
association between apoE4 and increased atherosclerosis risk.  We expect that humans vary in 
their basal expression of LDLR, and its levels influence the atherosclerosis risk differently 
depending on the apoE genotype (Figure 3.4).  Control of diet would then be more important in 
individuals with apoE4 than those with apoE2 or apoE3 when the LDLR level is relatively high.   
  
65 
Figure 3.4. Interaction between apoE isoforms and LDLR level.  On the left-hand side are mice 
expressing the different apoE isoforms with a relatively low wild-type LDLR level.  On the 
right-hand side are the same mice with elevated LDLR level.  We suggest that the human LDLR 
level mean is centered between the extremes in our mice 
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Abstract 
Apolipoprotein E (apoE) and the low density lipoprotein receptor (LDLR) are well 
recognized determinants of atherosclerosis. In addition to hepatocytes, where both are highly 
expressed and contribute to plasma lipoprotein clearance, they are expressed in vascular cells and 
macrophages. In this study, we examined the effects of human apoE isoforms and LDLR levels 
in atherogenic pathways in primary macrophages ex vivo and atherosclerosis development after 
bone marrow transfer in vivo using mice expressing human apoE isoforms and different levels of 
LDLR expression. Increases in LDLR expression significantly increased cholesterol delivery into 
macrophages in culture, and the effects were more prominent with lipoproteins containing apoE4 
than those containing apoE3. Conversely, increased LDLR expression reduced cholesterol efflux 
in macrophages expressing apoE4 but not in macrophages expressing apoE3. Furthermore, 
apoE3 protected VLDL from oxidation in vitro more than did apoE4. In LDLR-deficient mice 
expressing the human apoE4 isoform, Apoe4/4 Ldlr–/–, the replacement of bone marrow cells with 
those expressing LDLR increased atherosclerotic lesions in a dose-dependent manner compared 
with mice transplanted with cells having no LDLR. In contrast, atherosclerosis in Apoe3/3 Ldlr–/– 
mice, expressing the human apoE3 isoform, did not differ by the levels of macrophage LDLR 
expression. Our results demonstrate that apoE4, but not apoE3, in macrophages enhances 
atherosclerotic plaque development in mice in an LDLR-dependent manner and suggests that this 
interaction may contribute to the association of apoE4 with an increased cardiovascular risk in 
humans.  
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Introduction 
Elevated levels of cholesterol in plasma, carried by remnant particles of very low density 
lipoproteins (VLDL) and low-density lipoproteins (LDL), are well known risk factors for 
atherosclerosis.  The bulk of these atherogenic lipoproteins are cleared from the circulation by 
the LDL receptor (LDLR) in the liver with apolipoprotein E (apoE) and apoB100 as ligands.  
There are three common apoE isoforms in humans: apoE2, apoE3, and apoE4, each having 
distinct influences on both lipid metabolism and atherogenesis in humans [6].  Possession of at 
least one copy of the APOE*2 allele is associated with higher plasma apoE and triglyceride but 
lower LDL cholesterol levels and atherosclerosis risk when compared to APOE*3 homozygotes 
[6].  In contrast, the presence of at least one APOE*4 allele is associated with lower plasma 
apoE, increased LDL cholesterol, and a greater risk of coronary artery disease than APOE*3 
homozygotes.  This association is thought to be mainly due to differences in lipoprotein 
clearance and is counterintuitive considering the LDLR affinity of apoE2 is lower while the 
affinity of apoE4 is slightly higher than apoE3 [13, 14].   
To gain insights into the mechanisms underlying the relationship between atherosclerosis 
risk and apoE isoform in humans, we previously made mice expressing human apoE2, apoE3, or 
apoE4 in place of the endogenous mouse apoE [14, 33, 34].  Notably, the atherosclerosis risk 
associated with the resulting mice was different from that in humans; mice with apoE2 had 
increased plasma lipids and develop atherosclerosis while mice with apoE3 and apoE4 were 
normolipidemic and resistant to atherosclerosis.  To further test whether the apoE isoform-
dependent atherosclerosis risk is affected by the LDLR expression, we also developed mice in 
which the endogenous mouse Ldlr gene was replaced with a gene (hLdlr) coding for human 
LDLR.  The transcriptional regulation of the hLdlr gene was normal but the steady state levels of 
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its mRNA in the liver were elevated because the transcripts carry a more stable 3’ untranslated 
region (UTR) sequence than normal.  Somewhat unexpectedly, we found that, when this hLdlr 
allele was introduced into mice expressing human apoE isoforms, physiologic overexpression of 
the LDLR was protective in mice with apoE2 but caused severe atherosclerosis in mice with 
apoE4, recapitulating the associations between apoE isoforms and atherosclerosis risk seen in 
humans [39, 69].  These data suggest that the LDLR apoE interaction is central to the increased 
atherosclerosis risk associated with apoE4.  
A substantial portion of the atherosclerosis risk associated with apoE4 is likely due to its 
hepatic metabolism by the LDLR and the resultant changes to plasma lipids.  However, there is 
ample in-vitro evidence that apoE’s interaction with the LDLR in the liver may not be entirely 
responsible for the risk of coronary artery disease associated with apoE4 in humans [50, 56, 70].  
Both ApoE and the LDLR are expressed in many cell types and are thought to play roles in the 
atherosclerotic process beyond their role in lipoprotein clearance [71].  The effects on 
atherogenesis of apoE isoforms and levels of LDLR in extrahepatic tissues, for example in 
macrophages, are difficult to study in vivo because their combined effects on plasma lipids are 
confounding.   
Herein, we address the effect of LDLR expression level and human apoE3 and E4 
isoforms on lipoprotein uptake and efflux in macrophages isolated from mice having human 
apoE isoforms and different levels of LDLR expression.  We also examined in vivo whether the 
interactions between apoE and LDLR in macrophages, independent of global LDLR expression, 
affect atherosclerosis after bone marrow transfer (BMT) in  mice expressing human apoE3 or 
apoE4 and lacking LDLR (3ko or 4ko) [72].  We found that the expression of LDLR in 
macrophages directly correlated with the extent of atherosclerosis in mice with human apoE4.  In 
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contrast, macrophage LDLR expression did not affect atherosclerosis in mice expressing apoE3.  
These results indicate that apoE4 exerts adverse effects on bone marrow derived cells in the 
vessel wall in an LDLR dependent manner and may contribute to its pathogenesis.   
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Material and Methods 
Mice - All the mutant mouse strains used in this work were individually backcrossed at 
least 6 generations to C57BL/6 genetic background before intercrossing.  Mice heterozygous for 
a targeted replacement of the mouse Ldlr gene with the stabilized human Ldlr minigene 
(Apoe+/+Ldlrh/+) [37] were bred to mice homozygous for replacement of the mouse apoE gene 
with either the human APOE*3 or APOE*4 allele (Apoe3/3Ldlr+/+ and Apoe4/4Ldlr+/+) [14, 33, 34]. 
The littermates generated by crossing Apoe3/3Ldlr+/+ (3m) with Apoe3/3Ldlrh/+ (3h) and 
Apoe4/4Ldlr+/+ (4m) with Apoe4/4Ldlrh/+ (4h) respectively, were used in experiments as donors of 
bone marrow cells.  Mice with human APOE*3 and lacking LDLR (3ko) and mice with human 
APOE*4 and lacking LDLR (4ko) were generated by crossing either Apoe3/3 or Apoe4/4 mice with 
Ldlr-/- mice [39], and maintained as Apoe3/3 Ldlr-/- (3ko) or Apoe4/4 Ldlr-/- (4ko) respectively (see 
Table 3.1 for genotypes and nomenclature).  Mice were fed either normal mouse chow (NC) 
containing 4.5% (wt/wt) fat and 0.022% (wt/wt) cholesterol (Prolab RMH 3000, Agway Inc) or a 
high-fat Western-type diet (HFW) containing 21% (wt/wt) fat and 0.2% (wt/wt) cholesterol 
(TD88137; Teklad).  The animals were handled under protocols approved by the Institutional 
Animal Care and Use Committees of the University of North Carolina–Chapel Hill. 
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Table 4.1 Genotypes of mice  
Mice Genotype Description 
3m Apoe3/3, Ldlr+/+ human apoE3 
3h Apoe3/3, Ldlrh/+ human apoE3 and increased LDLR 
3ko Apoe3/3, Ldlr-/- human apoE3 and no LDLR 
4m Apoe4/4, Ldlr+/+ human apoE4 
4h Apoe4/4, Ldlrh/+ human apoE4 and increased LDLR 
4ko Apoe4/4, Ldlr-/- human apoE4 and no LDLR 
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Peritoneal Macrophage Isolation - Macrophages (MPM) were obtained from the 
peritoneal cavity of mice 4 days after intra-peritoneal injection of 1 ml of 4% (w/v) thioglycolate 
(Becton Dickinson). The cells obtained were either directly used for gene expression analyses 
(below) or washed with Ham's Nutrient Mixture F10 media (F10), spun at 1000g for 5 minutes 
and plated in 12-well plates at a density of 6 x 105 cells/well in F10 media supplemented with 
10% Fetal Bovine Serum, 100 U/ml penicillin, 100 µg/ml streptomycin and 2 mM L-glutamine.  
Cells were washed 2 hours later to remove non-adherent cells.  Cells were cultured in media 
without FBS for 24 hours prior to experiments. 
 
Lipoprotein Uptake - LDL was isolated from human plasma as described [69].  Mouse 
VLDL fractions enriched with human apoE3 or apoE4 were isolated from pooled plasma of 3ko 
or 4ko mice respectively by ultracentrifugation at d<1.006.  Lipoproteins were labeled with 1,1′-
dioctadecyl-3,3,3′,3′- tetramethylindocarbocyanine perchlorate (DiI C18; Molecular Probes Inc., 
Eugene, Oregon, USA), as described by Stephan and Yurachek [73].  Macrophages in culture 
were washed and incubated in F10 medium without FBS for 24h, followed by incubation with 
medium containing 1µg/ml of DiI -labeled human LDL or mouse VLDL.  After 2hrs, cells were 
washed with fresh medium and fluorescence was observed with an IX70 inverted microscope 
(Olympus) equipped with a filter set for Texas red (exciter 560/55, dichroic 595, emitter 645/75; 
Chroma Technology Corp).  Fluorescence pixel intensity of each cell was recorded with a SPOT 
RT Slider digital camera, and analyzed with SPOT version 4.0.9 (Diagnostic Instruments) and 
ImageJ 1.33u (NIH) software.    
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Cholesterol Efflux- MPM were cultured 24 hrs in F10 medium without FBS.  Cells were 
radio-labeled by incubating with 2 µCi/ml [3H] cholesterol (Perkin Elmer) for 24hrs. They were 
then washed and further incubated for 24hrs with F10 media with or without 10 µg/ml of 
apolipoprotein A-I (apoA-I) protein (Sigma).  Following incubation, medium was removed, spun 
at 12,500 g for 15 min, and assayed for radioactivity. Cells were washed with ice-cold PBS, 
lipids were extracted with isopropanol for 4 hrs, and assayed for radioactivity.  Radiolabel in the 
medium and the cellular isopropanol extract was measured, and percentage effluxed was 
calculated as the ratio of radioactivity in the medium divided by the total (cells + media).  To 
analyze efflux of cholesterol from cholesterol-loaded foam cells, MPM were incubated with 
acetylated human LDL (AcLDL) and 2 µCi/ml [3H]-cholesterol for 24 hrs, and efflux was 
measured after 16 hrs.  LDL (density1.019-1.063 g/ml) was acetylated by acetic anhydride [74]. 
 
Western blot - To measure ApoE protein content, MPM in culture were washed and 
cultured in lipid free F10 medium.  After 24 hrs, apoE protein amount associated with cells and 
in the medium was a measured using Western blot with antibody against human apoE 
(Calbiochem).  Protein loading was controlled by the amount of tubulin using anti-tubulin 
antibody (Sigma) and gel to gel control for densitometric analysis was done with a standard 
amount of apoE. 
 
Oxidative Stress- VLDL (1 µg protein) from the 3ko or 4ko mice was incubated with 
10µM CuSO4 as described [49].  Oxidation and the increase in the formation of conjugated 
dienes were measured by recording their absorbance at 234 nm every 20 min for 3hrs.  The lag 
time was determined graphically.  Amounts of thiobarbituric acid-reactive substances (TBARS) 
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in plasma, VLDL, and cultured media were assayed as described [49].  MPM were cultured with 
VLDL isolated from apoE deficient mice (50 µg per ml F10 medium) for 24hrs. Oxidized VLDL 
was prepared by incubating VLDL in 10µM CuSO4 for 24 hrs. 
 
Gene Expression - RNA was extracted from MPM using RNAeasy kit (Qiagen, Valencia, 
California, USA) according to the manufacturer’s protocol, either directly from peritoneal cells 
of mice that underwent BMT or cultured MPM from mice fed HFW diet.  Cultured macrophage 
cells were incubated with F10 media or F10 media + 50 µg/ml apoE-deficient VLDL for 16hrs.  
Real-time RT-PCR amplifications (8) were performed in a 96-well plate in the ABI Prism 7700 
sequence detector (PE Biosystems) in a total volume of 30 µl, which included 10 µl of RNA 
sample from the ABI Prism 6700 plus 20 µl of a reaction mixture. Each RT-PCR amplification 
was performed in duplicate: 30 min at 48°C for the RT reaction, then 10 min at 94°C, followed 
by a total of 40 temperature cycles (15 sec at 94°C and 1 min at 60°C). During the amplification, 
the fluorescence of FAM (or TET), TAMRA, and ROX (a passive reference dye) was measured 
by the 7700 sequence detector in each well of the 96-well plate.  To determine total Ldlr mRNA 
levels, a primer probe system specific for murine exon 1, which is also present in mice targeted 
for the hLdlr, was used [37].   
 
Bone Marrow Transfer - Bone marrow cells were collected from the femurs and tibias of 
donor male mice by flushing with F10 media.  Recipient female mice, 6- 8 weeks of age, were 
lethally irradiated (9.5 Gy), and injected with 2x106 bone marrow cells in 0.2 ml medium 
through tail veins.  For 2 weeks after transplantation, mice were given drinking water acidified to 
pH 2.0 by HCl and containing 100 mg/L of neomycin.  Mice were fed a HFW diet for 3 months. 
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 Plasma Lipids, Lipoprotein Analysis - Plasma was isolated, and total cholesterol (free 
and esterified), and triglycerides were measured as described previously [39]. Lipoprotein 
distribution in pooled plasma samples (100 µL) was analyzed by fast protein liquid 
chromatography (FPLC) using a Superose 6 HR10/30 column (Pharmacia Biotech Inc., 
Piscataway, New Jersey, USA).   
 
Evaluation of Atherosclerotic Lesions - BM recipient mice were fed a high fat western 
diet (HFW) for 12 weeks before sacrifice. Mice were perfused through the apex of the left 
ventricle with 4% paraformaldehyde under physiological pressures. Segments of the aortic sinus 
were embedded, and sectioned, and the size of atherosclerotic plaques in aortic roots were scored 
as described previously [75].  
 
Statistical Analysis - The statistical significance of genotype effects were analyzed by 
using ANOVA (JMP software; SAS Inc., Cary, North Carolina, USA). Tukey-Kramer HSD was 
used for post-hoc pair-wise comparisons. 
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Results 
Downregulation of the LDLR Expression by Lipid in Macrophages - Our previous work 
[37, 39] showed that the 3’UTR modification within the hLdlr -allele made its transcripts in the 
liver more stable than the normal mouse allele, but the hLdlr -allele retained the transcriptional 
repression in response to dietary cholesterol intake. To test whether the expression of the hLdlr - 
allele is also normally regulated in macrophages by exogenous lipid, we isolated MPM from 3m, 
3h, 4m and 4h mice (see Table I) and placed them in culture. Both 3h and 4h MPM cells cultured 
for 16 hrs without VLDL had higher LDLR expression than 3m and 4m MPM cells by 
approximately 3-4 fold (Fig 4.1, p≤0.0001).  The levels of Ldlr mRNA decreased in all MPM 
cells when they were incubated with apoE-deficient VLDL for 16 hrs, and the decrease was 
proportional whether cells had wildtype or elevated LDLR.  However, cells with apoE4 had a 
greater proportional decreases in LDLR expression compared to cells with apoE3.  Thus the 
hLdlr gene in macrophages retains its normal feedback response to increased intracellular lipid 
and can be downregulated by high levels of lipid, but its transcripts remain 2-3 fold higher than 
the wildtype Ldlr mRNA.  
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Figure. 4.1. Expression of the Ldlr gene in the primary culture of mouse peritoneal 
macrophages.  MPM from 3m, 3h, 4m, and 4ko mice were cultured in lipid free F10 medium 
with or without 50 µg/ml of VLDL isolated from apoE-deficient mice for 16 hours.  Total 
mRNA amount for the Ldlr gene was measured by RT-PCR, using the exon 1 sequence that is 
common between wild type mouse allele and hLdlr allele, normalized with the beta actin 
expression and shown as expression levels of 3m equal to 100%.  White bars indicate expression 
in cells cultured with VLDL and black bars indicate without VLDL. *p≤0.05, ***p≤0.0005 for 
effect of VLDL , and ### p≤0.0005 for the effect of LDLR with Tukey-Kramer HSD.  
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LDLR Expression and Lipoprotein Uptake in Macrophages – To test whether increased 
expression of the LDLR in macrophages increases uptake of lipoproteins we isolated MPM from 
4ko, 4m, and 4h mice and incubated them with DiI-labeled human LDL in culture.  After two 
hours, intracellular fluorescent intensity in 4h macrophages was twice that of 4m macrophages 
and three times higher than 4ko cells (Figure 4.2A), demonstrating that the LDL uptake by 
macrophages directly correlates with LDLR expression. In hyperlipidemic mice, as well as 
humans, lipoprotein particles accumulate not only in LDL fractions but also in VLDL fractions. 
For example, in the plasma of LDLR -/- mice with human apoE, VLDL particles are enriched 
with cholesterol and triglyceride, as well as apoE protein [69].  We therefore incubated the MPM 
with VLDL fractions enriched in apoE3 or apoE4 from 3ko and 4ko mice.  Uptake of the mouse 
apoE3 enriched VLDL particles by 3h MPM was modestly but significantly increased compared 
to that by 3ko MPM (9%, p=0.02, Figure 4.2B). Uptake of apoE3 enriched VLDL by the 4h 
MPM was not different from the uptake by the 4m MPM.  In marked contrast, both 3h and 4h 
MPM incorporated significantly more apoE4 enriched VLDL than 3ko and 4ko MPM (33%, 
p≤0.0001, and 26%, p≤0.0001, respectively) (Figure 4.2C).  This suggests that the apoE isoform 
present on the VLDL particle and the LDLR in the macrophages, but not macrophage apoE, 
influences uptake, and that apoE4 in the particles promotes VLDL uptake more than apoE3.  
Taken together, the data suggest that increased LDLR in macrophages by mRNA stabilization 
causes increased uptake of LDL particles as well as VLDL particles, and the VLDL uptake 
would be more pronounced when the particles contain apoE4 rather than apoE3. 
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Figure 4.2.  Lipoprotein uptake. (A)  MPM from 4ko, 4m, and 4h mice were cultured and 
incubated for 2hr with 1µg/ml DiI labeled human LDL. Cells were washed three times with PBS 
and fluorescent intensity was measured using NIH Image J.  (B) MPM from 3ko, 3h, 4ko and 4h 
mice were incubated for 2hrs with 1µg/ml each of DiI labeled 3ko VLDL, or (C) 4ko VLDL.  
Pixel intensities reflecting VLDL uptake were measured from four wells per experiment with 
cells pooled from at least 3 mice of each group, and averages of three experiments are shown as 
mean uptake of 3ko cells as 100%.  Effect of VLDL *p≤0.05, ***p≤0.0005 with Tukey-Kramer 
HSD. 
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Effects of ApoE4 and LDLR Expression on Cholesterol Efflux from Macrophages - To 
examine whether the different apoE isoforms facilitate cholesterol efflux from macrophages 
differently and whether the effect is dependent on the levels of LDLR expression in 
macrophages, we measured cholesterol efflux from MPM isolated from mice expressing human 
apoE isoforms with high levels of LDLR (3h and 4h) or without LDLR (3ko and 4ko).  In 
unloaded cells expressing, cholesterol efflux was not influenced by the LDLR expression when 
cells were incubated without apoA-I.  In contrast, the LDLR expression had a significant effect 
when cells expressed apoE4, and the efflux from the 4h cells was 30% less than from 4ko cells 
(p≤0.0005, Figure 4.3A). Addition of apoA-I to the culture medium increased cholesterol efflux 
from cells regardless of apoE isoforms (Figure 4.3B).  ApoA-I-mediated efflux from the 4h cells 
with elevated expression of LDLR was significantly higher than 4ko cells not expressing LDLR.  
The difference was larger and significant between 4ko and 4h cells (p<0.003), than between 3ko 
and 3h cells (not significant).  In contrast, efflux of cholesterol from cholesterol loaded foam 
cells after incubation with AcLDL depended on LDLR but not on apoE genotype (Figure 4.3C).  
These data demonstrate that the LDLR expression in macrophages influences the cholesterol 
efflux in an apoE isoform dependent fashion when macrophages are cultured in lipid free media, 
and suggest that both apoE isoform and LDLR expression may be important determinants for 
foam cell formation. However, when cells were loaded with AcLDL, apoE-isoform effects were 
no longer detectable.   
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Figure 4.3.  Cholesterol efflux from MPM.   Thioglycolate-elicited MPM were isolated from 
mice and incubated with [3H] cholesterol for 24hrs. Cells were then washed and incubated 24hrs 
in media without FBS (A)  or with the same media containing 10 µg/ml of apoA-I for 24 hr (B). 
Radiolabel in medium and the cellular isopropanol extract were quantified, and percentage efflux 
was calculated as the ratio of radioactivity in the medium divided by total radioactivity (cells + 
media) x 100%. Data are mean ± SE for 3 mice of the indicated genotypes assayed in 
quadruplicate. (C) Cholesterol efflux from MPM loaded with 50 µg /ml AcLDL and [3H] 
cholesterol for 24hrs.  (D) ApoE that is cell-associated or secreted into culture medium from 
MPM incubated for 24 hrs in lipid free media.  *p≤0.05,  **p≤0.005, ***p≤0.0005. 
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ApoE secretion from cultured MPM- To address whether cholesterol efflux is related to 
the intracellular levels of apoE isoforms, we examined the apoE contents associated with cells 
and in medium 24hrs after culturing in lipid-free F10 medium by Western blot analysis. The 
intracellular apoE contents in both 3h and 4h cells were consistently higher than in 3ko and 4ko 
cells (Figure 4.3D).  Similarly, apoE protein contents in culture media of 3ko and 4ko cells were 
lower than those of 3h and 4h cells. Relative amounts between apoE3 cells and apoE4 cells 
somewhat varied culture by culture, and were not consistently different.  We conclude that 
LDLR expression in MPM significantly affects apoE uptake and secretion, and likely influences 
the cholesterol efflux. 
 
VLDL Oxidation- We next tested whether lipoprotein oxidation in our mice is apoE 
isoform-dependent which may be due to the free cysteinyl groups on apoE3 and apoE2 [49, 50].  
ApoE2 has two free cysteinyl groups and apoE3 has one, and both have been shown to function 
as a better antioxidant than apoE4 protein which has no free cysteinyl group. We isolated human 
apoE-enriched VLDL particles from 2ko, 3ko, and 4ko mice, and tracked conjugated diene 
formation during Cu2+ -mediated oxidation of these lipoprotein particles. The lag time for 
conjugated diene formation was 24 min in VLDL isolated from 4ko mice compared to 49 min in 
VLDL from 3ko mice and the longest, 70 min, in 2ko VLDL (Figure 4.4A).  Measurement of 
thiobarbiturate reactive substances (TBARS) after overnight oxidation showed that apoE4-
VLDL contained 3-fold more TBARS than did apoE3-VLDL (Figure 4.4B).  
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Figure 4.4.  VLDL oxidation.  (A) VLDL from 3ko and 4ko mice (1 µg) was incubated with 
10µM Cu2+.  Ordinate shows lag time, average of three experiments, until inflection point on 234 
nm absorption curves. (B) TBARS after Cu2+ oxidation of VLDL isolated from 3ko and 4ko 
mice.  TBARS were measured after 16 hr incubation with 10µM Cu2+ at 0.5 mg protein/ml.  (C) 
TBARS in the media of MPM incubated with VLDL in culture.  Thioglycolate-elicited MPM 
isolated from either 4ko or 3ko mice was incubated with 50 µg/ ml of apoE-deficient VLDL.  
TBARS in media were measured after 24 hrs.   *p≤0.05, **p≤0.005,  ***p≤0.0005 with Tukey-
Kramer HSD. 
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To test whether expression of LDLR in macrophages influences VLDL oxidation in an 
apoE-dependent manner, we next cultured MPM in medium with apoE-deficient VLDL for 24 
hrs, and measured TBARS in media as an indicator for oxidized lipids.  The amounts of TBARS 
were borderline detectable, and were slightly higher in media cultured with apoE4 macrophages 
than with apoE3 and lower with elevated LDLR than with no LDLR, but neither apoE genotype 
nor LDLR had statistically significant effects by two-way ANOVA. These data suggest that 
apoE4 isoform does not protect lipoprotein particles from oxidation as well as apoE3 when a 
strong oxidative stress is applied in vitro.  However, effects of apoE isoforms in macrophages on 
oxidation in culture are not significant, even under conditions of elevated triglycerides and 
cholesterol. In addition, we did not detect any statistical differences in the amount of TBARS or 
reduced glutathione (GSH) in the plasma of 3ko and 4ko recipient mice (data not shown). 
 
BMT, and Plasma Lipids- The experiments above indicate that apoE4 proves to be 
impaired relative to apoE3 in several pathways important to lipid homeostasis in macrophages 
and perhaps atherosclerosis lesion formation, and the effects are influenced by the levels of 
LDLR expression in macrophages.  To test whether the observed differences could alter overall 
atherogenesis in vivo, we carried out BMT in mice lacking LDLR but expressing human apoE3 
(3ko) or apoE4 (4ko). To alter macrophage expression of LDLR, 3ko or 4ko females were 
lethally irradiated and transplanted with BM isolated from male mice with the same ApoE 
genotype, having no LDLR (3ko, 4ko), wild type LDLR (3m, 4m), or elevated expression of 
LDLR (3h, 4h).  Three months after BMT, PCR of the Ldlr gene in the blood cells of the 
recipient animals showed only the products corresponding to the genotype of the donor cells, and 
no visible products corresponding to the recipient genotype (ko) were detected in the mice that 
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received (m) or (h) BM cells (Figure 4.5A). This confirmed that the replacement of the BM 
derived cells in the recipients by the donor cells was likely complete. The total Ldlr mRNA 
levels in the peritoneal cells isolated from representative recipient mice showed that the 
macrophages in the 3ko mice receiving 3h BM cells had 4 fold higher Ldlr gene expression than 
the macrophages in the 3ko mice receiving 3m BM cells.  Similarly, total expression of the Ldlr 
gene in macrophages from the 4ko mice receiving 4h BM cells was 4 fold higher than in those 
receiving 4m cells (Figure 4.5B).  Thus the levels of Ldlr mRNA in mice that received 3h or 4h 
bone marrow are elevated compared to those in mice that received wildtype LDLR to similar 
degrees as the MPM cells in culture as shown in Figure 4.1A.   
Feeding HFW diet increased plasma cholesterol levels approximately 3-fold in both 3ko 
and 4ko mice regardless of donor Ldlr genotype (Table 4.2). Both 3ko and 4ko mice have 
elevated cholesterol in VLDL fractions as well as LDL fractions. HDL-cholesterol were very low 
in both 3ko and 4ko mice on HFW diet, and the plasma apoA-I levels were not different between 
them (not shown). The transfer of bone marrows with differing expression levels of LDLR did 
not cause any significant changes in plasma lipoprotein distribution in either the 3ko or 4ko mice 
by fast protein liquid chromatography analyses (Figure 4.5C).  We conclude that the increased 
macrophage LDLR expression is not sufficient to alter plasma VLDL clearance in the LDLR -/- 
mice with apoE3 or apoE4. Consistent with previous work, the LDLR expression in BM-derived 
cells had no influence over plasma lipid profiles [57]. 
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Table 4.2.Plasma lipids expressing human apoE3 or apoE4 after BMT and fed HFW diet 
BM Recipient 3ko 3ko 3ko  
 
4ko 4ko 4ko 
BM Donor  3ko 
 
3m 
 
3h 
 
 4ko 4m 
 
4h 
 
Number 15 15 15  14 15 12 
TC (mg/dl) 1,324±57 1,313±46 1,394±23  1,245±49 
 
1,217±43 1,184±97
TG (mg/dl) 186±61 177±43 221±16  111±17 95±22 133±17 
 
Table 4.3.  Lipids and atherosclerosis in LDLr-/- mice expressing human apoE3 or apoE4 fed a NC diet  
Mice 3ko 3ko 4ko 4ko 
gender Male Female Male Female 
Number 11 12 12 12 
TC (mg/dl) 241±18 386±12 313±25 427±32 
TG (mg/dl) 109±12 102±6 225±22 114±2 
Lesion size 
(103µm2) 
13.4±3.1 55.5±7.2 12.0±2.7 71.0±14.4
Occlusion (%) 1.3±0.3 5.1±0.5 1.0±0.2 5.4±0.8 
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Figure 4.5.  Bone Marrow transfer.  (A), Verification of bone marrow engraftment. DNA was 
isolated from buffy coat cells of recipient mice, and Ldlr genotype was determined by multiplex 
PCR.  First seven lanes are recipients of ko cells showing a single PCR fragment.  Next six lanes 
are recipients of hLdlr cells showing two bands; the upper band corresponds to the wild type 
mouse Ldlr allele and the lower band corresponds to the hLdlr allele.  The last four lanes are 
recipients of m-Ldlr cells showing only the wild type allele.  No bands corresponding to the ko 
allele was detected in the recipients of h or m cells.   (B), Macrophage Ldlr mRNA level.  
Thioglycolate-elicited peritoneal cells were collected from bone marrow transfer recipients. 
Real-time quantitative PCR was used for Ldlr mRNA levels using exon 1 sequence that is 
common to hLdlr and wild type alleles. Averages from mice are shown relative to the expression 
of 3m-donor as 100. **p≤0.005,  ***p≤0.0005.  (C), Lipoprotein distribution in plasma isolated 
from the 3ko or 4ko recipient mice that received BM cells with different Ldlr expression levels.  
Plasma (100 µl) pooled from at least five mice of each group was size-fractionated on an FPLC 
Superose 6 column, and the cholesterol and triglyceride contents of each fraction were measured 
with an enzymatic assay.  
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Macrophage LDLR Expression and Atherosclerosis in Mice with ApoE4 – Both 3ko and 
4ko mice develop lesions in the aortic sinus as summarized in Table 4.3.  Feeding the recipient 
mice with HFW diet for 12 weeks increased atherosclerotic plaque size in both 3ko and 4ko mice 
which received either control 3ko or 4ko BM.  There were no significant apoE genotype effects 
on the lesion area (346 ± 19x103 µm2, n=12, in 3ko vs. 386 ± 28x103 µm2, n=14, in 4ko, p=0.3; 
Figure 4.6).   
We also found no change in the lesion area of 3ko mice as macrophage LDLR level 
increased (Figure. 6).  Thus 3ko mice that received 3m and 3h BM had a mean area of 356 ± 
28x103µm2 (n=13), and 338 ± 28x103 µm2 (n=13) respectively p=0.9.  In contrast, 4ko mice 
developed larger lesions as their macrophages expressed increasing amounts of LDLR.  Thus 
4ko mice that received 4m BM and 4h BM had mean lesion areas of 459 ± 41x103 µm2 (n=15) 
and 511 ± 34x103 µm2 (n=13), respectively.  The difference between the lesion sizes in mice that 
received 4h donor cells and 4ko donor cells was significant (p≤ 0.05).  When all six groups were 
analyzed together, the difference in atherosclerosis between 3ko mice with 3h BM and 4ko mice 
with 4h BM was also significant (p≤0.01).  
Taken together, our data demonstrate that there is an interaction between the apoE 
genotype and LDLR expression of macrophages in determining atherosclerosis development.  In 
the LDLR-/- mice, increased expression of LDLR in BM derived cells has no effect when 
animals are expressing apoE3, while it is detrimental in mice expressing apoE4.  
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Figure 4.6.  Atherosclerotic lesions.  Mean aortic sinus atherosclerotic lesion areas of 3ko mice 
that received 3m, 3h, and 3ko BM cells and of 4ko mice that received 4m, 4h, and 4ko BM cells 
are shown. *p≤0.05 (4ko vs 4h)  , # p≤0.01 (3h vs 4h) with Tukey-Kramer HSD. 
97 
 
98 
Gene Expression in the Peritoneal Macrophages of Mice after BMT- To gain insight into 
the mechanism of the interaction between macrophage LDLR expression and apoE expression in 
atherosclerosis development, we isolated MPM from mice receiving BM transfer 4 days after 
stimulation with thioglycollate. Quantitative RT-PCR of peritoneal cells showed that the 
expression of genes coding for monocyte chemotactic protein-1 (MCP1), CD36, LDLR, apoE, 
and scavenger receptor A (SR-A) were not significantly different among recipients who received 
the donor cells with different LDLR levels (Table 4.4).  Thus the effect of apoE4 isoform and 
LDLR level in atherogenesis does not appear to involve pathways affecting expression of MCP1, 
CD36, or SR-A in macrophages. In contrast, ABCA1 expression was increased in MPM that 
expressed elevated LDLR compared to ko MPM regardless of apoE genotype, although the 
increases was statistically significant only in 3h cells compared to 3ko cells.  The up-regulation 
of ABCA1 in 3h and 4h macrophages may indicate higher intracellular cholesterol content in 
these cells relative to 3ko and 4ko cells [76, 77]. This is also consistent with an increased 
cholesterol efflux from 3h and 4h macrophages compared to 3ko and 4ko macrophages when 
exogenous apoA-I acceptor protein  is given to the culture (Figure 4.3B). 
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Table 4.4. Relative mRNA levels of the genes were calculated by the ratio of expression to the levels of 
β-actin mRNA.  Values are mean ±SE and relative to 3ko which was adjusted to 100.  ABCA1 levels 3h 
cells were significantly different from 3ko. *p≤0.05 
 
Table 4.4.  Gene expression of peritoneal macrophage isolated from BM recipients 
Recipient 3ko 3ko 3ko  
 
4ko 
 
4ko 4ko 
macrophage 3ko 
 
3m 3h  4ko 
 
4m 4h 
 
Number 6 7 8  6 
 
2 8 
ABCA1 100±9 126±22 210±32*  111±14 76±4 156±20 
MCP1 102±8 74±17 97±11  79±22 107±22 62±33 
CD36 100±23 102±27 118±25  102±12 
 
70±6 111±12 
SR-A 104±13 64±10 72±23  67±14 
 
78±7 52±10 
ApoE 101±7 125±27 116±21  119±30 108±44 156±28 
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Discussion 
ApoE, as a ligand for the removal of lipoproteins, is generally considered atheroprotective; 
however, the extent to which depends on its isoform, concentration, and location [3, 6, 16, 78].  In this 
study, we tested the interaction of apoE isoforms with LDLR on several atherosclerosis pathways in 
macrophages.  We then used BMT in mice to investigate whether their interaction in macrophages affect 
atherosclerosis development.  Our results showed that expression of macrophage LDLR in the presence of 
apoE4 enhanced atherosclerosis.  In contrast, these same LDLR increases in mice with apoE3 did not 
affect atherosclerosis.  Thus, our results demonstrate, for the first time in animal models, that some of the 
risk associated with human apoE4 isoform may be due to its interaction with the LDLR in macrophages 
as well as with hepatic LDLR.   
We found that apoE isoforms expressed by the macrophages had only a modest, nonsignificant 
effect on apoA-I-stimulated cholesterol efflux from MPM, but that the levels of LDLR expressed by the 
macrophages significantly increased apoA-I-assisted cholesterol efflux from apoE4 macrophages and less 
so from apoE3 macrophages.  Cholesterol efflux, when apoA-I was not present, was generally low but 
affected by LDLR expression only in apoE4 macrophages and in an inverse direction.  Thus, high LDLR 
expression did not alter efflux from macrophages with apoE3, but significantly inhibited efflux from 
macrophages with apoE4. A likely explanation for this is that apoE4 is more efficient than apoE3 for 
capturing and re-uptake of cholesterol containing particles by macrophages. Alternatively, the possible 
increased amount of intracellular apoE4 compared to apoE3 may retard cholesterol secretion with the 
endogenous apoE thus yielding the apparent difference in efflux. In contrast, in cholesterol-loaded foam 
cells, high LDLR expression inhibited efflux in both apoE3 and apoE4 macrophages. The interaction 
between LDLR and apoE4 resulted in significant effects only in un-loaded cells in which LDLR 
expression is high. The difference in efflux between apoE3 and E4 is small in loaded foam cells, in which 
expression of LDLR is down regulated.  In the present work, we observed that cultured MPM expressing 
LDLR have more cell-associated apoE than MPM without LDLR regardless of apoE genotype. 
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Nevertheless, the difference between apoE3 and E4 in intracellular trafficking and accumulation has been 
established [79] and may be contributing to the difference in cholesterol efflux.  Supporting this 
possibility, we reported earlier, in collaboration with Dr. Mazzone and his colleagues at the University of 
Illinois, that MPM with increased LDLR expression showed reduced apoE secretion compared to MPM 
with basal LDLR expression and that the relative reduction was greater with apoE4 than with apoE3. 
Further studies are necessary to elucidate the possible relationships between cholesterol efflux and 
intracellular localization of apoE3 and apoE4 in MPM.  [80].  
Increased cholesterol uptake increases ABCA1 expression and efflux to acceptor proteins [76, 
77].  Thus we observed that macrophages isolated from Ldlr-/- mice receiving BM cells with high Ldlr 
gene expression showed elevated ABCA1 expression. This increase in ABCA1 expression likely accounts 
for the increased apoA-I-mediated cholesterol efflux in the presence of LDLR in macrophages.  In 
addition, the presence of a large amount of apoA-I could interfere with the apoE-mediated re-uptake of 
lipid particles.  Our observation of isoform-specific effects of apoE on cholesterol efflux is consistent 
with previous reports by other investigators.   For example, Cullen et al. observed using macrophages 
isolated from human subjects with different apoE isoforms, that apoE4 macrophages effluxed less 
cholesterol than apoE2 or apoE3 and suggested that a combination of enhanced uptake and degradation of 
apoE4 by macrophages leads to lower cholesterol efflux [56]. Similarly, in a murine macrophage cell line, 
Hara et al. demonstrated that adenovirus-mediated expression of apoE isoforms reduced cellular 
cholesterol in a manner inversely proportional to the LDLR affinity of apoE [81]. Effects of LDLR were 
not investigated in either study by Cullen et al. or Hara et al.  
 The apoE3 and apoE2 proteins carry either one or two free cysteinyl groups respectively, and 
may function as a better antioxidant than apoE4 protein which does not have a free cysteinyl group. It has 
been shown in vitro that lipoprotein oxidation is apoE isoform-dependent [49, 50].  Similarly, we show 
that lipid peroxidation in vitro by Cu2+ of mouse VLDL particles enriched with apoE4 is more susceptible 
to lipid peroxidation than particles with apoE3 or apoE2. However, we were not able to demonstrate the 
antioxidant effects of apoE in-vivo.  Antioxidant effects of apoE in vivo are likely to be small. 
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Nevertheless, differences in the antioxidant capacity of apoE isoforms could be significant when excess 
oxidative stress is applied, such as in lipid-loaded macrophages in the atherosclerotic plaques. 
Many of the functions of apoE in vascular tissues are isoform-specific and have been implicated 
as contributing factors to the well-established increased atherosclerosis risk associated with apoE4 in 
humans.  For example, apoE has been shown to inhibit smooth muscle cell proliferation, with apoE4 
being less effective than apoE2 or apoE3 [82].  This anti-proliferative function may also be related to 
isoform dependent nitric oxide release [83].  ApoE has been shown to reduce atherosclerosis when 
expressed in the arterial wall without affecting lipid levels [46]. Human apoE3 expressed in macrophages 
binds LDLR and is internalized, and a proportion of the internalized apoE is recycled in both hepatocytes 
and macrophages [47, 48].  Consistent with its increased LDLR affinity, apoE4 recycling is impaired 
relative to apoE3 in hepatocytes [79].  Decreased recycling of apoE4 in the subendothelial space of blood 
vessels could result in prolonged retention and modification of lipoproteins.  In contrast, apoE3 and 
apoE2 may exert their anti-atherosclerotic effects multiple times if recycled back to the intimal space.  
 Macrophage LDLR metabolizes LDL and VLDL/chylomicron remnants [6, 20, 74, 84], and 
uptake of LDL by macrophages through the LDLR can induce foam cell formation in culture [84, 85].  
Thus previous studies have shown that WT mice that received BM cells with WT LDLR develop larger 
diet-induced plaques compared to the WT mice that received cells lacking LDLR [57, 85]. However, 
macrophage expression of the LDLR did not significantly increase atherosclerosis in the hyperlipidemic 
setting of LDLR-/- mice recipients when their macrophages expressed WT LDLR [57, 71, 86].  All of 
these experiments used mice with wild type mouse apoE and LDLR.  We now show, in the present paper, 
that the pro-atherogenic effects of human apoE4 isoform are LDLR expression dependent even under the 
severe hyperlipidemic setting.  Mice with apoE3 showed no difference in atherosclerosis when 
macrophage LDLR expression level was changed under the same hyperlipidemic condition. 
Together, our results show that there is an important interaction between the apoE genotypes and 
LDLR expression levels in macrophages in determining cholesterol regulation in the cell (Fig 4.7).  Thus 
the higher LDLR binding affinity of apoE4 increases cholesterol delivery to macrophages compared to 
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apoE3.  This effect is enhanced when lipoprotein particles are enriched with apoE4.  The pro-atherogenic 
effects of apoE4 are further enhanced by a reduction in sterol efflux that is also apoE4 specific and LDLR 
dependent.  This is particularly important when cholesterol acceptors such as HDL and apoA-I are 
reduced in hyperlipidemia. Additionally, the reduced capacity of apoE4 to protect lipoproteins from 
oxidation compared to that of apoE3 could increase the atherogenicity of apoE4 containing lipoproteins.  
Although differences in the individual effects of apoE4 compared to apoE3 are small, the combined 
effects are of importance and likely contribute to the adverse effects of apoE4 on plaque development in 
an LDLR dependent fashion in macrophages.  A similar mechanism is likely to operate in humans during 
the development of atherosclerosis.   
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Figure 4.7.  Hypothetical interactions between macrophage LDLR and apoE isoforms in mice 
that underwent BMT.  Increasing LDLR results in increased macrophage uptake of apoE 
containing VLDL and LDL (solid arrow). The relative uptake of apoE3 containing lipoproteins 
(A) is less than the uptake of apoE4 containing lipoproteins (B).  Elevated LDLR reduced efflux 
in macrophages that were loaded with cholesterol as well as unloaded apoE4 macrophages (open 
arrow).  ApoE3 has greater antioxidant capacity than apoE4. The antioxidant capacity increases 
as more apoE is retained by LDLR (shaded arrow).  Overall the combined effects are balanced in 
apoE3 macrophages and its atherogenicity is not influenced by LDLR expression.  In contrast, 
the combined effects are not balanced in apoE4 macrophage and the atherogenicity is increased 
as LDLR expression increases.  
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Abstract 
Apolipoprotein E (apoE) and the low-density lipoprotein receptor (LDLR) are both well-
recognized determinants of plasma cholesterol levels.  In this study, we investigated the 
contribution of the LDLR expression to the localization of human apoE-isoforms in the liver of 
mice.  Adenoviral overexpression of the LDLR decreased plasma cholesterol in mice with 
human apoE2, but led to a dramatic accumulation of cholesterol-rich VLDL in mice with human 
apoE4 on a western-type high fat diet. Primary hepatocytes with apoE2 secreted more apoE into 
medium than the hepatocytes with apoE4.  Higher LDLR expression decreased the secretion of 
apoE4 and increased its degradation.  ApoE4-GFP fusion protein expressed by adenovirus in the 
liver of apoE-deficient mice accumulated in the space of Disse, but apoE2-GFP protein did not.  
Additionally, LDLR levels significantly influenced the amount of apoE4-GFP on the hepatocyte 
surface.  While the liver of mice with apoE2 and high LDLR avidly internalized DiI-labeled 
VLDL, internalization was slower in the liver with apoE4 and high LDLR despite that the DiI-
VLDL accumulated quickly on the hepatocyte surface.  These data indicate that apoE4 co-
localizing with the LDLR on the surface of hepatocytes is a poorer mediator of VLDL uptake 
than apoE2 despite its higher LDLR binding-affinity. 
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Introduction 
The low-density lipoprotein receptor (LDLR) plays a pivotal role in clearance of 
lipoproteins thereby reducing plasma cholesterol, a leading determinant of atherosclerosis 
susceptibility [6].  Lipoprotein clearance is mediated through the binding to the LDLR of 
apolipoprotein E (apoE) and apolipoprotein B (ApoB), constituents of lipoproteins, in the liver 
where most of LDLR, apoB, and apoE production is found [15] [16]. 
 ApoE is a 34kDa exchangeable protein associated primarily with Triglyceride Rich 
Lipoproteins (TRL) and HDL [6].  In humans the APOE gene is polymorphic, resulting in 
production of three common isoforms apoE2, E3, and E4.  These isoforms differ from one 
another by an amino acid difference at two positions, E2 having a Cys at both position 112 and 
158, E3 having an Arg at 112 and a Cys at 158, and E4 having Arg at both positions.  These 
structural changes alter the LDLR binding affinity; apoE4 binds LDLR with highest affinity 
while apoE2 has drastically reduced binding compared to the other two isoforms [13, 14, 87].  
There is a well-established association between apoE-isoforms and different plasma 
lipid/lipoprotein phenotypes and coronary artery disease risk in humans.  Thus, although a 
majority of individuals homozygous for apoE2 have slightly higher plasma triglycerides and 
lower LDL cholesterol, 5-10% of them develop type III hyperlipoproteinemia characterized by 
significantly elevated plasma levels of triglycerides and cholesterol [6].  In contrast, possession 
of an apoE4 allele is associated with high LDL cholesterol, low plasma triglycerides and 
increased risk of atherosclerosis [2, 3, 6, 16, 19, 71].  The molecular mechanisms whereby the 
apoE isoforms and the LDLR affect these associations are still not clear, and mice with the wild 
type Apoe gene replaced with human APOE*2, APOE*3 and APOE*4 alleles do not simply 
replicate these phenotypes.  Thus all mice expressing apoE2 exhibit type III 
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hyperlipoproteinemia and develop atherosclerosis even on normal, low cholesterol and low fat 
diet, while those expressing apoE3 or apoE4 are normolipidemic and resistant to atherosclerosis 
development [14, 33, 34]. 
Previously we have shown that the Ldlrh allele coding for human LDLR, which has a 
truncation of the 3'-untranslated region, resulted in increased mRNA stability and 2-3 fold 
elevation of expression in mice [37-40].  Surprisingly, introduction of the Ldlrh allele into mice 
expressing human apoE isoforms reproduced the human-like phenotypes associated with apoE 
isoforms. On a HFW diet, mice with apoE4 over-expressing the LDLR (Apoe4/4Ldlrh/+) have 
increased plasma VLDL/Chylomicron Remnants, decreased HDL cholesterol levels, and develop 
atherosclerosis, while mice with human apoE3 and the Ldlrh allele (Apoe3/3Ldlrh/+) have 
significantly decreased HDL cholesterols as well as total cholesterol levels and do not develop 
atherosclerosis.  Global over-expression of LDLR in mice with apoE2 (Apoe2/2Ldlrh/+) resulted in 
lower plasma cholesterol and the absence of atherosclerotic lesions [37-40].  We hypothesized 
that the adverse effects of increased LDLR expression in mice with apoE4 is because the high 
affinity of apoE4 for the LDLR limits its availability for enrichment on larger TRL particles 
consequentially promoting a rapid conversion of these particles to poorly cleared smaller, 
cholesterol enriched remnants.   
This hypothesis predicts the following.  First, the over-expression of LDLR in the liver of 
mice with human apoE isoforms will replicate the phenotypes seen in mice with global LDLR 
expression.  Second, over-expression of apoE4 protein will overcome the hyperlipidemia in 
Apoe4/4Ldlrh/+ mice.  Third, a majority of apoE4, but not apoE2, proteins will co-localize with 
LDLR in the liver cells and accumulate proportionally to the LDLR expression levels.  In the 
present study we have tested these predictions using adenoviral mediated gene transfers.  We 
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show here that LDLR expression in the liver is sufficient, and likely responsible, for the 
hyperlipidemia in the Apoe4/4Ldlrh/+ mice.  We also show that a substantial amount of apoE4 and 
to a lesser extent apoE3, but not apoE2, is co-localized with LDLR to the surface of hepatocytes.  
This interaction with the LDLR increases the association of apoE4 with hepatocytes, limits 
apoE4 secretion, and enhances its degradation in primary cultured hepatocytes.   
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Material and Methods 
Mice- ApoE-deficient mice (Apoe-/-), LDLR-deficient mice (Ldlr-/-), mice homozygous 
for replacement of the mouse apoE gene with either the human APOE*2, APOE*3 or APOE*4 
allele (Apoe2/2. Apoe3/3, and Apoe4/4) and mice over-expressing the human LDLR minigene 
(Ldlrh/+) were individually backcrossed at least 6 generations to C57BL/6 genetic background 
[14, 33, 34, 37].  Mice with various combinations of the Apoe and Ldlr loci were produced by 
intercross of these mutants for the present work as listed in Table 5.1.  Mice were fed either 
normal mouse chow (NC) containing 4.5% (wt/wt) fat and 0.022% (wt/wt) cholesterol (Prolab 
RMH 3000, Agway Inc) or a high-fat Western-type diet (HFW) containing 21% (wt/wt) fat and 
0.2% (wt/wt) cholesterol (TD88137; Teklad). The animals were handled under protocols 
approved by the Institutional Animal Care and Use Committees of the University of North 
Carolina–Chapel Hill. 
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Table 5.1  Genotypes and Descriptions 
Mice Genotype Description 
Apoe2/2 human apoE2 
Apoe2/2 Ldlrh/+ human apoE2 and increased LDLR 
Apoe3/3 human apoE3 
Apoe3/3 Ldlrh/+ human apoE3 and increased LDLR 
Apoe4/4 human apoE4 
Apoe4/4 Ldlrh/+ human apoE4 and increased LDLR 
Apoe4/4 Ldlr-/- human apoE4 and no LDLR 
Apoe-/- no apoE 
Apoe-/- Ldlrh/h no apoE and increased LDLR 
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Culture of primary mouse hepatocytes—Mice were anesthetized using avertin (2,2,2-
tribromo ethanol), the portal vein was cannulated with a 24-gauge plastic cannula, and the liver 
was perfused with Ca2+/Mg2+-free Hanks' Balanced Salt Solution containing glucose (10 mM) 
and HEPES (10 mM) at a flow rate of 3 ml/min for 10 min. The perfusion was continued for 
another 10 min with the same solution containing collagenase (0.05%, type I, Sigma). The liver 
was removed from the animal, minced in phosphate buffered saline (PBS), and the dissociated 
cells were dispersed by shaking followed by filtration through 100-µm nylon cell strainers 
(Falcon). The liver capsule and dish were rinsed in Dulbecco's modified Eagle's medium 
(DMEM) containing 0.02 µg/ml dexamethasone, 100 units/ml of penicillin and 100 µg/ml of 
streptomycin. The cells were pelleted by gravity sedimentation in Percoll for 5 min. at 4 °C. The 
medium was aspirated, leaving 5 ml total volume, and fresh medium was added to 10 ml. The 
cells were resuspended and viability was assessed by trypan blue exclusion. The yield of 
hepatocytes ranged from 3x106 to 6x106 cells/g of liver, and viability was greater than 80%. The 
cells were plated onto 60-mm mouse collagen IV-coated dishes (Falcon) at a density of 1.2x106 
viable cells/dish in 2 ml of the above medium containing 10% FBS unless otherwise stated.  
 
Quantitation of apoE and apoA1— The medium from the primary hepatocytes was 
centrifuged at 13,000 x g for 10 min at 4 °C. Cell associated proteins were isolated from primary 
hepatocytes that were washed 3 times in PBS and  resuspended in 50 mM Tris-HCl, pH 8.0, 2 
mM CaCl2, 80 mM NaCl, and 1% Triton X-100 on ice for 10 min. After centrifugation for 10 
min with 13,000 x g at 4 °C, the supernatants were harvested and cell associated protein 
concentrations were determined by Bradford assay (Bio-Rad). Cellular proteins and media were 
separated by 4–15% SDS-PAGE gradient gels (Bio-Rad), and immunoblotted using goat anti-
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human apoE antibody (Calbiochem). After incubation with peroxidase-conjugated rabbit anti 
goat IgG antibody (Calbiochem), the reaction product was visualized using the ECL system 
(Amersham Biosciences).  Additionally apoE and apoA1 were quantitated by enzyme-linked 
immunosorbent assay (ELISA). 96 well immunoplates were coated with 1.5 µg/ml mouse 
monoclonal anti-human apoE antibody (calbiochem) or anti-apoA1 in 0.2 M Na2CO3/NaHCO3 
buffer.  
 
35S labeling of primary mouse hepatocytes-- Primary hepatocytes were cultured for 16 h 
in low glucose DMEM containing 1% bovine serum albumin. The cells were pulsed with 0.5 ml 
medium containing 35S methionine (100 µCi/ml Amersham).  After a 60 min pulse, the medium 
was removed, and the cells were washed twice with PBS and chased for 1 and 4 h in fresh 
medium with excess cold methionine. ApoE was immunoprecipitated from the media using a 
goat anti-human polyclonal antibody (Calbiochem). The precipitates were dissolved in sample 
buffer and separated by SDS-PAGE.  The gels were dried and signal was visualized by a Fla-
3000 phosphoimager (FujiFilm).  
 
Adenoviruses— The adenoviral vector containing the human LDLR cDNA (Ad-LDLR, 
[28]) was a gift from Dr. Joachim Herz at the University of Texas, Southwestern Medical Center. 
The plasmid vectors containing cytomegalus viral promoter-driven cDNA for fusion proteins, 
ApoE2-GFP, apoE3-GFP, and apoE4-GFP, were provided by Dr. Robert DeKroon at Duke 
University.  These vectors express fusion proteins with EGFP (enhanced green fluorescent 
protein) attached to the C terminal end of each apoE isoform [88].  Adenoviral vectors encoding 
apoE2-GFP, apoE3-GFP, and apoE4-GFP were made using the AdEasy adenoviral system 
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(Stratagene) according to the manufacturer's instructions.  Ad-LDLR and Ad-apoE-GFP were 
amplified in 293 cells, purified by CsCl density gradient ultracentrifugation and dialyzed against 
10 mM Tris pH 8.0, 2mM MgCl2, 4% sucrose. Recombinant adenovirus stock stored at –80 °C 
was diluted with PBS and 1x109 PFU in 0.2 ml of adenovirus was injected to a mouse via tail 
vein.  
 
Plasma lipoprotein analysis, DiI labeling and injection. Plasma was isolated, and total 
cholesterol and triglycerides were measured as described [69].  Pooled plasma samples (100 µL) 
were fractionated by fast protein liquid chromatography (FPLC) using a Superose 6 HR10/30 
column (Pharmacia Biotech Inc).  Plasma HDL was determined by precipitation with dextran 
sulfate (Sigma) according to Warnick et al [89]. For precipitation with dextran sulfate and MgCl2 
was dissolved in PBS. 5 microliters of dextran sulfate (1.0 mg/ml) was mixed with 5 µl of plasma 
and incubated at room temperature for 5 min and subsequently centrifuged at 3,000 g for 10 min. 
HDL cholesterol was determined from the supernatant. The VLDL fraction was isolated from 
pooled plasma by ultracentrifugation at d<1.006 g/ml and labeled with 1,1′-dioctadecyl-3,3,3′,3′- 
tetramethylindocarbocyanine perchlorate (DiI C18; Molecular Probes Inc.), as described by 
Stephan and Yurachek [73].  DiI-labelled VLDL (100 µg protein) was injected into tail veins of 
mice, and livers were fixed with PFA either 10 or 20 min later.  DiI-labeled VLDL remaining in 
the plasma was determined using a microscope fluorometer (Olympus FV500 with a SPOT 
2 digital camera) at 2min 10 min and 20 min using a modification of the fluorometric procedure 
described by Lorenze et al to DiI flouresence [90]. 
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Tissue processing for immunohistochemistry and confocal analyses.  Animals were given 
a lethal overdose of 2, 2, 2-tribromo ethanol.  Livers were perfused through the portal vein at 2 
ml/min with 10 ml’s of 4% paraformaldehyde, excised from animals and further fixed overnight 
in 4% paraformaldehyde.  Liver sections were paraffin embedded and 5 µm thick sections were 
made for immunohistochemistry.  Slides with consecutive liver sections were incubated 
overnight at 4 °C with either goat anti-human apoE antiserum or goat anti-LDLR antibodies 
(1:1000, Calbiochem) followed by an incubation with FITC conjugated anti-goat (1:500, Santa 
Cruz). Slides were cover slipped after application of Vectashield anti-fade mounting medium 
(Vector H-1000, Vector Laboratories,) and were observed with an IX70 inverted microscope 
(Olympus) equipped with a filter set for FITC (exciter 560/55, dichroic 595, emitter 645/75; 
Chroma Technology Corp), and images were captured with a SPOT 2 digital camera (Diagnostic 
Instruments) and analyzed with SPOT version 4.0.9 (Diagnostic Instruments) and ImageJ 1.33u 
(NIH) software.  For confocal microscopic analysis of apoE-GFP expressing tissues, 100 µm-
thick sections were cut with a vibratome and stored free-floating in PBS at 4º C.  Before analyses 
with an Olympus FV500 confocal microscope, individual sections were treated with sodium 
borohydride (1mg/ml in PBS) for 30 minutes at room temperature, and then washed in PBS three 
times for five minutes each at room temperature to reduce fixative-induced fluorescence. 
Individual vibratome sections were also stained with fluorescent (TRITC or AlexaFluor633) 
labeled Wheat germ agglutinin (WGA) (50 micrograms/ml) for 30 min.  For GFP fluorescence, 
the 514 line of an Argon laser was used for excitation and the 535-565 band-pass filter was used 
for emission.  To acquire TRITC labeled WGA images, the 543 line of a Helium/Neon-green 
laser was used for excitation and the 660 band-pass filter for emission (Cy5).  GFP and TRITC 
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fluorescence images were scanned independantly with only their respective excitation and 
emission frequencies to eliminate bleed through. 
Statistical analysis.  The significance of differences between means was calculated by 
using one-way ANOVA (JMP software; SAS Inc). 
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Results 
Overexpression of LDLR in the liver of mice with human apoE.  To determine the 
contribution of hepatic LDLR expression to plasma lipids, we injected Ad-LDLR carrying 
cDNA for the human LDLR (Herz and Gerard 1993) into mice expressing human apoE isoforms 
fed a HFW diet.  Apoe2/2 mice had high plasma cholesterol levels at baseline (733±68 mg/dl, 
n=7) but they decreased to 267±18 mg/dl by day 5 after Ad-LDLR injection.  FPLC analyses of 
plasma showed substantial reductions in their VLDL and LDL fractions and increases in their 
HDL compared to the base line (Figure 5.1A).  Apoe3/3 mice showed little change in total 
cholesterol (140±10 mg/dl to 149±9 mg/dl at day 5, n=8) or in lipoprotein distribution (Figure 
5.1B).  In contrast, liver directed over-expression of LDLR in Apoe4/4 mice increased total 
cholesterol from 126±9 mg/dl to 388±66 mg/dl (n=10) by day 5.  Cholesterol, but not 
triglycerides, were markedly increased mainly in the VLDL/IDL fractions, while HDL 
cholesterol was decreased (Figure 5.1C). The plasma lipid/lipoprotein profiles induced by the 
Ad-LDLR in the Apoe2/2, Apoe3/3 and Apoe4/4 mice are identical to those observed in 
Apoe2/2Ldlrh/+, Apoe3/3Ldlrh/+, and Apoe4/4Ldlrh/+ mice that express 2.5X normal levels of LDLR 
globally [37, 39].  Since gene expression from a recombinant adenoviral vector is mainly 
restricted to the liver [28, 91], we conclude that the interactions between apoE and the LDLR in 
the liver are responsible for the association between apoE isoforms and plasma lipid profiles, and 
that over-production of liver LDLR leads to an accumulation of cholesterol-rich, triglyceride-
poor remnants in mice expressing human apoE4. 
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Figure 5.1.  Adenovirus mediated overexpression of the human LDLR in mice with human apoE 
isoforms. A. Change in total cholesterol over 5 days after Ad-LDLR (left column). Distribution 
of lipids within different lipoprotein fractions, as assessed by FPLC of mice on HFW diet (center 
column) and 5 days after Ad-LDLR (right column) after Ad-LDLR infection. A. Mice with 
ApoE2 before (left), and after 5 days Ad-LDLR (center).  B. Mice with ApoE3. C. Mice with 
ApoE4. 
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Secretion of ApoE from liver and primary hepatocytes.  An increased interaction between 
apoE4 and LDLR in the liver lead to the reduction of apoE associated with plasma lipoproteins 
[39].  Slot blot analysis of plasma and liver apoE from Apoe2/2, Apoe3/3, Apoe4/4, and 
Apoe4/4Ldlrh/+ mice on NC diet confirmed that apoE affinity for the LDLR determines plasma 
apoE levels in mice.  The higher affinity apoE4 in Apoe4/4 mice had the lowest plasma 
concentration among the different isoforms and was further reduced by overexpression of the 
LDLR in Apoe4/4Ldlrh/+ mice (Figure 5.2A). ApoE isoform and LDLR also had modest affects on 
liver apoE concentration (Figure 5.2A). To determine the cellular metabolism of the different 
apoE isoforms, we isolated primary hepatocytes from mice expressing different apoE isoforms 
and compared the apoE protein by using Western blot analysis.   
After culturing in DMEM without FBS for 24 hours, primary hepatocytes from Apoe2/2 
mice secreted more than 10 fold apoE protein into the medium compared to the cells from 
Apoe4/4 mice and had double the ratio of medium apoE to cell-associated apoE (Figure 5.2B).  
After 24 hours in culture, ratios of medium apoE to cell-associated apoE in the Apoe2/2 
hepatocytes were significantly higher than those in the Apoe3/3 or Apoe4/4 mice (Figure 5.2B).  
These results indicate that the affinity of apoE isoform for the LDLR is an important factor for 
the secretion of apoE from the liver.   
In addition, LDLR level affected the amount of apoE secreted from the cell in cultured 
primary hepatocytes and the higher the LDLR receptor expression levels were, the higher the 
cellular apoE increase, and lower the apoE in the medium (Figure 5.2B).  Thus, the ratio of 
medium apoE to cell-associated apoE in the cultured Apoe4/4Ldlrh/+ hepatocytes was significantly 
lower than in Apoe4/4 cells.  In turn, the ratio in Apoe4/4Ldlr-/- hepatocytes lacking LDLR 
expression was significantly higher than in Apoe4/4 hepatocytes.  
123 
These data indicate that the relative amount of cell-associated apoE is a direct 
consequence of its affinity to the receptor and the levels of LDLR expression. The same 
relationships were also seen in liver slices that were isolated from mice with the human apoE 
isoforms and incubated in lipoprotein-free medium at 37oC for 24 hrs (not shown).   
Effects of LDLR on synthesis and degradation of apoE in primary hepatocytes.  The ratio 
of extracellular to intracellular apoE amounts is likely determined by the uptake, but could also 
be due to changes in apoE synthesis or degradation.  To determine how the LDLR expression 
levels affect production and degradation of apoE, we used a pulse chase system in the primary 
hepatocytes isolated from Apoe4/4 and Apoe4/4Ldlrh/+ mice. The synthesis during a 30 min pulse 
was not significantly different between Apoe4/4 and Apoe4/4Ldlrh/+ hepatocytes indicating that a 
2.5X higher LDLR expression had no effect on the apoE production rate (Figure 5.2F).  
Although Apoe4/4Ldlrh/+ cells had a slightly higher, though not significant, apoE at the start of the 
chase incubation compared to that in Apoe4/4 cells, intracellular apoE after a 4hr chase was the 
same in hepatocytes of both genotypes.  However, consistent with the observation described 
above, a higher LDLR expression led to a decreased amount of apoE secreted from hepatocytes, 
and apoE4 secreted from Apoe4/4Ldlrh/+ cells into the medium was about 40% of the level 
secreted from Apoe4/4 cells.  The sum of the secreted and cell-retained amounts in Apoe4/4 and 
Apoe4/4Ldlrh/+ cells was 65% and 31% respectively, of the initial synthesis amounts.  The 
increased loss of labeled apoE in Apoe4/4Ldlrh/+ cells suggests that an elevated LDLR also 
increases apoE degradation.  This result is consistent with the finding that increased LDL 
receptor expression reduced the secretion and enhanced the degradation of apoE4 in peritoneal 
macrophages of mice by Lucic et al [40].   
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Figure 5.2. ApoE isoform and LDLR modulate apoE secretion from Liver and primary 
hepatocytes. A. Pooled (n=3) plasma (left graph) and liver (right graph) apoE in Apoe2/2, Apoe3/3, 
Apoe4/4, and Apoe4/4Ldlrh/+ mice on NC diet by slot blot.  B. Ratio of apoE in the medium or cell 
associated after over night culture (24hrs) in Apoe2/2, Apoe3/3, Apoe4/4  (left) and Apoe4/4Ldlr-/-, 
Apoe4/4, Apoe4/4Ldlrh/+ (right) primary hepatocytes. C. Pulse chase analysis of Apoe4/4 and 
Apoe4/4Ldlrh/+ hepatocytes. Cells were labeled for 30 min (synthesis), washed and incubated 4hrs.  
Labeled apoE intracellular (retention) and extracellular (secretion) was determined. Values 
shown are means of the duplicate measurements.   * # p≤0.05, **, ## p≤0.005, ***, ### 
p≤0.0005   
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Effect of Ad-apoE-GFP on plasma lipid levels.  In order to track hepatic localization of 
apoE isoforms, we chose to express apoE-GFP fusion proteins using recombinant adenovirus in 
mice expressing different levels of LDLR.  The apoE-GFP fusion proteins appear to function 
normally when mice were infected with Ad-apoE-GFP.  All isoforms lowered cholesterol levels 
in Apoe-/- mice except that apoE2-GFP did not decrease as quickly or to the same levels as 
apoE3-GFP or apoE4-GFP (Figure 5.3A).  However in Apoe-/-Ldlrh/h mice, lacking apoE but 
expressing high levels of LDLR, transfection with Ad-apoE2-GFP normalized cholesterol levels 
to approximately the same as apoE3-GFP and apoE4-GFP (Figure 5.3B).  In contrast, decreases 
in the cholesterol levels of Apoe-/-Ldlrh/h mice injected with Ad-apoE4-GFP were somewhat 
slower to respond than those injected with Ad-apoE3-GFP, or Ad-apoE2-GFP (Figure 5.3C).  
Despite the delayed response, however, apoE4-GFP ultimately decreased cholesterol to similar 
levels as apoE3-GFP, or apoE2-GFP in Apoe-/-Ldlrh/h mice.  Similarly, both Ad-apoE4-GFP or 
Ad-apoE3-GFP was able to ameliorate the hypercholesterolemic phenotype in Apoe4/4Ldlrh/+ 
mice fed a HFW diet (not shown). 
ApoE-GFP was detectable in the plasma of transfected mice and was associated with all 
lipoprotein subclasses by Western blotting (Figure 5.3 E, F).  These data demonstrate that apoE-
GFP fusion proteins are functional and appear to retain isoform-specific characteristics.  Since 
apoE4-GFP can lower cholesterols when over-expressed by adenoviral vector in the liver of 
Apoe4/4Ldlrh/+ mice, adverse effects of LDLR must be dependent on relative ratios between 
apoE4 and LDLR. 
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Figure 5.3. Ad-apoE-GFP decreases plasma lipids in Apoe-/- and Apoe-/-Ldlrh/h mice. A. 
Cholesterol levels in Apoe-/- mice transfected with  Ad-apoE2-GFP, Ad-apoE3-GFP, Ad-apoE4-
GFP, or Ad-GFP over a 5 day span. B. Day 5 distribution of lipids within different lipoprotein 
fractions, as assessed by FPLC.  C. Apoe-/-Ldlrh/h mice with Ad-apoE2-GFP, Ad-apoE3-GFP, 
Ad-apoE4-GFP 5 day Cholesterol time course.   D. Day 5 distribution of lipids within different 
lipoprotein fractions, as assessed by FPLC.  E.  SDSPAGE of plasma isolated from Apoe-/-  mice 
transfected with Ad-apoE3-GFP (lane1), without transfection (lane 2),  VLDL isolated from Ad-
apoE3-GFP transfected Apoe-/-  mice (lane 3), Wt B6 transfected with Ad-apoE3-GFP (lane 4), 
and Wt plasma apoE (lane 5).  F.  Ad-apoE3-GFP associated with VLDL (fraction 15), LDL 
(fraction 23), and HDL (fraction 28).   
 
128 
 
Day 5 FPLC
10 15 20 25 30 35
0
5
1020
40
60
80
µg
 c
ho
le
st
er
ol
10 15 20 25 30 35
0
10
20
40
60
80
Fraction
µg
 c
ho
le
st
er
ol
0 1 2 3 4 5 6 7
0
200
400
600
adE2GFP
adE3GFP
adE4GFP
adGFP
m
g/
dl
 c
ho
le
st
er
ol
0 1 2 3 4 5 6 7
0
100
200
300
400
days after infection
m
g/
dl
 c
ho
le
st
er
ol
A B
C D
Figure 5.3
E F
 1    2     3    4   5     Lane
ApoEGFP
ApoE
ApoEGFP
 1    2     3      Lane
129 
Localization of apoE in the liver. The microenvironment of the liver is unique and plasma 
lipoproteins bind receptors on the hepatic surface in the space of Disse, the space formed 
between hepatocytes and fenestrated endothelial cells in the liver sinusoids.  Immunostaining 
with an antibody against human LDLR of the liver sections of mice carrying the Ldlr*h allele 
illustrated the sinusoidal localization of the human LDLR (Figure 5.4A top row).  ApoE4 co-
localized with LDLR in the Apoe4/4Ldlrh/+ liver as highlighted by the very intense staining of 
sinusoids with antibody against human apoE.  Thus, overproduction of LDLR forces apoE4 to 
accumulate in the space of Disse.  In contrast, apoE4 staining in the Apoe4/4Ldlr+/+ liver was 
diffuse and also present in the cytoplasm in a punctate pattern (arrow in Figure).  Very similar 
staining patterns were observed in the livers from Apoe3/3Ldlrh/+ and Apoe3/3 mice, except that 
the sinusoidal staining relative to cytoplasmic staining was less intense in the Apoe3/3Ldlrh/+ liver 
than in the Apoe4/4Ldlrh/+ liver.  This suggests that the LDLR levels influence sinusoidal 
localization of apoE4 and, to a lesser extent, of apoE3.  Apoe2/2 and Apoe2/2Ldlrh/+ mice both had 
low sinusoidal staining and more intra-hepatic punctate staining than other apoE isoforms 
(Figure 4A bottom row) and   Apoe2/2Ldlrh/+ mice had more intra-cellular staining than Apoe2/2 
mice.  
To compare the hepatic microenvironment localization of apoE2 and apoE4 and the 
effect of increased LDLR in more detail, we injected Ad-apoE2-GFP and Ad-apoE4-GFP into 
Apoe-/- and Apoe-/-Ldlrh/h mice which are deficient of apoE.  ApoE localization was analyzed 
under confocal microscopy in the liver sections stained with the TRITC-labeled lectin to 
demarcate liver sinusoids, endothelial cells, and the space of Disse [92].  Both apoE4-GFP and 
apoE2-GFP were visible as bright green hepatocytes with perinuclear concentration in the 
cytoplasm of 70-80% of the infected liver (Figure 5.4B).  However, substantially more apoE4-
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GFP was also present in the space of Disse than apoE2-GFP (SD in Figure 5.4B).  The sub-
endothelial accumulation of apoE4-GFP was more pronounced in the liver of the Apoe-/-Ldlrh/h 
mice injected with Ad-apoE4-GFP (Figure 5.4B, second column).  In contrast, injection of these 
mice with Ad-apoE2-GFP showed little accumulation of apoE2-GFP on the hepatocyte surface 
despite the increased LDLR and efficient reduction of plasma cholesterol (Figure 5.4B). 
Inspection under higher magnification reveals that GFP and TRITC signals were not 
overlapping, suggesting that the accumulation of apoE4-GFP is sub-endothelial in the space of 
Disse, between hepatocytes and endothelial cells (Figure 5.4C).  These data demonstrate that the 
accumulation of apoE on the hepatocyte surface in the space of Disse is dependent on its affinity 
to the LDLR and the expression levels of LDLR.   
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Figure 5.4. Localization of apoE2, apoE3, and apoE4 in mice overexpressing the LDLR. A. 
Immunodetection of LDLR (red) in Apoe4/4, and Apoe4/4Ldlrh/+  in liver using an anti-huLDLR 
IgG (top row).  Second row shows apoE (green) in apoE isoform mice (left) with elevated LDLR 
(right). Apoe4/4Ldlrh/+ staining for anti-apoE showed similar sinusoidal pattern (second row) as 
anti-huLDLR (arrows). Apoe3/3Ldlrh/+  also had increased sinusoidal apoE compared to Apoe3/3 
(3rd row) but less than Apoe4/4Ldlrh/+.  Apoe2/2Ldlrh/+  had increased intracellular apoE (circled) 
(last row) B. Ad-apoE2GFP (top panels) and Ad-apoE4GFP (bottom panels) were injected into 
Apoe-/- (left panels) and Apoe-/-Ldlrh/h  (right panels) mice were sacrificed after 5 days.  100 µm 
sections were stained with TRITC labeled lectin (red) to show structure and examined confocally 
C. (1500x) AdapoE4-GFP in to Apoe-/-Ldlrh/h mice.  (SD) space of Disse, (EC) endothelial cell, 
(RBC) red blood cell. 
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Sinusoidal localization of apoE and remnant uptake. VLDL remnants are normally 
converted to LDL and cleared by apoB100-binding to LDLR, or directly cleared by apoE-
binding to LDLR and LRP. The striking differences between apoE2 and apoE4 in their cellular 
localizations of Apoe2/2Ldlrh/+ and Apoe4/4Ldlrh/+ livers raises a question regarding the 
physiological relevance of apoE accumulated on the sinusoidal surface in the remnant clearance. 
Apoe2/2 , Apoe2/2Ldlrh/+ , and Apoe4/4Ldlrh/+ mice represent phenotypic extremes in lipoprotein 
profiles and atherosclerosis risk (Figure 5.5A) [37, 39].   Apoe4/4Ldlrh/+ mice have plasma apoE 
levels 30% of Apoe4/4 mice, while apoE in the livers of Apoe4/4Ldlrh/+ mice were slightly higher 
than in the livers of Apoe4/4 mice (Figure 5.2A).  Apoe4/4Ldlrh/+ had 10-fold lower plasma apoE 
than Apoe2/2Ldlrh/+ mice (Figure 5.5D).   The reduced plasma apoE in Apoe4/4Ldlrh/+ was 
associated with a reduced HDL compared to both Apoe2/2Ldlrh/+and Apoe2/2 mice (38.0 ± 4.8 
n=4, 89.5 ± 7.2  n=5, 94.6 ± 15.5 n=4 respectively, Figure 5.5 E).  Apoe2/2, Apoe2/2Ldlrh/+ and 
Apoe4/4Ldlrh/+ mice have markedly different accumulation of apoE in sinusoids as described 
above.  Despite little VLDL and LDL,  Apoe2/2Ldlrh/+ mice have substantially more apoE in their 
larger lipoprotein fractions than Apoe4/4Ldlrh/+ mice.  Apoe2/2Ldlrh/+ mice also have more plasma 
apoA1 than Apoe4/4Ldlrh/+ mice (Figure 5.5B).  To examine how these different phenotypes 
affect plasma VLDL clearance and liver uptake we injected them with DiI labeled Apoe-/- VLDL.   
Decay of plasma DiI-labeled Apoe-/-VLDL particles after injection into these mice showed that 
the Apoe2/2 mice had the slowest clearance of Apoe-/- VLDL (Figure 5.6A, left panel). While the 
decay in the Apoe2/2Ldlrh/+ and Apoe4/4Ldlrh/+ mice were not different at 10 min after injection, 
the disappearance of plasma VLDL during the next 10 min was significantly more in the 
Apoe2/2Ldlrh/+ mice than in Apoe4/4Ldlrh/+mice.  At 20 min post injection, DiI-VLDL were barely 
detectable in the liver of Apoe2/2 mice (Figure 5.6A, second panel), but were avidly internalized 
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in the Apoe2/2Ldlrh/+ liver (Figure 5.6A third panel). Most of the signal was intracellular (circled) 
and surface-bound DiI-VLDL was negligible (arrows SD).  In marked contrast, DiI-signal was 
strongly associated with the hepatic surface in Apoe4/4Ldlrh/+ liver (arrow SD), while intracellular 
DiI-VLDL was minimum (circled in Figure 5.6A, right panel).  Thus while apoE2, which is 
elevated in the plasma and minimally associated with the hepatocyte surface, can facilitate 
internalization of apoE-deficient VLDL remnants in the presence of increased LDLR.  In 
contrast higher LDLR affinity apoE4 that is accumulated on the hepatocyte surface appears to be 
less efficient in internalizing the remnant particles. 
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Figure 5.5. LDLR expression and apoE isoform modulate liver apoE secretion and HDL levels.  
A. Distribution of lipids within different lipoprotein fractions, as assessed by FPLC of mice on 
HFW diet.  B. ApoE and apoA1 ELISA on plasma FPLC fractions on mice fed HFW diet. 
Densitometry of n=3 separate plasma samples.  C.  Western blot for apoE liver cytosol (C) and 
membrane (M) fractions and plasma D. Densitometry of n=3 separate plasma samples. E.  
Plasma HDL cholesterol on mice fed HFW diet. 
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We next sought whether the surface bound apoE4 can  associate with VLDL lacking 
apoE and facilitate lipoprotein internalization, and injected DiI labeled Apoe-/- VLDL into Apoe-/-
Ldlrh/h mice that were infected with Ad-apoE4-GFP 5 days earlier.   When livers were examined 
10 min after the injection for the distribution of apoE4-GFP, strong GFP signal was again on the 
hepatic cell surface (Figure 5.6B left panel). Strong DiI signals demarcated microvessels as well 
as punctated within the cytoplasm of hepatocytes (Figure 5.6B middle panel). Most of the DiI-
labeled VLDL was co-localized with apoE4-GFP in both cell surface and in cytoplasm, but there 
remained significant amount of cell surface apoE4 that was not associated with DiI (Fig 5.6B 
right panel).  This indicates that the cell surface apoE4 is minimally contributing to the 
internalization of exogenous lipoproteins.  
To examine how VLDL, with apoE2 or apoE4 already present on their surface, would 
localize in the liver, we isolated VLDL fractions from Apoe-/- mice 5 days after transfection with 
Ad-apoE2-GFP or Ad-apoE4-GFP and introduced them into Apoe-/-Ldlrh/h mice through tail 
veins.  When livers were examined under confocal microscopy 5 minutes after the injection, 
apoE4-GFP was already localized on hepatocyte surfaces (Figure 5.6C right).  This suggests that 
lipoproteins that aquire apoE4 during the circulation can accumulate in the space of Disse very 
efficiently. In contrast, very little apoE2-GFP was localized on the hepatocyte surface, but there 
were a few cells with some GFP signals (Figure 5.6C).  
Taken together, apoE4 containing VLDL avidly binds and accumulates in the space of 
Disse. While apoE4 on the surface of hepatocytes trapped by the LDLR may play roles in 
sequestering remnant particles to cell surface, they appear to have only a limited capacity to 
participate in the internalization of remnant lipoproteins.  That hepatic surface bound apoE 
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accumulation inhibits clearance is also supported by the absence of apoE2 on the hepatocyte 
surface and its association with better VLDL internalization. 
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Figure 5.6.  Effects of ApoE isoform and LDLR levels on localization and clearance of Apoe-/-  
VLDL and apoE-enriched VLDL.  A. DiI-labeled Apoe-/- VLDL injected into Apoe2/2, 
Apoe2/2Ldlrh/+, and Apoe4/4Ldlrh/+ mice.  (first panel) Plasma DiI was measured at 2, 10, and 20 
minutes. 2 min was taken as 100%.  The liver was removed and analyzed by fluorescence 
microscopy for DiI-VLDL (yellow) distribution. TRITC labeled lectin (blue) shows structure.  B. 
DiL VLDL (250 µg of protein) from Apoe-/- mice was injected into the tail vein of Ad-apoE4-
GFP infected Apoe-/-Ldlrh/h mice, and localizes to the SD, and overlaps with apoE4-GFP in the 
SD.  C. VLDL isolated from Apoe-/- mice transfected to express Ad-apoE4-GFP or Ad-apoE2-
GFP was injected into tail veins of untransfected Apoe-/-Ldlrh/h mice.  5 min after injection 
apoE4-GFP (left panel) was visible subendothelially in the space of Disse (SD).  ApoE2-GFP 
(right panel).  
140 
 
141 
Discussion 
The higher binding affinity of the apoE4 isoform to the LDLR than apoE2 or apoE3 has 
been implicated in leading to increased plasma LDL cholesterol and atherosclerosis in 
individuals carrying apoE4 [2, 3]. In this study, we used Adenovirus mediated LDLR and apoE-
GFP expression in mouse models to investigate the effects of LDLR expression on the 
localization of the different apoE isoforms in the liver.  Our data show that over-expression of 
LDLR in the liver of mice with apoE4 elevates plasma cholesterol levels while reducing it in 
mice with apoE2.   ApoE4 co-localizes with LDLR on the sinusoidal surface of the liver, and 
increased LDLR expression enhances this accumulation.  In contrast, apoE2 is minimally present 
on the sinusoidal surface of the liver even when LDLR expression is elevated.  
 The liver is the main source of plasma apoE, although low levels of extra-hepatic apoE 
are sufficient for normalization of hyperlipidemia, since Apoe-/- mice that were transferred with 
wild type bone marrows have near normal plasma cholesterol levels [93].  Remnant lipoproteins 
are cleared in the liver mainly by LDLR and by LRP, but the uptake by these receptors require 
the remnants to acquire and be enriched with apoE proteins [47, 94-96]. Liver-derived and 
localized apoE facilitates the receptor-mediated internalization of remnants in the liver [96, 97].  
Linton et al demonstrated, using bone marrow transfer of apoE marrow to Apoe-/-Ldlr-/- mice, 
that intense immunoreactivity for extrahepatic apoE was present on the cell surface and in the 
space of Disse but the pattern of punctuated staining was not detected within the cytoplasm 
indicating that no uptake of apoE-containing lipoproteins was occurring [93]. The authors 
concluded that whereas the LDLR efficiently clears remnant lipoproteins irrespective of the site 
of origin of apoE, endocytosis by the chylomicron remnant receptor (LRP) is absolutely 
dependent on hepatic expression of apoE.   In contrast, Yu, et al. showed that the chylomicron 
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remnant clearance by the apoE-deficient liver depends on the amount of apoE associated with the 
remnant particles and hepatic apoE is not a pre-requisite for clearance, although the addition of 
hepatic apoE can accelerate their uptake [98].  Previously we showed in mice that all human 
apoE-isoforms are less effective ligands to non-LDLR mediated clearance of TG-rich 
lipoproteins than mouse apoE, and that VLDL remnants with very high cholesterol and apoE 
accumulates in the absence of LDLR [69].  Dependence of remnant clearance on LDLR are 
likely to be exaggerated in mice with human apoE isoforms.   
We earlier observed that mice globally expressing 2-3 times the normal Ldlr gene exhibit 
hypercholesterolemia when fed a HFW diet only when they are also carrying the human apoE 
allele [39].  We hypothesized that a high-affinity interaction between LDLR and apoE4 in the 
liver limits the transfer of apoE protein to the TG-rich lipoproteins, limiting their clearance. 
Over-expression of the LDLR by adenoviral vector raised plasma cholesterol levels only in the 
Apoe4/4 mice, confirming our first prediction based on this hypothesis and demonstrating that the 
interaction between increased LDLR and apoE4 in the liver is sufficient to cause the 
hypercholesterolemia.  Furthermore, adenoviral over-expression of apoE4-GFP fusion protein 
was able to overcome this phenotype in HFW fed Apoe4/4Ldlrh/+ mice, suggesting that a ratio 
between apoE4 and LDLR in the liver is an important factor for this phenotype.  Neither Ad-
LDLR nor Ad-apoE4-GFP expression is physiological as both vectors use a CMV promoter 
which does not respond to physiological gene regulation.  However, since a 2-3 fold decrease in 
the apoE4/LDLR ratio in Apoe4/4Ldlrh/+ mice compared to Apoe4/4 mice causes a dramatic 
phenotypic change [39], a small difference in the basal levels of these two proteins between 
humans and mice may be sufficient to cause the association between apoE4 and the small 
increase in plasma cholesterol seen in humans. 
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The paradoxical association of apoE4 with elevated plasma cholesterol in humans may be 
due to its high LDLR affinity and a reduced ability to exchange onto and clear TRLs and 
remnants.  In cell culture binding or in-vivo clearance, when apoE is already present on the 
particle, apoE4 containing particles show enhanced binding and clearance compared to apoE3 
and apoE2 [14, 19, 99].  In contrast, apoE deficient-VLDL binding and clearance is reduced 
when cells or animals express apoE4 compared to apoE3 [14].  Here we show that apoE2, with 
the lowest LDLR affinity, clears VLDL faster than apoE4 when they are expressed by the liver 
in-vivo and apoE-deficient particles are used.  Thus the clearance of exogenous apoE deficient 
VLDL is faster when the recipient animal expresses apoE with low LDLR affinity and higher 
LDLR level.  Newly secreted chylomicron and VLDL that have yet to acquire apoE, combined 
with the reduced plasma apoE level associated with apoE4, increases the plasma retention time 
of these lipoproteins.  This is consistent with the higher post prandial lipemia in apoE4 humans 
[68] as well as Apoe4/4Ldlrh/+ mice on HFW diet [39].   In contrast, the lower LDLR affinity of 
apoE2 increases its plasma concentration and increases VLDL clearance (Figure 5.7A).  
Previous studies have demonstrated the presence of apoE immunoreactivity along the 
sinusoidal front of hepatocytes together with some punctated cytoplasmic staining in the liver of 
wild type rat and mouse [100, 101].  Electron microscopic examinations by Hamilton et al 
further demonstrated that the immuno-gold labeling for apoE clustered on hepatocytic microvilli 
projecting into the space of Disse[100].  In addition, endosomes near the sinusoidal front and 
multivesicular bodies in the Golgi/biliary area were labeled intensely with apoE.  Confirming 
these observations, we found intense apoE immunoreactivities demarcating the space of Disse 
and as punctated perinuclear staining in the liver of both Apoe3/3 and Apoe4/4 mice.  Importantly, a 
higher expression of LDLR in the Apoe3/3Ldlrh/+ and Apoe4/4Ldlrh/+ animals enhanced the 
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intensity of sinusoidal immunostaining relative to the cytoplasmic staining, and appeared to do 
so more in the liver of mice with apoE4 than with apoE3. We also found intense fluorescence on 
the hepatocyte surface of Apoe-/-Ldlr+/+ mice that received Ad-apoE4-GFP, but the levels in the 
livers of mice that received Ad-apoE2-GFP showed minimal localization of apoE2 in the space 
of Disse.   Injecting Ad-apoE2-GFP to Apoe-/-Ldlrh/h mice did not increase the apoE2-GFP on the 
hepatocyte surface.  Thus these results clearly demonstrate that a majority of apoE4 but not 
apoE2 proteins co-localizes with LDLR on the hepatocyte surface, and that the accumulation 
depends on both affinity to LDLR and on the levels of LDLR. 
Neither immunostaining nor Ad-apoE4-GFP expression allows us to dissociate whether 
apoE accumulating on the hepatocyte surface is newly synthesized by the hepatocyte or 
originated from lipoproteins in circulation.  However, we note that not all the cells demarcated 
by intense sinusoidal apoE4-GFP signals have strong intracellular GFP signals, suggesting that a 
substantial part of the apoE4-GFP may be derived from apoE4-GFP synthesized by other 
infected hepatocytes.  This is also consistent with the apoE4-GFP accumulation in the space of 
Disse of Apoe-/- liver shortly after injection of VLDL particles enriched with apoE4-GFP, while 
no such accumulation of apoE2-GFP was seen (Figure 5.5C).  Multiple experiments both in vivo 
and in vitro have shown that a substantial amount of apoE internalized with TG-rich lipoproteins 
by the liver are recycled back to the cell-surface and re-secreted [52, 79, 102].  HDL appears to 
stimulate this process, serving as an acceptor for recycled apoE in hepatocytes [24, 47, 48].  For 
example, Heeren et al. demonstrated that cell-surface binding and internalization of TG-rich 
lipoprotein-derived apoE4 are increased compared with apoE3 in HuH7 hepatoma cells [79].  
They also showed that HDL-induced recycling of apoE4 is reduced in these cells compared to 
recycling of apoE3. These experiments were carried out with VLDL enriched with human apoE3 
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or apoE4 in vitro and human hepatoma cells which synthesize endogenous apoE, while our 
experiments used genetic models with the VLDL remnants enriched with apoE isoforms in vivo, 
and recipient livers were either apoE-deficient or making the same isoform.  Nevertheless, 
impaired recycling measured by the reduced re-secretion of apoE4 into medium from the 
cultured cells relative to that of apoE3 observed by Heeren et al is consistent with the enhanced 
cellular localization of apoE4 we observed in vivo. Additionally, our experiments showed that 
the localization of apoE4 on the hepatocyte surface is dependent of LDLR levels and that apoE4 
accumulated to this location had enhanced binding but a limited capacity to internalize remnant 
lipoproteins.   
Our results are consistent with and support our “apoE4 trapping by LDLR” as a 
mechanism to explain the hypercholesterolemia associated with apoE4.  Retention of apoE4 at 
the hepatic surface by LDLR reduces its availability in the plasma to bind to and mediate 
remnant internalization. We do not know the form of apoE4 interacting with LDLR on the 
hepatocyte surface at present, but they are unlikely to be free proteins considering the report by  
Ruiz et al. that both LDLR and LRP prefer lipid bound forms of apoE [41].  HDL, which can 
modulate apoE recycling, and is a source of plasma apoE, is a likely regulator of this process [47, 
94, 103-105]. HDL as an apoE carrier may be necessary for timely apoE exchange to other 
lipoproteins such as TRLs, allowing nascent lipoproteins to enter the plasma without immediate 
apoE-mediated reuptake and also to remove them before they become slowly cleared remnant 
LDL.  Modulation of HDL levels by LDLR is apoE isoform dependent; increased LDLR 
expression leads to increased HDL-cholesterol in mice with apoE2 and decreases HDL levels in 
mice with apoE4 [37, 39].  Elevated HDL associated with apoE2 could enrich apoE-poor VLDL 
and promote their clearance.  In contrast, reduced HDL and apoE4 trapped in the space of Disse, 
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directs apoE-poor VLDL to remnant conversion rather than internalization. The decreased apoE 
content on TRLs can increase conversion to remnants by LPL [22, 106-108].  Further studies are 
necessary to elucidate the form of apoE and potential role of HDL in the isoform-specific 
interactions between LDLR and apoE and whether other apolipoproteins are involved in these 
interactions. 
In conclusion, our study in mice with apoE isoform and elevated LDLR revealed that 
there may be a critical range of LDLR levels for proper ratios of cholesterol carried by 
atherogenic non-HDL lipoproteins and by HDL particles (Figure 5.7B).  The optimum range of 
LDLR levels is different for each apoE isoform and proportional to each isoform’s LDLR 
affinity.  For instance, all apoE isoforms mice have elevated VLDL and LDL when the LDLR is 
absent [69].  With wildtype levels of LDLR, both Apoe4/4 and Apoe3/3 mice have high HDL and 
low non-HDL cholesterol [14]. However, ApoE2/2 mice have high non-HDL /HDL ratios [34].  
When LDLR levels are elevated, HDL cholesterol levels dramatically decrease in both Apoe4/4 
Ldlrh/+ and Apoe3/3Ldlrh/+ mice.  Since non-HDL cholesterol are elevated only in Apoe4/4 Ldlrh/+ 
mice their non-HDL /HDL ratios are critically high, while Apoe3/3Ldlrh/+ mice have nonHDL 
/HDL ratios that are modestly increased.  Apoe2/2Ldlrh/+ mice have reductions in their VLDL and 
elevated HDL levels and thus have low non-HDL /HDL.  If we apply the same relationships to 
phenotypes associated with apoE isoforms in humans, one may predict that LDLR activity in 
humans are in the upper ranges of Figure 5.7B where apoE2 is beneficial and apoE4 is somewhat 
detrimental.  In the lower range of LDLR activities, the decreased affinity of apoE2 may cause 
apoE2-rich TRLs to accumulate, similar to the 5% of apoE2 homozygous humans who develop 
type III hyperlipidemia characterized by elevated TG.  Careful titration of apoE and LDLR levels 
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may shed light on the relevance of this mechanism to the well-established associations between 
the risk for coronary heart disease and apoE isoforms. 
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Figure 5.7.  Hypothetical mechanism to explain apoE LDLR affinity affect on VLDL 
metabolism.   
A.Top diagram shows apoE2 metabolism of apoE-poor VLDL.  The lower LDLR affinity 
of apoE2 increases plasma apoE level (green arrow).  This increases the enrichment of apoE2 
onto VLDL which facilitates LDLR and HSPG mediated uptake.  A.  Lower diagram shows 
apoE4 metabolism of apoE-poor VLDL. High LDLR affinity of apoE4 keeps it bound to the 
hepatic surface, which decreases VLDL enrichment.  VLDL at the hepatic surface are not 
internalized and subsequently converted to remnants and LDL possibly by LPL. 
 B. Interaction between LDLR level and apoE affinity and resulting atherosclerosis risk 
(non-HDL cholesterol /HDL cholesterol) in mice.  Legend on the left: darker shaded area shows 
a decreased non-HDL/HDL.  Upper unshaded areas reflect elevated non-HDL/HDL and 
hyperlipidemia. Panel on the right shows non-HDL/HDL ratio (by amount of shading) in mice, 
determined by their LDLR level (y-axis) and apoE affinity (x-axis). Shaded areas reflect a good 
balance between LDLR level and apoE isoform.  Unshaded area is a poor non-HDL/HDL and 
hyperlipidemia.   Similar non-HDL/HDL levels occur at different levels of LDLR for each apoE 
isoform reflected by the change in position of the shaded region. 
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Abstract  
The pathology of atherosclerotic lesions that develop in mouse models of atherosclerosis, 
such as those lacking apolipoprotein E or lacking the low density lipoprotein receptor, is very 
similar to that seen in human patients. Consequently, genetic approaches to studying 
atherosclerosis in these mouse models have produced a wealth of information relevant to the 
genetic factors and pathways that modify the early stages of atherosclerosis in humans.  Despite 
these advances, the later stages of atherosclerosis in humans, including spontaneous plaque 
rupture and hemorrhage, have not been observed reliably in current mouse models.  Increasing 
sophistication and use of genetic manipulations, however, has produced significant advances in 
modeling these processes.  The use of genetic tools to examine the physiology, pathology, and 
cell biology of atherosclerosis will enhance elucidation of the pathogenesis of the disease and 
lead to the development of novel therapeutic strategies. 
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Introduction 
The development of atherosclerosis is largely influenced by genetic factors.  It is also 
modified by a host of non-genetic factors including diet, social habits such as smoking and 
exercise, and pre-existing diseases such as diabetes and hypertension, though arguably even 
these factors have genetic components. Thus multiple genetic risk factors exist, and 
atherosclerosis susceptibility is likely to be determined by unfavorable combinations of small 
variations in the function or quantity of proteins involved in multiple pathways.   
The mouse is a uniquely suited model system for studies of complex diseases.  Its overall 
biology is closely comparable to that of humans and the characteristics of many pathologic 
conditions are quite similar in both species.  The existence of numerous well-characterized and 
recently sequenced inbred mouse strains provides a rich resource for genetic analysis.  Various 
genetic techniques, like transgenesis and gene targeting, are now common laboratory procedures 
for generating specific mutations in mice.  Lastly, not only can the effects of genes be studied in 
mice in controlled environments, but also gene-gene and gene-environment interactions can be 
assessed relatively easily.  In this review we discuss genetic models of atherosclerosis and the 
recent use of the mouse as a genetic tool to identify the genes and pathways involved in various 
stages of atherogenesis. The use of these genetic models, tools, and techniques will ultimately 
identify novel targets for the development of therapeutics to treat and hopefully prevent the 
development of atherosclerosis. 
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I. Genetic Models of Hyperlipidemia and Atherosclerosis   
Atherosclerosis is the leading cause of death in Western society.  Elevated concentrations 
of low-density lipoproteins (LDL) and reduced concentrations of high density lipoproteins 
(HDL), are both clearly associated with increased risk of atherosclerosis in humans and are 
significantly influenced by the genetic makeup of the individual [109, 110]. 
The high prevalence of atherosclerosis among humans contrasts with the fact that none of 
the common laboratory mouse strains develop atherosclerotic plaques.  This is true even when 
the mice are maintained on diets (high fat Western type, HFW; 21 % fat, 0.15% cholesterol) 
similar to those consumed by humans in Western societies.  This difference in susceptibility is 
mainly attributed to the different plasma lipid profiles of the two species.  For example, the 
average plasma cholesterol concentration of wild type mice on a normal chow (NC) diet (4.5% 
fat, 0.022% cholesterol) is approximately 80 mg/dL.  Most of this cholesterol is carried by HDL 
particles.   Mice have very low concentrations of LDL and other atherogenic lipoproteins such as 
remnants of intestinal-derived chylomicrons and liver-derived very low-density lipoproteins 
(VLDL).  This profile is in marked contrast to humans in which most of the plasma cholesterol 
(200 mg/dL) is associated with apolipoprotein B100 (apoB)-containing LDL particles.  These 
differences are often attributed to variations in lipoprotein metabolism between mice and 
humans.  For example, mice lack cholesterol ester transfer protein (CETP) activity that transfers 
cholesterol esters from anti-atherogenic HDL to atherogenic LDL and VLDL in humans [31].  In 
addition, in mice approximately 70% of liver apoB mRNA undergoes post transcriptional 
editing, resulting in production of apoB48-containing VLDL by the liver.  In contrast, humans do 
not have hepatic apoB mRNA editing activity and secrete only the LDL precursor, apoB100-
containing VLDL [29].  However, while the mouse plasma lipoprotein profile is less atherogenic 
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than the profile in humans, the pathways for cholesterol transport and metabolism in the two 
species are sufficiently similar to suggest that inducing disturbances in plasma lipoprotein 
metabolism should trigger atherogenesis in mice.  Indeed, some inbred strains like C57BL/6 are 
susceptible to diet-induced hyperlipidemia and develop fatty streak lesions when fed an 
atherogenic diet (15.5% fat, 1.25% cholesterol) containing 0.5% sodium cholate [111]. 
The first genetic mouse models of atherosclerosis were generated by creating mice 
lacking functional alleles for either apolipoprotein E (apoE) [75, 112] or the LDL receptor 
(LDLR) [113].  ApoE plays a central role in lipoprotein metabolism and is required for the 
efficient receptor-mediated clearance of plasma chylomicrons and VLDL-remnants by the liver 
[16].  Lack of apoE in mice results in accumulation of cholesterol-rich remnant particles and 
elevation of plasma cholesterol concentrations to about 400 mg/dL, even when fed a NC diet.  
The apoE-deficient mice (Apoe-/-) spontaneously develop aortic atherosclerotic plaques similar to 
those seen in humans [75, 112].  The LDLR is crucial for the removal of apoE- and apoB-
containing lipoprotein particles from the circulation.  The Ldlr-/- mice, like humans deficient for 
LDLR function, have increased plasma LDL cholesterol, although they demonstrate less overt 
vascular disease than do the  Apoe-/- mice, and develop plaques more slowly on NC diet [113].  
Feeding  Ldlr-/- mice a HFW diet significantly accelerates atherosclerosis. These genetically 
well-defined hyperlipidemic Apoe-/- and Ldlr-/- mouse models quickly became the primary 
models for the study of atherosclerosis due to similarities to the human disease and the 
reasonable rate of disease progression.   
Many mutant mice with altered lipoprotein profiles that develop varying degrees of 
atherosclerosis have since been described, and some of them are listed in Table 1.  For instance, 
transgenic mice over-expressing a human Apob gene (HuApoB) in the liver have elevated levels 
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of circulating LDL and thus have lipoprotein profiles more similar to those of humans [114].  
These mice develop severe atherosclerosis when fed an atherogenic high fat diet [115].  
Interestingly, transgenic mice over-expressing mouse Apoa-II are also susceptible to diet-
induced atherosclerosis [116].  Although the role of apoA-II in HDL function is not clear, it 
appears that the altered ratio of apoA-I to apoA-II in HDL impairs the anti-atherogenic properties 
of HDL.  In addition to increased triglycerides and VLDL, the Apoa-II transgenic mice also 
exhibit traits associated with human insulin resistance syndrome [117]. 
Genetic manipulation in mice to create models of specific human genetic conditions has 
also been used to provide insight into the mechanisms of the corresponding human condition. 
While complete lack of apoE is extremely rare in humans, some apoE protein variants are 
associated with premature atherosclerosis [16].  Type III hyperlipoproteinemia is a condition 
characterized by elevated plasma cholesterol and triglycerides and an increased risk of premature 
atherosclerosis.  Both dominant and recessive inherited forms of Type III hyperlipoproteinemia  
are known in humans. The dominant inherited form is caused by defective apoE proteins, such as 
apoE3-Leiden or apoE (Arg112, Cys142), and is associated with a plasma accumulation of 
VLDL [78].  Transgenic mice carrying these variant apoE genes are susceptible to diet-induced 
atherosclerosis [118, 119].  The recessive form of Type III hyperlipoproteinemia occurs in 
approximately 5% of humans who are homozygous for APOE*2, one of the three common 
alleles of APOE in humans [23].  The apoE2 isoform binds with lower affinity to the LDLR than 
do the other two common isoforms, apoE3 and apoE4 [13-15].  Because not all APOE*2 
homozygotes develop hyperlipoproteinemia, other factors are thought to be necessary for 
manifestation of this condition in humans [23]. Yet in targeted mice all the homozygous Apoe2/2 
mice that express the human apoE2 isoform in place of mouse apoE exhibit Type III 
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hyperlipoproteinemia  regardless of their gender, age, or sex [34].  Additionally, all Apoe2/2 mice 
develop atherosclerosis that is significantly accelerated by a Western style high fat diet (HFW), 
while mice with apoE3 and apoE4 do not [14, 33, 34].  Apoe2/2 mice may reveal the causative 
factor for Type III hyperlipoproteinemia because the precise species difference necessary to 
precipitate the phenotype in some humans is apparently already present in these mice [34]. 
The Ldlr-/- mouse is a model of human familial hypercholesterolemia (FH) in which 
mutations in the Ldlr gene are the major cause of the autosomal dominant form of the disease 
[120].  In addition, gain of function mutations in the Pcsk9 gene coding for pro-protein 
convertase subtilisin/kexin type 9 cause some rare autosomal dominant cases [121].  PCSK9 
mediates LDLR degradation and therefore its activity is a major determinant of plasma LDL 
concentrations in humans [122].  Mice over-expressing PCSK9 in the liver show accelerated 
degradation of LDLR, and consequently have markedly increased plasma LDL concentrations 
[123, 124].  Autosomal recessive hypercholesterolemia (ARH) was shown to be caused by loss-
of-function mutations in the Arh gene that encodes an adaptor protein that is important for the 
internalization of LDLR [125].  Although plaque development has not been reported, both the 
transgenic mouse overexpressing human PCSK9 and the mouse lacking ARH are likely to be 
excellent models of atherosclerosis since they show plasma lipoprotein profiles similar to the 
Ldlr-/- mice. 
In aggregate the data from these studies suggest that once mice have plasma total 
cholesterol concentrations of over 200 mg/dL, and the cholesterol is primarily in non-HDL 
particles, they will eventually develop atherosclerosis.    However, the data provide no 
compelling evidence that any particular model is more ideal than others for studying the overall 
process of atherogenesis.  The predominance of studies employing Apoe-/- mice and Ldlr-/- mice 
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in recent years likely reflects the relative ease of using mice with single gene defects and the fact 
that these models were the first to be made available.  However, it is important to bear in mind 
the specific mutations or deletions underlying the dyslipidemia in individual models, as certain 
models may be uniquely suited for the study of particular pathways that contribute to the 
atherosclerotic process.    
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Table 6.1.  Mouse Models of Hyperlipidemia and Atherosclerosis  
 
Models Mutation Dieta Notes reference 
C57BL/6  Wild type inbred HFC Relatively more susceptible to diet-induced atherosclerosis than other 
common inbred strains of laboratory mice. 
[111] 
Apoe-/- Homozygous KO NC Elevated cholesterol-rich remnants, and spontaneous atherosclerosis [75, 112] 
Apoe+/- Heterozygous KO HFC Severe atherosclerosis only when fed high fat diet.  [126, 127] 
Ldlr-/- Homozygous KO HFW Elevated LDL-cholesterol and severe atherosclerosis on high fat diet.   [113] 
CETP tg Transgene HFC Accelerated diet-induced atherosclerosis. [128] 
HuApoB tg Transgene HFC Elevated LDL cholesterol and severe diet-induced atherosclerosis  [114] 
ApoAII tg Transgene HFC High plasma triglyceride levels. Increased diet-induced atherosclerosis.  [116] 
ApoE3Leiden, ApoE 
(Arg112,Cys142) tg 
Transgene HFW Type III hyperlipoproteinemia and severe atherosclerosis [118, 119] 
Apoe2/2 Gene replacement HFW Type III hyperlipoproteinemia and severe atherosclerosis in 
homozyotes.   
[34] 
Apoe4/4 Ldlrh/+ Gene replacement HFW Accumulation of CH-rich, TG poor remnants and severe  
atherosclerosis only when mice are on high fat diet. 
[39] 
Srb1-/-, Apoe-/- Double KO NC Very severe atherosclerosis and death at 5 weeks of MI. Treatment with 
probucol prolongs the life span to 40 weeks 
[129] 
sg/sg  
(RORα-/-) 
Natural mutant HFC Staggerer mouse has a mutation in nuclear receptor RORα.   
hypoalphaproteinemia, neurodegeneration  
[130] 
KOR-SHL Natural mutant NC Hyperlipidemic and develop severe xanthomas,  
Spontaneous deletion of the Apoe gene. 
[131] 
a:  Diets necessary to induce atherosclerosis; NC; regular mouse chow generally containing 4.5% (w/w) fat and 0.02% (w/w) cholesterol, HFW; 
Western type high fat diet containing 21.5% (w/w) fat and 0.15% cholesterol; or HFC, atherogenic diet with 15.5% (w/w) fat, 1.25% (w/w) 
cholesterol and 0.5% (w/w) sodium cholate.  
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II. Quantitative Trait Loci Mapping to Identify Atherosclerosis-Susceptible Genes  
The atherosclerotic process is altered by interactions among products of genes from 
throughout the genome, many of which have likely not yet been discovered.  Mapping the 
location of significant quantitative trait loci (QTL) for atherosclerosis in mice appears 
particularly promising due to the number of inbred strains available and because the mouse 
genome is relatively well annotated with markers.  To this end the Jackson Laboratory, using 
43 inbred mouse strains, employed large scale, comprehensive phenotyping efforts to find 
among these strains differences in a number of metabolic and disease parameters [132].  The 
large number of strains was chosen specifically to mimic human genetic diversity.  Mice 
were fed a high fat, high cholesterol, cholate-containing diet; and body weight, percent body 
fat, percent lean mass, bone mineral density, total cholesterol, HDL, triglycerides, glucose, 
leptin, and insulin were measured.  There was a large range in the measured parameters, and 
certain sets of characteristics assorted in a strain-dependent manner.  Notably, CAST/EiJ, 
CBA/J, and MSM/Ms strains were identified as mimics of the human metabolic syndrome, 
for which a mouse model is currently lacking [132].  Results from this study and many other 
smaller phenotyping efforts are available from the Mouse Phenome Project’s database at 
www.jax.org/phenome.  In parallel, a large-scale effort to develop a sizeable group of 
recombinant inbred strains useful for mapping complex disease QTLs, including 
atherosclerosis, is on-going [133]. 
In addition to wild type inbred mouse strains, the Apoe-/- and Ldlr-/- mice on several 
different genetic backgrounds have been generated and intercrossed to map genetic loci that 
modify atherosclerosis characteristics or susceptibility [134, 135].  A large number of QTL 
maps have been created from these crosses.  They have identified multiple chromosomal loci 
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for new QTLs as well as QTLs that span or confirm previous reports.  Used individually, or 
combined with human QTL maps, they promise to accelerate atherosclerosis-related gene 
and therapeutic target discovery.  As mouse genome sequencing efforts expand and marker 
density increases, the ability to pinpoint causative genetic variations for these QTLs will 
continue to improve.   
While it is often difficult to definitively identify a causative gene for atherosclerosis 
susceptibility based on QTL mapping studies, some genes have been identified in recent 
years.  For example, the gene coding for A20, a regulator of nuclear factor-kappa B (NFκB), 
on chromosome 10 was identified using crosses between susceptible (C57BL/6J Apoe-/-) and 
atherosclerosis resistant (FVB/N Apoe-/-) mice [136].  Interestingly, despite C57BL/6J Apoe-/- 
being the susceptible strain in this cross, the C57BL/6J-A20 allele conferred resistance to 
atherosclerosis.  A20, also called tumor necrosis factor α induced protein 3 (TNFαip3), 
terminates activation of NFκB following its stimulation by various agents including TNFα.  
A Glu at position 627 in C57BL/6J-A20 introduces a putative casein kinase 2 
phosphorylation site making it a less effective terminator of TNFα-stimulated NFκB 
activation than the FVB/N-A20 with Ala at 627.  Recently, common A20 polymorphisms in 
humans have been shown to result in significant differences in A20 expression that are 
associated with the susceptibility to coronary artery disease in people with type 2 diabetes 
[137].  In this case, the QTL mapping of A20 in mice led to the detection of a set of 
polymorphisms in humans that are likely to play a role in human atherosclerosis 
susceptibility. 
A second example of gene identification through QTL mapping is the determination 
of the gene underlying Ath1.  The QTL designated Ath1 was originally mapped on 
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chromosome 1 in mice fed an atherogenic diet [138].  The C57BL/6J strain was 
atherosclerosis susceptible and C3H/HeJ and BALB/cJ strains were resistant [139].  Earlier 
studies suggested the Prdx6 gene, coding for peroxiredoxin 6, a thiol-specific antioxidant 
protein, as a likely candidate for the causative gene in the Ath1 QTL.  Elevated Prdx6 
expression levels were associated with both resistant strains and with smaller lesions within 
strains.  Additionally, the most susceptible strain, C57BL/6J, had an Ala124Asp substitution 
in Prdx6 [139].  However, subsequent studies of mice overexpressing Prdx6 showed no 
protection against atherosclerotic plaque development [140].  Eventually, the powerful 
combination of mouse genetics and human association studies helped to find a convincing 
candidate for Ath1, and led to the identification of Tnfsf4 by Wang et al. [141].  Tnfsf4, 
coding for Ox40 ligand (Ox40L), is expressed in the aorta and the level of its expression was 
significantly higher in the atherosclerosis susceptible C57BL/6J strain than in the resistant 
C3H/HeJ strain.  Furthermore, mice overexpressing the Ox40L developed more 
atherosclerosis than wild type mice, and mice lacking Ox40L were protected from 
atherosclerosis.  In support of the potential atherogenic role of Ox40L, a mouse 
atherosclerosis QTL was found on chromosome 4 near the gene coding for Ox40, the 
receptor for Ox40L [135].  In addition, a human mutation association study showed that 
mutations in Ox40L are predictive of myocardial infarction risk [141].  Together this 
evidence suggests that Tnfsf4 is likely to be the gene underlying Ath1.   The Ox40L-Ox40 
pathway is known to control lymphocyte proliferation and survival.  Finally, monoclonal 
antibody inhibition of Ox40L-Ox40 signaling effectively decreased atherosclerotic lesions 
more than 50% in Ldlr-/- mice [142].  The Ath1 story is a lesson in perseverance and 
demonstrates the power of utilizing human association studies in conjunction with mouse 
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genetics to identify the gene responsible for a QTL as well as test potential targets for anti-
atherosclerosis therapy. 
A third example used QTL mapping to identify 5-Lipoxigenase (5LO) as an 
atherosclerosis susceptibility gene located on chromosome 6.  5LO is the rate-limiting 
enzyme in leukotriene synthesis and is expressed primarily in leukocytes, including 
monocytes and macrophages.  Leukotrienes are potent pro-inflammatory lipid mediators and 
5LO could play a role in atherosclerosis by regulating these pathways [143].  The QTL was 
mapped in a C57BL/6J x CAST/Ei F2 population [144].  Two conserved 5LO amino acid 
changes were associated with reduced 5LO expression in the congenic C57BL/6J mice 
carrying the CAST atherosclerosis 5LO allele [143].  In addition, the 5LO hemizygous Ldlr-/- 
mouse model showed significantly smaller atherosclerotic lesions.  However, 5LO is not 
completely responsible for this QTL.  Creation of reciprocal subcongenic lines (in this case a 
C57BL/6J mouse with just the locus of interest derived from CAST/Ei and visa versa) 
showed that two other loci within the same QTL, named Ath37 and Ath38, play a significant 
role in the effect of this QTL [145].  Although rare to find three sizeable effect QTLs so close 
together, it is not uncommon for the large intervals found in most QTLs to subdivide into 
multiple responsible loci.  While gratifying to find one responsible locus for each QTL, the 
likelihood of multiple genes being responsible is significant when the QTL is large. 
Causal relationships between the majority of the atherosclerosis QTLs and the 
responsible strain-dependent genetic variants for atherosclerosis susceptibility remain to be 
proven.  Nevertheless, with the completion of the human and multiple mouse genome 
sequences, as well as genome sequencing of other species, comparative genetics will 
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facilitate genome-wide mapping approaches and the identification of new genes and 
pathways.   
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III. Testing Candidate Genes by Intercross of Genetically Altered Mice  
A highly effective approach to test the contribution of a candidate gene to 
atherosclerosis development in mouse models is to cross Apoe-/- or Ldlr-/- mice with mice 
carrying the candidate mutation. The contributions of many such tested loci to atherosclerosis 
development in mouse models have been extensively reviewed [146-154].  The majority of 
the mutations tested in this manner have been loss of function mutations, which are rare in 
humans.  In addition, because plaque rupture and subsequent thrombi are very rare in Apoe-/- 
mice and Ldlr-/- mice, current evaluations of genetic modifiers in mice focus mainly on the 
development of plaques and their progression to complex lesions.   
Mouse models have confirmed the importance of inflammatory processes in 
atherogenesis and helped identify potential therapeutic targets.  Inflammatory processes are 
crucial in all stages of atherosclerosis [72].  Initiation of the fatty streak is thought to involve 
monocyte recruitment, rolling, adherence, transendothelial migration and activation.  
Absence of monocyte chemoattractant protein-1 (MCP1) decreases lesion size in Ldlr-/- mice 
by at least 20% [44, 155]; absence of its receptor, chemokine receptor 2 (CCR2), limits 
lesion formation and development in Apoe-/- mice [156, 157].  Since plaques still develop in 
the Ccr2-/- Apoe-/- mice and continue to mature with time, the MCP1-CCR2 system cannot be 
the only pathway that is important for the recruitment of monocytes during the initiation of 
an atheroma.  Other chemokines, cell adhesion molecules and various integrins are also 
involved in the recruitment and migration of monocytes.   
Fatal vascular events in humans are rarely the result of lumen occlusion by the 
developing plaque.  Instead they result from plaque rupture that leads to formation of 
occlusive thrombi and subsequent tissue ischemia.  Plaque rupture and thrombosis followed 
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by infarction and heart failure is rarely seen in mice.  However, evidence of unstable plaques 
such as low collagen content and thinning and disruption of the fibrous cap have been 
observed in several models [158-160].  In addition, studies demonstrating intraplaque 
hemorrhage without thrombosis in advanced lesions in the brachiocephalic artery of Apoe-/- 
mice show that lesions in this model progress to the late unstable stages seen in human 
plaque development [161].  Indeed, plaques in high fat fed Apoe-/- mice often show evidence 
of healed or buried plaque ruptures [161-163].  Ruptures in mice may often heal without the 
incidence of pathologic thrombosis [163]. Lack of consistent pathologic thrombosis and 
infarction in murine atherosclerosis models may be due to species and strain differences in 
circulation and coagulation.   
At least one mouse model has shown signs of plaque rupture with resulting 
myocardial infarction and heart failure.  Severe atherosclerosis accompanied by heart disease 
and early death was observed in Apoe-/- mice that also carried a homozygous deletion of the 
high-density lipoprotein receptor SR-BI (scavenger receptor class B, type I) [129].  The 
Scarb1-/-Apoe-/- mice develop coronary artery occlusions with complex fibrin-containing 
lesions.  The dramatically accelerated occlusive atherosclerotic disease observed in these 
mice may be caused by an alteration in their lipoprotein metabolism leading to decreased 
biliary cholesterol, increased plasma cholesterol and decreased reverse cholesterol transport 
[129, 164].  Treatment with probucol, a drug with antioxidant and cholesterol-lowering 
effects, prevented early coronary heart disease and death in the Scarb1-/-Apoe-/- mice, and 
extended their life span from 6 weeks to an average of 36 weeks [129, 164].  Although it is 
not clear if thrombosis contributes to their myocardial infarctions, the Scarb1-/-Apoe-/- mouse 
is currently the only model that demonstrates early atherosclerotic death.  Interestingly, they 
167 
combine mutations from two fundamental pathways in atherosclerosis development-
hyperlipidemia and monocyte cholesterol handling.   
Interpretation of the data obtained from intercrosses of mutants generated by genetic 
engineering must be undertaken only with careful consideration of the genetic background, 
age, gender and diet of the mice, as these factors can significantly influence the experimental 
results.  When the effects of a specific mutation itself are small and/or they interact with 
other yet-to-be-identified factors, the results may vary from one experiment to another due to 
other influences.  For example, the role of inducible nitric oxide synthase (Nos2) on 
atherogenesis has been investigated by four different groups.  Two groups reported a 
significant reduction of plaque development in the Nos2-/-Apoe-/- mice [165, 166]  while two 
others reported no change [167, 168].  Diet, age, and genetic background of the mice used by 
the four groups differed slightly and likely influenced the outcome.  Effects can also be 
gender specific, as reported by Whitman et al., who found that interferon-gamma (IFN-γ) 
deficiency had no effect on lesion size in female Apoe-/- mice, but profoundly decreased it in 
males [169].  In contrast, Matsui et al. observed that lack of osteopontin, a non-collagenous 
adhesive protein, decreased atherosclerosis in female Apoe-/- mice but had no effect in males 
[170].  In a cross of Ldlr-/- mC57BL/6J x fFVB and mFVB x fC57BL/6J  mice, both lineage 
specific and sex-specific effects were apparent suggesting that genetic imprinting and 
hormone mediated effects are likely both important [171].  The mechanisms underlying the 
sex-limited effects of these factors are not known, but constitute an important area for future 
studies.  
 
168 
IV. Tissue Specific and Temporal Gene Modification 
Tissues of both the vessel wall and the bone marrow contribute to the atherosclerotic 
process.  The involvement of certain cell types at different stages of plaque development 
suggests that certain genetic pathways, and therefore the function of certain genes, are 
temporally relevant.  Mouse models with tissue-specific or temporal gene expression can test 
the contribution of certain cell types to plaque progression, or their function at different 
stages of atherosclerosis development, respectively.  Dissecting the spatial and temporal 
functions of the molecules, cells, and pathways involved in atherogenesis will be critical for 
understanding the disease process and for developing new therapeutic strategies.   
Bone marrow transfer (BMT) protocols are widely used to investigate macrophage-
dependent pathways that contribute to the atherosclerotic process.  Reconstitution of lethally 
irradiated atherosclerosis-prone mice, such as Apoe-/- or Ldlr-/- mice, with bone marrow cells 
from mice carrying additional mutations have allowed investigators to separate the function 
of gene products in the bone marrow derived cells from their function in the tissues of the 
recipient animals.  For example, proteins involved in lipid metabolism such as LDLR have 
established functions in the liver as well as macrophages.  BMT allows their tissue-specific 
roles to be examined in-vivo.  Macrophage LDLR binds LDL and VLDL/chylomicron 
remnants, and the resulting lipid uptake can induce foam cell formation in culture [85, 172].  
BMT studies have shown that wild type mice that received wild type bone marrow cells 
develop larger diet-induced plaques compared to the mice that received Ldlr -/- bone marrow 
cells [57, 85].  However, macrophage expression of the LDLR did not significantly increase 
atherosclerosis in the hyperlipidemic setting when Ldlr -/- recipient mice were given wild type 
bone marrow cells [86, 173]. 
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We recently showed that LDLR expression affects atherosclerosis development but in 
an apoE isoform dependent manner.  Thus in Apoe4/4 Ldlr-/- mice, the replacement of native 
bone marrow cells with those expressing LDLR increased atherosclerotic lesions in a dose 
dependent manner [38].  In contrast, atherosclerosis was not altered in Apoe3/3 Ldlr-/- mice 
that express the human apoE3 isoform, when the level of macrophage LDLR expression was 
varied.  Results of these BMT experiments suggest that the interaction of macrophage LDLR 
expression with Apoe genotype may contribute to the association in humans between the 
apoE4 isoform and an increased cardiovascular risk. 
Genetic models that employ BMT are also useful for examining the atherogenic role 
of a gene product in hematopoietic cells when mice lacking the product fail to thrive.  For 
example, mice lacking cyclooxygenase 2 (COX2) die before weaning age [174].  Burleigh et 
al. were able to generate Ldlr-/- mice lacking macrophage COX2 by transplanting fetal liver 
cells from the COX2 deficient pups into Ldlr-/-  adults [174, 175].  The Ldlr-/- mice that 
received the COX2-deficient bone marrow cells had significantly smaller atherosclerotic 
lesions than control mice receiving wild type bone marrow cells.  The investigators 
concluded that Cox2 expression in macrophages is pro-atherogenic, and provided further 
confirmation of the anti-atherosclerotic effects of COX2 inhibition. 
 Tissue-specific gene modification is a useful technique for determining the 
role of a gene product in certain tissues, or when global modification is embryonic lethal.  
The Cre/loxP system can be used to delete or activate a gene of choice in a tissue-specific 
manner.  An excellent example in a mouse model of atherosclerosis is the use of this system 
to achieve smooth muscle cell-restricted deletion of the LDL receptor-related protein 1 
(LRP1).  Lack of LRP1 is embryonic lethal in mice.  Therefore, Boucher et al. used the 
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Cre/loxP system to generate viable Ldlr-/- mice that lack LRP1 only in vascular SMCs [176].  
They found that absence of LRP1 in SMCs resulted in the thickening of vessel walls that 
normally occurs as a consequence of SMC proliferation.  Feeding a Western-type high fat 
diet to these mice increased their atherosclerosis burden as much as 10 fold compared to 
Ldlr-/- mice with intact LRP1 in their SMCs.  In addition, a significant aneurysm-related 
dilatation of the aorta was observed in association with large plaques.  The authors further 
demonstrated that LRP1 forms a complex with a receptor for the platelet-derived growth 
factor (PDGF) and controls activation of the receptor.  Thus, models of tissue-specific gene 
deletion helped show that LRP1 plays a pivotal role in protecting the vascular wall and 
preventing atherosclerosis by suppressing SMC proliferation.   
Combining tissue-specific deletion of a gene with BMT allows researchers to ask 
sophisticated questions about the mechanisms of atherogenesis.  Transcription factors, such 
as peroxisome proliferator gamma (PPARγ), often have distinct roles in different cell types.  
Deletion of the Pparγ gene in mice is lethal in the developing embryos [177-179].  Babaev et 
al. generated mice with macrophage-specific deletion of Pparγ using the Cre/loxP system.  
Using BMT, the authors were able to demonstrate that the Ldlr-/- recipients of bone marrow 
with macrophage - PPARγ -/- cells had significantly larger atherosclerotic lesions than mice 
receiving bone marrow with wild type macrophage cells. The authors concluded that Pparγ 
expression in macrophages is anti-atherogenic [180]. The pleiotropic nature of molecules 
such as PPARγ and their prospect as therapeutic targets underscores the importance of 
detailing their tissue specific functions. 
While some genes have important tissue-specific functions, other genes may be 
important at different stages of the disease process.  Advanced human plaques have thick 
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fibrous caps and high collagen content.  Degradation and remodeling of the extracellular 
matrix in these advanced lesions likely determines their vulnerability to rupture.  
Macrophages are believed to regulate plaque stability through their release of matrix 
metalloproteinases (MMP) [181-183].  Gough et al. transferred bone marrow cells that 
overexpress an auto-activating form of MMP-9 into older apoE-deficient mice with existing 
atherosclerosis.  Overexpression of MMP-9 led to plaques with disrupted fibrous caps, 
increased fibrin deposits and intraplaque hemorrhage in the brachiocephalic artery and the 
aortic arch [184].  
Modeling the temporal effect of gene expression has also been investigated using 
drug-inducible changes of gene expression, such as by doxycycline, that can reversibly 
control transgene expression [185, 186].  Environmentally produced reactive oxygen species 
(ROS) have been implicated in atherosclerosis; however, the contribution of metabolically 
produced ROS from oxidative phosphorylation in mitochondria is not clear.  Uncoupling 
protein 1 (UCP1) expression lowers the efficiency of mitochondrial ATP production by 
increasing mitochondrial matrix proton permeability.  Bernal-Mizrachi et al. created 
transgenic mice with doxycycline-inducible expression of UCP1 in SMCs and crossed them 
with Apoe-/- mice [187].  UCP1 expression measurably increased the metabolic production of 
ROS in the aorta and lowered nitric oxide levels, which led to an elevated blood pressure and 
increased atherosclerosis, confirming that metabolically-produced ROS can modulate the risk 
of atherosclerosis.    
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V.  Humanizing the Mouse Systems.  
In some mouse models of atherosclerosis the phenotype does not precisely model all 
aspects of the human disease, even when genetic defects identical to those occurring in 
humans are introduced into the mouse genome.  Humans are genetically diverse, while most 
studies in mice utilize a genetically uniform population.  In certain cases, altered 
atherosclerotic susceptibility between humans and genetic mouse models may be due to 
differences in the concentration, activity, or pattern of expression of a particular homologous 
protein.  Novel techniques have been used to create genetic alterations in mice that can reveal 
and begin to overcome some of these difficulties.  As human therapeutics become 
increasingly tailored to certain mutations and protein isoforms, mouse models that contain 
the human target, or replicate the human physiological system, will allow us to better 
determine their mechanism of action, efficacy, and safety.   
 We tested whether mice can faithfully recapitulate a component of human 
lipid metabolism by replacing the mouse Apoe gene with the three human alleles [14, 33].  In 
humans the APOE  alleles are strongly associated with both the plasma concentration of 
LDL-cholesterol and the risk of atherosclerosis, (in the order APOE*2 < APOE* 3 < APOE* 
4 ) [3].  This association between apoE-isoforms and plasma lipoprotein profiles is one of the 
best predictors of cardiovascular disease in humans [2, 3, 188]. However the mechanisms 
underlying this association are still not clear since apoE4 binds to the receptor with a slightly 
higher affinity than apoE3 while apoE2 binds to the receptor with much less affinity than 
apoE3 or apoE4 [15].  A widely held explanation for this observation is that the high affinity 
of apoE4 for the LDLR leads to an increase in apoE-mediated cholesterol uptake and 
subsequent down-regulation of the Ldlr gene.  Low LDLR levels in humans with apoE4 
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could account for their elevated plasma LDL and increased atherosclerosis.  Conversely, the 
low affinity of apoE2 is thought to lead to up-regulation of Ldlr and decreased plasma LDL 
[3, 19]. 
Unexpectedly, mice expressing human apoE2, E3 or E4, in place of mouse apoE, 
recapitulate the human relationship, but only when the mice also express a high level of the 
human LDLR [37, 39].  Thus, in contrast to the current hypothesis, an increased expression 
of the LDL receptor in the mice with human apoE4 caused a marked accumulation of 
cholesterol-rich, apoE-poor remnants in plasma and severe atherosclerosis.  We hypothesize 
that the LDLR can trap apoE4, and reduce its availability for transfer onto lipoproteins, thus 
delaying their clearance, which increases the plasma concentration of slowly-cleared apoE-
poor remnants.  The overall consequence is that increased LDLR expression is pro-
atherogenic in mice with apoE4 and anti-atherogenic in mice with apoE2.   
In humans who carry the APOE*4 allele, the phenotypic effect is significant but not 
as pronounced as we observe in genetic mouse models.  Nevertheless, the adverse effect of 
the apoE4-LDLR interaction in remnant clearance observed in mice can explain, at least in 
part, the increased risk of atherosclerosis in humans associated with the APOE*4  genotype.  
Our explanation is also consistent with observations that humans carrying APOE*4 have 
prolonged post-prandial lipemia [2, 64, 68].  This work suggests that humans and mice differ 
in their relative use of apoE and LDLR in lipoprotein metabolism.  It also provides an 
example that species differences should not be simply dismissed, because they can reveal 
new insight into old problems.   
These studies demonstrate that genetic models of atherosclerosis that humanize the 
mouse can potentially enhance our understanding of the human disease process.  This 
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approach may be particularly important when studying therapeutic targets to overcome 
species-specific differences in the function of particular gene products.  For instance, 
investigating therapeutic monoclonal antibodies (Mab) in mouse disease models is 
complicated because the target protein may differ from the human homolog.  Recently mice 
with humanized VEGF-A, generated by gene-targeting, were used for testing the efficacy of 
Mab directed against VEGF [106].  In contrast to the cell culture promise of anti-
angiogenesis, anti-VEGF Mab had little effect on tumourogenesis in the in-vivo model, but 
did cause kidney damage.  This model also shows the potential utility of genetic mouse 
models in testing toxicity and efficacy in the early stages of drug development. 
Differences between the human and mouse immune systems result in other challenges 
to using genetic mouse models for disease study and drug discovery.  The role of the immune 
system in atherogenesis is clearly established, but the divergence of genes in the two species 
has resulted in differences both in the innate and adaptive immune systems.  For example, 
mouse A20-binding inhibitor of NFκB-3 (ABIN-3), induced selectively by the anti-
inflammatory cytokine IL-10, is incapable of inhibiting murine NFκB while human ABIN-3 
protein does inhibit human NFκB [189].  One solution would be to replace divergent mouse 
factors with their human counterparts.  For example, replacement of the mouse immune 
system by transferring human hematopoietic stem cells into immunodeficient NOD/SCID 
mice can be used to model human immune responses in mice [190].   
Transgenic mice carrying a large fragment of human genomic DNA often yield more 
human-like temporal and spatial expression of a transgene when compared with the 
endogenous mouse gene.  To this end, techniques have been developed to replace a large 
segment of the mouse genome with the syntenic human region [191].  Finally, although not 
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yet practical for general use, transmission of a whole human chromosome to a mouse has 
been demonstrated in a transspecies aneuploid mouse line carrying an almost complete 
human chromosome 21 that models aspects of human Down syndrome [192].   
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VI. Identifying targets in atherosclerotic disease using systems biology approach. 
Large scale genome analyses and genetic manipulations using transgenic expression, 
knockout, and gene replacement technologies have led successfully to a recent explosion in our 
understanding of the in-vivo molecular and cellular mechanisms of atherosclerosis.  Assessing 
the contribution of a single target and grouping genes and their products according to their 
functional pathophysiology, however, is somewhat tedious.  Scientists are beginning to look 
beyond the analysis of single genes, proteins, or lipids to study the function of these individual 
constituents as components of a larger integrated biologic system.  Systems biology has the 
potential to delineate the components of a given system, define the interaction among those 
components, and thereby help explain the behavior and function of the system.  Recent 
publications detail the systems biology approach to studying atherosclerosis [193-195]. 
Ideally, the study of a complex disease process using systems biology would incorporate 
relevant data and information about the genome, transcriptome, proteome, metabolome, and 
phenome.  To date, integrating these diverse data sets and other methodology challenges has 
limited the systems biology approach to the examination of interactions among a smaller subset 
of these data sets.  Nevertheless, the power of this approach to studying a complex disease such 
as atherosclerosis is evident.  For example, King et al. performed comprehensive micro-array 
gene expression analysis of human coronary artery atherosclerotic lesions and then developed 
pathway generation and network analysis tools to integrate their expression profiles with 
previously known information  [196].  This approach allowed the authors to establish a network 
of interacting genes relevant to the disease process.  It also identified “nexus” genes that are 
pivotal components of the network and therefore are interesting targets both for understanding 
the disease process and for pharmaceutical development.  Similar array and quantitative PCR-
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based approaches were used with human samples to construct pathways with known and novel 
components that are important to the response of endothelial cells to oxidized phospholipids and 
to the process of in-stent restenosis, again identifying interesting therapeutic targets [197, 198] 
Investigators are beginning to apply systems biology techniques to mouse genetic models 
of atherosclerosis.  For example, de Roos et al. used a proteomics approach in Apoe-/- mice to 
examine the pattern of differentially expressed hepatic proteins in response to dietary isomers of 
conjugated linoleic acid [199].  They identified isoform-specific regulation of certain proteins 
and metabolic pathways as well as isoform-dependent linkages to pathways that contribute to 
insulin resistance and the inflammatory response.  Similarly, Mayr et al. compared wild-type and 
Apoe-/- aortic tissue using proteomics combined with metabolomics to describe a set of 
atherosclerosis-related alterations in proteins and metabolites [200].  The results identified 
components of pathways in energy metabolism, oxidative stress, inflammation, and the immune 
response that contribute to atherogenesis. 
Genetic mouse models of atherosclerosis are also yielding gene expression profiles 
associated with this disease.  A recent study used the F2 mice from an intercross of sensitive and 
resistant strains and compared the gene expression profile of bone marrow-derived macrophages 
from animals with large or small lesions [201].  The researchers used the data to identify 
transcription factor binding sites, within promoter elements, that were differentially associated 
with either large or small atherosclerotic lesions.  In combination with QTL data previously 
generated, they used the gene expression data to propose two candidate gene products, Williams-
Bueren syndrome protein (Wbscr) and adaptor protein with pleckstrin and SH2 domains (Aps),  
as possible modifiers of lesion size. 
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In another study, gene expression data was collected from mouse strains with varying 
susceptibility to atherosclerosis, on a normal or high fat diet, and at defined points along the 
course of the disease [202].  Appropriate tools were developed and applied to confirm the 
involvement of known genes and to identify novel genes as well as molecular and biologic 
pathways involved at various stages of the atherosclerotic process.  They combined these data 
with the expression data derived from the study of coronary artery disease in humans to identify 
subsets of differentially expressed genes particularly relevant to describing disease progression 
and severity and distinguishing between native and in-stent atherosclerotic processes [197].  
These examples highlight the potential of the systems biology approach to identify novel 
targets and pathways that contribute to de novo atherosclerosis and related pathologic processes.  
This approach will help to define the complex relationships among, and regulation of, the 
functional components of atherosclerosis and other complex diseases.  A single study can 
generate numerous possible targets to explore.  As methodology improves, these studies are 
becoming more feasible and informative, and they have great potential to unravel complex 
disease processes.  They also provide us with the challenge of validating each of the identified 
components as legitimate and feasible targets for therapeutic manipulation.  In large part, target 
validation in the study of atherosclerosis currently utilizes genetically manipulated mouse 
models including transgene expression and gene knockout.  Thus, systems biology will help us to 
understand the genetics of atherosclerotic disease by identifying potential therapeutic targets.  It 
will simultaneously heighten the need for genetic-based validation of potential therapeutic 
targets using genetic mouse models of atherosclerosis to study the disease process. 
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Conclusion   
The etiology of atherosclerosis is complex. Its pathogenesis is influenced by a 
number of biologic systems including lipoprotein metabolism, inflammation, coagulation, 
and others.  Genetic mouse models of atherosclerosis have allowed us to identify certain 
components of these systems and examine their contribution to the mechanisms of 
atherogenesis. Yet, other components of these systems remain to be discovered, as do their 
precise contributions to atherosclerosis.  The number and nature of genetic tools to identify 
and examine these contributing factors is expanding and they are being used more frequently.  
Our understanding of the complex process of atherosclerosis will be enhanced if we integrate 
the knowledge derived from these different models.  Systems biology approaches will help 
reveal the fundamental mechanisms of atherosclerosis, as well as model-specific mechanisms 
of atherosclerosis. As these mechanisms are better understood, therapeutic targets for 
modulation of atherogenesis will become evident and be validated.  The genetic models of 
atherosclerosis can then also be used to test new therapeutic agents and therefore will lead to 
the development of effective treatments for atherosclerosis (Figure 6.1). 
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Conclusion and future directions 
The higher binding affinity of the apoE4 isoform to the LDLR than apoE2 or apoE3 
has been implicated in leading to increased plasma LDL cholesterol and atherosclerosis in 
individuals carrying apoE4 [2, 3]. Combining mice targeted with human apoE crossed to 
either HuLDLR overexpressing or LDLR knock outs, along with adenovirus mediated LDLR 
and apoE-GFP expression, we investigated the effects of LDLR expression on the 
localization of the different apoE isoforms in the liver.  Additionally, apoE isoforms have 
been shown to have seemingly lipid independent in-vitro affects on oxidation, SMC 
migration, and inflammation.  Using a BMT system we determined that the apoE-LDLR 
interaction has affects on atherosclerosis independent of their affect on lipid levels in the 
plasma.  Our results demonstrate, for the first time in animal models, that some of the risk 
associated with human apoE4 isoform may be due to its interaction with the LDLR in 
macrophages as well as with hepatic LDLR.   
The liver is the main source of plasma apoE.  Remnant lipoproteins are cleared in the 
liver mainly by LDLR and by LRP, but the uptake by these receptors require the remnants to 
acquire and be enriched with apoE proteins [47, 94-96]. Liver-derived and localized apoE 
facilitates the receptor-mediated internalization of remnants in the liver [96, 97].  Previously 
we showed in mice that all human apoE-isoforms are less effective ligands to non-LDLR 
mediated clearance of TG-rich lipoproteins than mouse apoE, and that VLDL remnants with 
very high cholesterol and apoE accumulates in the absence of LDLR [69].  Dependence of 
remnant clearance on LDLR is likely to be exaggerated in mice with human apoE isoforms.   
We earlier observed that mice globally expressing 2-3 times the normal Ldlr gene 
exhibit hypercholesterolemia when fed a HFW diet only when they are also carrying the 
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human apoE allele [39].  We hypothesized that a high-affinity interaction between LDLR and 
apoE4 in the liver limits the transfer of apoE protein to the TG-rich lipoproteins, limiting 
their clearance.   
The paradoxical association of apoE4 with elevated plasma cholesterol in humans 
may be due to its high LDLR affinity and a reduced ability to exchange onto and clear TRLs 
and remnants.  In cell culture binding or in-vivo clearance assays, when apoE is already 
present on the particle, apoE4 containing particles show enhanced binding and clearance 
compared to apoE3 and apoE2 [14, 19, 99].  Assaying apoE LDLR interaction this way may 
be misleading when used to interpret in vivo clearance mechanisms because it does not 
account for apoE isoform dependent differences in VLDL apoE-enrichment.  Acquiring apoE 
is necessary for VLDL remnant clearance.  For example apoE4, due to its high LDLR 
affinity, may stay stuck in or on cells and out of the plasma, leaving circulating VLDL apoE-
poor.  In fact , apoE deficient-VLDL binding and clearance is reduced when cells or animals 
express apoE4 compared to apoE3 [14].  We have shown that apoE2, with the lowest LDLR 
affinity, clears apoE deficient VLDL faster than apoE4 when they are expressed by the liver 
in-vivo and apoE-deficient particles are used.  Thus the clearance of exogenous apoE 
deficient VLDL is faster when the recipient animal expresses apoE with low LDLR affinity 
along with a higher LDLR level.  This may be more relevant to in vivo apoE-LDLR 
interaction because newly secreted chylomicron and VLDL have yet to acquire apoE.  
Combined with the reduced plasma apoE level associated with apoE4, this could increase the 
plasma retention time of these lipoproteins.  Interestingly, this is consistent with the higher 
post prandial lipemia in apoE4 humans [68] as well as Apoe4/4Ldlrh/+ mice on HFW diet [39].  
In contrast, the lower LDLR affinity of apoE2 increases its plasma concentration and HDL 
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levels and this circulating apoE2 has ample opportunity to exchange onto and increases 
VLDL clearance.   For a visual depiction of the clearance of apoE deficient-VLDL in animals 
that synthesize apoE versus the clearance of apoE-containing VLDL see figure 7.1. 
In summary, LDLR affinity determines whether plasma lipoproteins can acquire 
apoE. Acquisition of apoE determines lipoprotein clearance.  Higher affinity apoE4 is not 
available to transfer to nascent VLDL in the plasma and consequently these VLDL 
accumulate. 
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Figure 7.1.  Proposed mechanism to explain apoE effect on VLDL metabolism.  Left 
Diagrams show apoE-poor VLDL clearance by apoE secreting hepatocytes.  Right diagrams 
show apoE-enriched VLDL clearance by apoE deficient hepatocytes. Top left shows apoE2 
metabolism of apoE-poor VLDL.  The lower LDLR affinity of apoE2 increases plasma apoE 
level (green arrow) possibly via its elevated HDL level.  This increases the enrichment of 
apoE2 onto VLDL which facilitates LDLR and HSPG mediated uptake.  A.  Lower diagram 
shows apoE4 metabolism of apoE-poor VLDL.  High LDLR affinity of apoE4 keeps it bound 
to the hepatic surface, which decreases VLDL enrichment.  VLDL at the hepatic surface are 
not internalized and subsequently converted to remnants and LDL possibly by LPL.  When 
VLDL is isolated with, or enriched with apoE clearance of VLDL directly reflects the LDLR 
affinity of apoE.  Right top low affinity apoE2 is poorly cleared.  Right bottom, High affinity 
apoE4-enriched VLDL is rapidly cleared. 
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Our results are consistent with and support our “apoE4 trapping by LDLR” as a 
mechanism to explain the hypercholesterolemia associated with apoE4.  Retention of apoE4 
at the hepatic surface by LDLR reduces its availability in the plasma to bind to and mediate 
remnant internalization.  HDL, which can modulate apoE recycling, and is a source of 
plasma apoE, is a possible regulator of this process [47, 94, 103-105].  HDL as an apoE 
carrier may be necessary for timely apoE exchange to other lipoproteins such as TRLs, 
allowing nascent lipoproteins to enter the plasma without immediate apoE-mediated reuptake 
and also to remove them before they become slowly cleared remnant LDL.  Modulation of 
HDL levels by LDLR is apoE isoform dependant; increased LDLR expression leads to 
increased HDL-cholesterol in mice with apoE2 and decreases HDL levels in mice with 
apoE4 [37, 39].  Elevated HDL with apoE2 could enrich apoE-poor VLDL and promote their 
clearance.  While reduced HDL and apoE4 trapped in the space of Disse, directs apoE-poor 
VLDL to remnant conversion rather than internalization.  Decreased apoE content on TRLs 
can increase conversion to remnants by LPL [22, 106-108].  It is interesting to also consider 
the inverse relationship between HDL and larger LDL and VLDL that exists in many mouse 
models and is typically observed in humans.  Perhaps increased HDL serves as reservoir for 
apoproteins ligands and cofactors to transfer onto larger lipoproteins.  Lack of apoE and 
other apoproteins on newly secreted VLDL and chylomicrons would ensure escape from the 
liver and allow lipid delivery to tissues.  Increased interaction with elevated HDL containing 
transferable apoprotein ligands, such as apoE, could help to clear these larger lipoproteins.   
Further studies are necessary to elucidate the form of apoE and potential role of HDL in the 
isoform-specific interactions between LDLR and apoE and whether other apolipoproteins are 
involved in these interactions.  High affinity ligands such as apoE4 may have difficulty 
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maintaining adequate plasma concentration of both apoE4 and HDL due to increased 
clearance.  Experiments to determine the role of apoE containing HDL in determining VLDL 
and LDL levels can be addressed using the mice in this work.  For instance, directly injecting 
apoE2 or apoE4 HDL into apoE-/- or apoE-/- Ldlrh/h   mice to see if their HDLs can mediate a 
decrease in VLDL remnants that accumulate in the absence of apoE.  Our hypothesis predicts 
that, if equal HDL or apoE is given, apoE4 HDL may assist remnant clearance better than 
apoE2.  However, if volumes of HDL that are actually observed in Apoe4/4Ldlrh/+ and 
Apoe2/2Ldlrh/+ mice are injected, then the elevated apoE2 and HDL in Apoe2/2Ldlrh/+ mice 
could be expected to mediate better VLDL clearance.  
An important difference in our model and apoE4 possessing humans is that the mice 
do not accumulate LDL and instead have elevated VLDL remnants.  This is often attributed 
to the editing of apoB in the mouse liver.  There are several apoB mouse models that have 
either apoB100 only or transgenics that overexpress human apoB100.  ApoB100 only mice 
without LDLR develop more LDL and atherosclerosis than those that still have apoB48 
VLDL, likely due to shunting of apoE VLDL to LRP uptake.  It is also likely that when 
crossed to our Apoe4/4Ldlrh/+ that increased apoB100 and LDL cholesterol will result.  This 
would be more similar to their human counterparts and thus a better model to continue 
studying the apoE isoform risk and interaction with LDLR in hepatic localization. 
Mice with apoE isoform and elevated LDLR revealed that there may be a critical 
range of LDLR levels for proper ratios of cholesterol carried by atherogenic non-HDL 
lipoproteins and by HDL particles. The optimum range of LDLR levels is different for each 
apoE isoform and proportional to each isoforms LDLR affinity.  For instance, all apoE 
isoforms mice have elevated VLDL and LDL when the LDLR is absent [69].  With wildtype 
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levels of LDLR, both Apoe4/4 and Apoe3/3 mice have high HDL and low non-HDL cholesterol 
[14]. However, ApoE2/2 mice have high non-HDL /HDL ratios [34].  When LDLR levels are 
elevated, HDL cholesterol levels dramatically decrease in both Apoe4/4 Ldlrh/+ and 
Apoe3/3Ldlrh/+ mice.  Since non-HDL cholesterol is elevated only in Apoe4/4 Ldlrh/+ mice their 
non-HDL /HDL ratios are critically high, while Apoe3/3Ldlrh/+ mice have nonHDL /HDL 
ratios that are modestly increased.  Apoe2/2Ldlrh/+ mice have reductions in their VLDL and 
elevated HDL levels and thus have low non-HDL /HDL.  If we apply the same relationships 
to phenotypes associated with apoE isoforms in humans, one may predict that LDLR activity 
in humans are in the upper ranges of figure 7.2 where apoE2 is beneficial and apoE4 is 
somewhat detrimental.  In the lower range of LDLR activities, the decreased affinity of 
apoE2 may cause apoE2-rich TRLs to accumulate, similar to the 5% of apoE2 homozygous 
humans who develop type III hyperlipidemia characterized by elevated TG.   
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Figure 7.2. Interaction between LDLR level and apoE affinity and resulting atherosclerosis 
risk (non-HDL cholesterol /HDL cholesterol) in mice.  Legend on the left: darker shaded area 
shows a decreased non-HDL /HDL.  Upper unshaded areas reflect elevated non-HDL/HDL 
and hyperlipidemia.  Darker shading represents a beneficial interaction; low LDL, high HDL.  
For each apoE isoform there is a different non-HDL/HDL level for each LDLR level.  Panel 
on the right shows non-HDL/HDL ratio (by amount of shading) in mice, determined by their 
LDLR level (y-axis) and apoE affinity (x-axis). Darker shaded areas reflect a good balance 
between LDLR level and apoE isoform that results in a good non-HDL/HDL.  Unshaded area 
is a poor non-HDL/HDL and hyperlipidemia.  For each apoE isoform as LDLR level goes up 
or down away from its critical range a poor non-HDL/HDL results. Similar non-HDL/HDL 
levels occur at different levels of LDLR for each apoE isoform reflected by the change in 
position of the shaded region.  For example on an Ldlr-/- background all mice are 
hyperlipidemic regardless of apoE isoform (unshaded area across the bottom).  As LDLR 
level is increased to wildtype mice with apoE3 and apoE4 have reductions in non-HDL 
(darker shading), while mice with apoE2 remain hyperlipidemic with a Type III phenotype 
(unshaded).  With elevated LDLR mice with apoE4 are out of range and hyperlipidemic, 
while mice with apoE2 are now in range and have elevated HDL.  Refer to lipoprotein 
profiles in figure 1.2 on page 22. 
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Careful titration of apoE and LDLR levels may shed light on the relevance of this 
mechanism to the well-established associations between the risk for coronary heart disease 
and Type III penetrance among apoE2 homozygotes as well as that of other apoE isoforms.  
Different doses of AdhuLDLR to induce varying LDLR expression levels combined with 
real-time PCR and western blotting for LDLR message and protein levels coordinated with 
lipid profiles could address this relationship and its predictions.   Determination of this 
relationship could also answer the surprising prediction by this hypothesis that elevation of 
LDLR in Apoe3/3Ldlrh/+ mice would further increase non-HDL lipoproteins.    
ApoE isoform mice that express varying levels of LDLR have generated interesting 
data that have led to novel hypothesis that appear to replicate and predict a consistent 
mechanism to explain the associated apoE isoform risks in humans.  It is important to 
continue to improve this model by elevating LDL and better replicating the human profiles.  
However ultimately these hypothesis will need to be tested in humans.  Human genetic 
variability and different environmental exposure often make these studies difficult to 
interpret and combined with sample availability almost impossible.  Surrogate indicators at 
the DNA level for expression level compared to plasma phenotype and apoE genotype have 
been initiated by Mullem et al. [203].  Immunohistochemical detection of apoE in human 
liver samples could, if similar to our studies, support our predictions.  In combination with 
plasma lipid, testing in human liver samples whether the pattern of elevated LDLR staining 
matches the prediction of a critical change for each isoform.  This would undoubtedly require 
large numbers of samples to first aquire the correct genotypes as well as reduce the sample 
variability. 
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Finally, after these studies, if in agreement with our predictions, the targeting of 
therapeutics to apoE isoform effects would be warranted and interpretable.  Our BMT 
experiments would suggest that the apoE4 isoform has a role in macrophage dependant 
atherosclerosis.   While our hepatic studies suggest that elevated LDLR increases lipid levels. 
Together this would indicate that the response to treatment of atherosclerosis, in humans with 
apoE4, with anti-inflammatory therapy and less reliance on LDLR up-regulating, statin, 
treatment should be investigated. 
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